Page last updated: 2024-10-30

lomustine and Benign Neoplasms, Brain

lomustine has been researched along with Benign Neoplasms, Brain in 488 studies

Research Excerpts

ExcerptRelevanceReference
" Here, we explored the incidence, and the consequences for treatment exposure and survival, of thrombocytopenia induced by lomustine in recurrent glioblastoma."9.69Thrombocytopenia limits the feasibility of salvage lomustine chemotherapy in recurrent glioblastoma: a secondary analysis of EORTC 26101. ( Brandes, AA; Clement, PM; Golfinopoulos, V; Gorlia, T; Idbaih, A; Le Rhun, E; Oppong, FB; Platten, M; Preusser, M; Taphoorn, MJ; van den Bent, M; Weller, M; Wick, W, 2023)
" We investigated Depatux-M in combination with temozolomide or as a single agent in a randomized controlled phase II trial in recurrent EGFR amplified glioblastoma."9.34INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma. ( Ansell, P; Brilhante, J; Chinot, O; Clement, PM; Coens, C; De Vos, F; Dey, J; Dubbink, HJ; Eoli, M; Franceschi, E; French, P; Frenel, JS; Golfinopoulos, V; Gorlia, T; Krause, S; Looman, J; Nuyens, S; Sanghera, P; Sepulveda, JM; Smits, M; Spruyt, M; Van Den Bent, M; Walenkamp, A; Weller, M; Whenham, N, 2020)
"Despite somewhat prolonged progression-free survival, treatment with lomustine plus bevacizumab did not confer a survival advantage over treatment with lomustine alone in patients with progressive glioblastoma."9.24Lomustine and Bevacizumab in Progressive Glioblastoma. ( Bendszus, M; Brandes, AA; Bromberg, JC; Campone, M; Clement, PM; Domont, J; Dubois, F; Fabbro, M; Golfinopoulos, V; Gorlia, T; Harting, I; Idbaih, A; Klein, M; Le Rhun, E; Platten, M; Sahm, F; Stupp, R; Taal, W; Taphoorn, M; van den Bent, MJ; von Deimling, A; Weller, M; Wick, W, 2017)
"Adding temozolomide (TMZ) to radiation for patients with newly-diagnosed anaplastic astrocytomas (AAs) is common clinical practice despite the lack of prospective studies demonstrating a survival advantage."9.22The role of temozolomide in the management of patients with newly diagnosed anaplastic astrocytoma: a comparison of survival in the era prior to and following the availability of temozolomide. ( Abuali, I; Grossman, SA; Lu, Y; Strowd, RE; Ye, X, 2016)
"The combination of galunisertib, a transforming growth factor (TGF)-β receptor (R)1 kinase inhibitor, and lomustine was found to have antitumor activity in murine models of glioblastoma."9.22A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma. ( Brandes, AA; Capper, D; Carpentier, AF; Cher, L; Chinot, O; Cleverly, A; Desaiah, D; Guba, SC; Gueorguieva, I; Kesari, S; Lahn, MM; Miles, C; Rodon, J; Sepulveda-Sanchez, JM; Smith, C; Specenier, P; Steinbach, JP; Wheeler, HR; Wick, W, 2016)
"We conducted a randomized, non-comparative, multi center, phase II clinical trial in order to investigate the efficacy of axitinib, an oral small molecule tyrosine kinase inhibitor with high affinity and specificity for the vascular endothelial growth factor receptors, in patients with recurrent glioblastoma following prior treatment with radiation and temozolomide."9.22Randomized phase II study of axitinib versus physicians best alternative choice of therapy in patients with recurrent glioblastoma. ( Bouttens, F; D'Haene, N; Du Four, S; Duerinck, J; Everaert, H; Le Mercier, M; Michotte, A; Neyns, B; Salmon, I; Van Binst, AM; Vandervorst, F; Verschaeve, V, 2016)
"Following maximal surgical resection, newly diagnosed children with nonmetastatic high-grade glioma underwent involved field radiotherapy with concurrent temozolomide."9.22Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children's Oncology Group ACNS0423 study. ( Brat, DJ; Burger, PC; Buxton, A; Cohen, KJ; Eckel, SP; Hamilton, RL; Jakacki, RI; Krailo, MD; Lavey, RS; Pollack, IF; Rosenblum, MK; Zhou, T, 2016)
" This trial evaluated the efficacy of low dose bevacizumab in combination with lomustine (CCNU) compared to standard dose bevacizumab in patients with recurrent glioblastoma."9.22A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma. ( Colen, RR; Conrad, CA; de Groot, JF; Gilbert, MR; Han, X; Liu, DD; Loghin, ME; O'Brien, BJ; Penas-Prado, M; Puduvalli, VK; Tremont-Lukats, I; Weathers, SP; Yung, WKA, 2016)
"In this side study of the BELOB trial, 141 patients with recurrent glioblastoma were randomised to receive single-agent bevacizumab or lomustine, or bevacizumab plus lomustine."9.20Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial. ( Beerepoot, L; Beije, N; de Vos, FY; Gratama, JW; Hanse, M; Kraan, J; Oosterkamp, HM; Otten, A; Sleijfer, S; Taal, W; van den Bent, MJ; van der Holt, B; van Linde, ME; Vernhout, RM; Walenkamp, AM, 2015)
" Adult patients (≥18 years of age) with a first recurrence of a glioblastoma after temozolomide chemoradiotherapy were randomly allocated by a web-based program to treatment with oral lomustine 110 mg/m(2) once every 6 weeks, intravenous bevacizumab 10 mg/kg once every 2 weeks, or combination treatment with lomustine 110 mg/m(2) every 6 weeks and bevacizumab 10 mg/kg every 2 weeks."9.19Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. ( Beerepoot, LV; Boerman, D; Brandsma, D; Bromberg, JE; Buter, J; de Vos, FY; Dinjens, WN; Dubbink, HJ; Enting, RH; Hanse, MC; Honkoop, AH; Jansen, RL; Oosterkamp, HM; Taal, W; Taphoorn, MJ; van den Bent, MJ; van den Berkmortel, FW; van der Holt, B; van Heuvel, I; Vernhout, RM; Walenkamp, AM, 2014)
"A randomized, phase III, placebo-controlled, partially blinded clinical trial (REGAL [Recent in in Glioblastoma Alone and With Lomustine]) was conducted to determine the efficacy of cediranib, an oral pan-vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor, either as monotherapy or in combination with lomustine versus lomustine in patients with recurrent glioblastoma."9.17Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. ( Ashby, LS; Batchelor, TT; Campone, M; Cher, L; Degroot, J; Gattamaneni, R; Jain, RK; Jürgensmeier, JM; Liu, Q; Mason, W; Mikkelsen, T; Mulholland, P; Nabors, LB; Neyns, B; Payer, F; Phuphanich, S; Rosenthal, M; Sorensen, AG; van den Bent, M; Wick, A; Xu, J, 2013)
"This phase III open-label study compared the efficacy and safety of enzastaurin versus lomustine in patients with recurrent glioblastoma (WHO grade 4)."9.14Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. ( Carpentier, AF; Chamberlain, MC; Cher, LM; Fine, HA; Hong, S; Liepa, AM; Mason, W; Musib, L; Puduvalli, VK; Thornton, DE; van den Bent, MJ; Weller, M; Wick, W, 2010)
"A phase I trial was conducted to determine the maximum tolerated dose (MTD) of temozolomide given in combination with lomustine in newly diagnosed pediatric patients with high-grade gliomas."9.13A phase I trial of temozolomide and lomustine in newly diagnosed high-grade gliomas of childhood. ( Adamson, PC; Blaney, SM; Flom, L; Ingle, AM; Jakacki, RI; Pollack, IF; Prados, MD; Timmerman, R; Yates, A; Zhou, T, 2008)
"To evaluate toxicity and efficacy of the combination of lomustine, temozolomide (TMZ) and involved-field radiotherapy in patients with newly diagnosed glioblastoma (GBM)."9.12Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03. ( Bamberg, M; Blaschke, B; Herrlinger, U; Hundsberger, T; Koch, D; Kortmann, RD; Loeser, S; Meyermann, R; Reifenberger, G; Rieger, J; Sommer, C; Steinbach, JP; Tan, TC; Weller, M; Wick, W, 2006)
"Temozolomide is an alkylating agent with activity in the treatment of melanoma metastatic to the brain."9.12A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma. ( Bate, SC; Beirne, DA; Eisen, TG; Gibbens, IM; Gore, ME; Hughes, SA; Larkin, JM; Patel, PM; Thomas, K, 2007)
"The authors investigated the results of PCV chemotherapy within a cohort of 24 patients treated within the EORTC study 26971 on temozolomide chemotherapy in recurrent oligodendroglioma."9.11Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas. ( Allgeier, A; Brandes, AA; Enting, RH; Frenay, M; Kros, JM; Menten, J; Stege, EB; Taphoorn, MJ; Tosoni, A; Triebels, VH; van den Bent, MJ; van Heuvel, I, 2004)
"To conduct a Phase II study to evaluate the long-term efficacy and safety of high-dose 5'-bromodeoxyuridine (BrdU) and accelerated radiotherapy followed by procarbazine, lomustine (CCNU), and vincristine (PCV) chemotherapy in patients with glioblastoma multiforme."9.09A phase II trial of high-dose bromodeoxyuridine with accelerated fractionation radiotherapy followed by procarbazine, lomustine, and vincristine for glioblastoma multiforme. ( Bruner, JM; Groves, MD; Hess, K; Jaeckle, KA; Kyritsis, AP; Levin, VA; Maor, MH; Meyers, C; Peterson, P; Sawaya, RE; Yung, WK, 1999)
"Although the efficacy of the nitrosourea-based combination chemotherapy procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, and vincristine (PCV) has been previously demonstrated in the setting of anaplastic/intermediate-grade gliomas, the benefit for glioblastoma patients remains unproven."9.09Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme. ( Bruner, JM; Chang, SM; Choucair, A; Flynn, PJ; Gleason, MJ; Hess, KR; Jaeckle, KA; Kyritsis, AP; Levin, VA; Prados, MD; Uhm, JH, 2000)
"To conduct a Phase II one-arm study to evaluate the long-term efficacy and safety of accelerated fractionated radiotherapy combined with intravenous carboplatin for patients with previously untreated glioblastoma multiforme tumors."9.08Phase II study of accelerated fractionation radiation therapy with carboplatin followed by vincristine chemotherapy for the treatment of glioblastoma multiforme. ( Bruner, J; Kyritsis, AP; Leeds, N; Levin, VA; Maor, MH; Rodriguez, L; Sawaya, R; Thall, PF; Woo, S; Yung, WK, 1995)
"There is no benefit to the treatment of high-grade astrocytomas in children with eight-drugs-in-1-day chemotherapy compared with CCNU, vincristine, and prednisone."9.08Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen. Childrens Cancer Group. ( Bertolone, SJ; Boyett, JM; Cherlow, JM; Finlay, JL; Geyer, JR; McGuire, P; Milstein, JM; Tefft, M; Wisoff, JH; Yates, AJ, 1995)
"A prospective phase II study of paclitaxel was performed in adult patients with recurrent hemispheric oligodendrogliomas."9.08Salvage chemotherapy with paclitaxel for recurrent oligodendrogliomas. ( Chamberlain, MC; Kormanik, PA, 1997)
"The regimen of procarbazine, CCNU, and vincristine is active against gliomas."9.08Dose-intensification of procarbazine, CCNU (lomustine), vincristine (PCV) with peripheral blood stem cell support in young patients with gliomas. ( Cornetta, K; Dropcho, E; Heilman, DK; Jakacki, RI; Jamison, C; Macdonald, DR; Mathews, VP; Williams, DA, 1998)
"In a study activated in 1983 and closed in 1987, the Brain Tumor Research Center of the University of California and the Northern California Cancer Center evaluated the effect of bromodeoxyuridine in the treatment of glioblastoma multiforme."9.07Evaluation of bromodeoxyuridine in glioblastoma multiforme: a Northern California Cancer Center Phase II study. ( Ahn, DK; Davis, RL; Flam, MS; Gutin, PH; Levin, VA; Phillips, TL; Prados, MD; Wara, WM; Wilson, CB, 1991)
" The protocol called for a randomized trial that compared the effects of following 60 Gy radiation/oral hydroxyurea treatment with either carmustine (BCNU) or the combination of procarbazine, lomustine (CCNU), and vincristine (PCV) for two histologic strata: glioblastoma multiforme and other anaplastic gliomas."9.06Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. ( Davis, RL; Gutin, PH; Hannigan, J; Levin, VA; Silver, P; Wara, WM; Wilson, CB, 1990)
"The majority of patients with high-risk lower grade gliomas (LGG) are treated with single-agent temozolomide (TMZ) and radiotherapy despite three randomized trials showing a striking overall survival benefit with adjuvant procarbazine, lomustine, and vincristine (PCV) chemotherapy and radiotherapy."9.05Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV. ( Atkins, KM; Dietrich, J; Loeffler, JS; McDuff, SGR; Oh, KS; Shih, HA, 2020)
"To assess the effectiveness and safety of procarbazine, lomustine, and vincristine (PCV) chemotherapy with other interventions in adults with recurrent high-grade glioma."8.95Procarbazine, lomustine and vincristine for recurrent high-grade glioma. ( Guo, J; Parasramka, S; Rosenfeld, M; Talari, G; Villano, JL, 2017)
"The methylhydrazine derivative Procarbazine (PCZ) as monotherapy or in combination with CCNU and vincristine (PCV) was evaluated in a vast number of clinical trials and is still used in patients with high-grade and low-grade gliomas."8.84Procarbazine--a traditional drug in the treatment of malignant gliomas. ( Bogdahn, U; Goerne, R; Hau, P, 2008)
"We evaluated O-(2-[18F]fluoroethyl)-l-tyrosine (FET) PET and MRI for early response assessment in recurrent glioma patients treated with lomustine-based chemotherapy."8.31Prediction of response to lomustine-based chemotherapy in glioma patients at recurrence using MRI and FET PET. ( Bauer, EK; Ceccon, GS; Fink, GR; Galldiks, N; Goldbrunner, R; Kabbasch, C; Langen, KJ; Lohmann, P; Stoffels, G; Tscherpel, C; Werner, JM; Wollring, MM, 2023)
" TTFields therapy is approved for treatment of newly-diagnosed glioblastoma (GBM) concurrent with maintenance temozolomide (TMZ)."8.31Tumor Treating Fields (TTFields) increase the effectiveness of temozolomide and lomustine in glioblastoma cell lines. ( Dor-On, E; Fishman, H; Giladi, M; Haber, A; Kinzel, A; Monin, R; Palti, Y; Weinberg, U, 2023)
" Here we describe the occurrence of pseudoprogression in patients with anaplastic oligodendrogliomas treated with postoperative procarbazine, lomustine and vincristine (PCV) chemotherapy alone."8.31T2-Fluid-attenuated inversion recovery (FLAIR) pseudoprogression in patients with anaplastic oligodendrogliomas treated with procarbazine, lomustine and vincristine (PCV) chemotherapy alone. ( Boutet, C; Carpentier, C; Dehais, C; Di Stefano, AL; Ducray, F; Esparragosa Vazquez, I; Figarella-Branger, D; Forest, F; Larrieu-Ciron, D; Meyronet, D; Ndiaye, M; Picart, T; Rivoirard, R; Seyve, A; Vassal, F; Younan, N, 2023)
"Glioblastomas (GBM) often acquire resistance against temozolomide (TMZ) after continuous treatment and recur as TMZ-resistant GBM (TMZ-R-GBM)."8.02Lomustine and nimustine exert efficient antitumor effects against glioblastoma models with acquired temozolomide resistance. ( Fujii, T; Ichimura, K; Kawauchi, D; Kobayashi, T; Kondo, A; Nakano, T; Narita, Y; Sasaki, N; Satomi, K; Takahashi, M; Tomiyama, A; Uchida, E; Wada, K; Yamamuro, S; Yoshino, A, 2021)
"IDH-mutant anaplastic astrocytomas (AAs) are chemosensitive tumors for which the best choice of adjuvant chemotherapy between procarbazine, lomustine, and vincristine (PCV) or temozolomide (TMZ) after radiotherapy (RT) remains unclear."8.02Radiotherapy Plus Procarbazine, Lomustine, and Vincristine Versus Radiotherapy Plus Temozolomide for IDH-Mutant Anaplastic Astrocytoma: A Retrospective Multicenter Analysis of the French POLA Cohort. ( Bronniman, C; Carpentier, C; Ciron, DL; Dehais, C; Ducray, F; Esteyrie, V; Figarella-Branger, D; Martin, E; Moyal, EC; Network, P; Pouessel, D; Uro-Coste, E, 2021)
"Following optimal local therapy, adjuvant Procarbazine, Lomustine and Vincristine (PCV) improves overall survival (OS) in low-grade glioma (LGG)."8.02One year of procarbazine lomustine and vincristine is poorly tolerated in low grade glioma: a real world experience in a national neuro-oncology centre. ( Aslam, R; Breathnach, OS; Coyne, Z; Grogan, L; Hennessy, BT; Hennessy, MA; Keogh, RJ; Morris, PG, 2021)
"In the EF-14 trial for newly diagnosed glioblastoma (ndGBM) patients addition of Tumour Treating Fields (TTFields) to temozolomide treatment resulted in a significantly improved overall survival (OS)."7.96Tumour Treating Fields (TTFields) in combination with lomustine and temozolomide in patients with newly diagnosed glioblastoma. ( Blau, T; Deuschl, C; Glas, M; Herrlinger, U; Kebir, S; Keyvani, K; Kleinschnitz, C; Lazaridis, L; Oster, C; Pierscianek, D; Schäfer, N; Scheffler, B; Schmidt, T; Stuschke, M; Sure, U; Teuber-Hanselmann, S; Tzaridis, T; Weller, J, 2020)
"Systematic evaluation of the effectiveness and safety of combined procarbazine, lomustine, and vincristine for treating recurrent high-grade glioma."7.96A comparative study of the effectiveness and safety of combined procarbazine, lomustine, and vincristine as a therapeutic method for recurrent high-grade glioma: A protocol for systematic review and meta-analysis. ( Cai, Y; Jiang, YG; Jiang, ZH; Tan, ZG; Wang, M, 2020)
"Radiotherapy with procarbazine, lomustine, and vincristine (PCV) improves overall survival in patients with anaplastic oligodendroglioma 1p19q codeleted."7.88Radiotherapy plus temozolomide or PCV in patients with anaplastic oligodendroglioma 1p19q codeleted. ( Castro-Martinez, E; Gonzalez-Aguilar, A; Guerrero-Juarez, V; Gutierrez-Aceves, A; Hernandez-Hernandez, A; Lopez-Martinez, M; Peiro-Osuna, RP; Reyes-Moreno, I; Santos-Zambrano, J, 2018)
"Taken together, these data suggest a potential role for a combination therapy of lomustine and DHA for the treatment of glioblastomas."7.81Enhanced anticancer properties of lomustine in conjunction with docosahexaenoic acid in glioblastoma cell lines. ( Cohen-Gadol, AA; Harvey, KA; Pollok, K; Saaddatzadeh, MR; Siddiqui, RA; Wang, H; Xu, Z, 2015)
"In this retrospective study, we identified adult patients with histologically confirmed glioblastoma (WHO grade IV) who were treated with lomustine or carmustine in combination with bevacizumab as a second or third regimen after failing an alternative initial bevacizumab-containing regimen."7.80Retrospective study of carmustine or lomustine with bevacizumab in recurrent glioblastoma patients who have failed prior bevacizumab. ( Alexander, BM; Beroukhim, R; Doherty, L; Hempfling, K; Huang, RY; LaFrankie, D; Lee, EQ; Nayak, L; Norden, AD; Rahman, R; Rai, A; Reardon, DA; Rifenburg, J; Rinne, ML; Ruland, S; Wen, PY, 2014)
" The validated method has been successfully applied to a pharmacokinetic study of thermosensitive liposome-encapsulated lomustine containing iohexol and lomustine solution after intravenous administration to C6 glioma rats."7.77HPLC method validation for the quantification of lomustine to study pharmacokinetics of thermosensitive liposome-encapsulated lomustine containing iohexol for CT imaging in C6 glioma rats. ( Derendorf, H; Gao, J; Li, M; Liu, C; Yu, F; Zeng, Y; Zhang, B; Zhuang, L, 2011)
" Among these tumors, a high percentage of low-grade oligodendrogliomas (ODG) are sensitive to chemotherapy with procarbazine, CCNU, and vincristine (PCV)."7.73Semi-quantification of methionine uptake and flair signal for the evaluation of chemotherapy in low-grade oligodendroglioma. ( Branle, F; De Witte, O; Goldman, S; Sadeghi, N; Tang, BN; Wikler, D, 2005)
"We have reported that carmustine (BCNU) and cisplatin administered before, during, and after radiotherapy did not improve the survival of patients with high-grade astrocytomas and were associated with more serious toxicities than radiotherapy plus BCNU."7.73Combination chemotherapy with carmustine and cisplatin followed by procarbazine, lomustine, and vincristine for adult high-grade astrocytoma. ( Jung, SM; Liau, CT; Tseng, CK; Wei, KC, 2005)
"To re-evaluate the cost effectiveness and median overall survival (OS) achieved in patients with recurrent malignant gliomas treated with temozolomide in British Columbia, as compared to previous lomustine use in the same patient population based on updated outcomes data."7.73Re-evaluation of the cost effectiveness of temozolomide for malignant gliomas in British Columbia. ( Mabasa, VH; Taylor, SC, 2006)
"The aim of this study was to evaluate the toxicity, response, and survival of patients with relapsed high-grade gliomas after radiation therapy (RT) combined with lomustine (CCNU)."7.70Reirradiation and lomustine in patients with relapsed high-grade gliomas. ( Arcicasa, M; Bidoli, E; Dedkov, A; Gigante, M; Roncadin, M; Trovò, MG, 1999)
"The authors reviewed the results of neoadjuvant (preradiation) procarbazine, CCNU, and vincristine chemotherapy for anaplastic oligodendrogliomas because, increasingly, chemotherapy is prescribed before radiation for oligodendroglial neoplasms."7.70Neoadjuvant procarbazine, CCNU, and vincristine for anaplastic and aggressive oligodendroglioma. ( Cairncross, JG; Macdonald, DR; Paleologos, NA; Vick, NA, 1999)
"Our results indicate that chemotherapy with a combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea is active for patients with recurrent anaplastic gliomas and glioblastomas not previously treated with nitrosourea-based chemotherapy but is inactive for patients with glioblastomas previously treated with chemotherapy."7.69Combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas. ( Bruner, J; Flowers, A; Gleason, MJ; Ictech, SE; Jaeckle, KA; Kyritsis, AP; Levin, VA; Yung, WK, 1996)
"Effective chemotherapy using PCV (procarbazine, lomustine and vincristine) has been documented in anaplastic oligodendrogliomas and oligoastrocytomas."7.69[Assessment of procarbazine, vincristine and lomustine association (PCV protocol) in oligodendroglioma and mixed glioma]. ( Bouffet, E; Bret, P; Helfre, S; Jouvet, A; Mertens, P; Mornex, F; Sindou, M; Thiesse, P, 1997)
"Twenty-eight evaluable children with the diagnosis of brain stem glioma were treated with 5-fluorouracil and CCNU before posterior fossa irradiation (5500 rads); during irradiation, the children received hydroxyurea and misonidazole."7.675-Fluorouracil and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) followed by hydroxyurea, misonidazole, and irradiation for brain stem gliomas: a pilot study of the Brain Tumor Research Center and the Childrens Cancer Group. ( Allen, J; Edwards, MS; Levin, VA; Ortega, J; Vestnys, P; Wara, WM, 1984)
"Twenty-one patients with recurrent malignant central nervous system gliomas were treated with a combination of 5-fluorouracil, CCNU, hydroxyurea, and 6-mercaptopurine."7.67Treatment of recurrent brain stem gliomas and other central nervous system tumors with 5-fluorouracil, CCNU, hydroxyurea, and 6-mercaptopurine. ( Edwards, MS; Fulton, D; Levin, V; Prados, M; Rodriguez, LA; Silver, P, 1988)
"Fourteen consecutive melanoma patients with evaluable metastatic disease were treated with combination chemotherapy including procarbazine, vincristine and lomustine (POC)."7.67Metastatic malignant melanoma treated with procarbazine, vincristine and lomustine (POC). ( Ardizzoni, A; Grimaldi, A; Repetto, L; Rosso, R; Sertoli, MR, 1987)
"Twenty consecutive patients with supratentorial Grade III and IV astrocytomas were treated with postoperative radiotherapy, and a simultaneous induction chemotherapy with 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU), procarbazine, bleomycin, and maintenance chemotherapy with CCNU."7.66Radiotherapy combined with procarbazine, bleomycin, and CCNU in the treatment of high-grade supratentorial astrocytomas. ( Greiner, RH; Markwalder, H; Seiler, RW; Zimmerman, A, 1978)
"Seven patients were treated with a combination of intraventricular methotrexate (MTX) and oral CCNU after resection and whole CNS irradiation of medulloblastomas."7.66Adjuvant chemotherapy with intraventricular methotrexate and CCNU after surgery and radiotherapy of medulloblastomas. ( Imbach, P; Seiler, RW; Vassella, F; Wagner, HP, 1978)
"Seventeen patients with recurrent medulloblastoma were treated with a combination of three drugs: procarbazine, CCNU, and vincristine (PCV)."7.66Chemotherapy of recurrent medulloblastoma with combined procarbazine, CCNU, and vincristine. ( Crafts, DC; Edwards, MS; Levin, VA; Pischer, TL; Wilson, CB, 1978)
"Axitinib is a small molecule tyrosine kinase inhibitor with high affinity and specificity for the family of vascular endothelial growth factor receptors."6.87Randomized phase II trial comparing axitinib with the combination of axitinib and lomustine in patients with recurrent glioblastoma. ( Andre, C; Bouttens, F; Chaskis, C; D'Haene, N; Du Four, S; Duerinck, J; Le Mercier, M; Michotte, A; Neyns, B; Rogiers, A; Salmon, I; Van Fraeyenhove, F; Verschaeve, V, 2018)
"Anaplastic oligodendroglioma are chemotherapy-sensitive tumors."6.78Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. ( Allgeier, A; Bernsen, HJ; Brandes, AA; Delattre, JY; Dinjens, WN; Enting, RH; Frenay, M; French, PJ; Gorlia, T; Grisold, W; Hoang-Xuan, K; Kouwenhoven, MC; Kros, JM; Lacombe, D; Sipos, L; Taphoorn, MJ; Tijssen, CC; van den Bent, MJ; Vecht, CJ, 2013)
"Intrinsic subtypes are highly prognostic in EORTC 26951 and improve outcome prediction when combined with other prognostic factors."6.78Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EORTC stu ( de Rooi, J; den Dunnen, WF; Eilers, PH; Erdem-Eraslan, L; French, PJ; Gorlia, T; Gravendeel, LA; Idbaih, A; Kros, JM; Sillevis Smitt, PA; Spliet, WG; Teepen, JL; van den Bent, MJ; Wesseling, P, 2013)
" The safety component reported here, which also investigated pharmacokinetics and preliminary clinical activity, required expansion and is therefore considered a phase I part to establish a recommended dosing regimen of the combination of CCNU (90-110 mg/m(2)) and dasatinib (100-200 mg daily)."6.77EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma. ( Allgeier, A; Brandes, AA; Franceschi, E; Gorlia, T; Hegi, M; Lacombe, D; Laigle Donadey, F; Lhermitte, B; Strauss, LC; Stupp, R; van den Bent, MJ; van Herpen, C, 2012)
"Anaplastic oligodendrogliomas are more responsive to chemotherapy than high-grade astrocytomas."6.72Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer p ( Allgeier, A; Bernsen, HJ; Brandes, AA; Carpentier, AF; Frenay, M; Gorlia, T; Grisold, W; Haaxma-Reiche, H; Kros, JM; Lacombe, D; Sanson, M; Sipos, L; Taphoorn, MJ; Tijssen, CC; van den Bent, MJ; van Kouwenhoven, MC; Vecht, CJ, 2006)
"Temozolomide was in general well tolerated; the most frequent side-effects were hematological."6.71Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. ( Baron, B; Boogerd, W; Bravo Marques, J; Chinot, O; De Beule, N; Kros, JM; Taphoorn, MJ; van den Bent, MJ; van der Rijt, CC; Vecht, CJ, 2003)
"Nine patients had brain metastases, and seven patients were systemically pretreated."6.68Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD) plus interferon alpha for metastatic melanoma: a multicentre phase II study. ( de Mulder, PH; Jansen, RL; Muller, EW; Punt, CJ; van Herpen, CM; Vreugdenhil, G, 1997)
"Glioblastomas are the most common malignant primary intrinsic brain tumors."6.66How did lomustine become standard of care in recurrent glioblastoma? ( Le Rhun, E; Weller, M, 2020)
" Here, we explored the incidence, and the consequences for treatment exposure and survival, of thrombocytopenia induced by lomustine in recurrent glioblastoma."5.69Thrombocytopenia limits the feasibility of salvage lomustine chemotherapy in recurrent glioblastoma: a secondary analysis of EORTC 26101. ( Brandes, AA; Clement, PM; Golfinopoulos, V; Gorlia, T; Idbaih, A; Le Rhun, E; Oppong, FB; Platten, M; Preusser, M; Taphoorn, MJ; van den Bent, M; Weller, M; Wick, W, 2023)
"In the randomized phase III trial CeTeG/NOA-09, temozolomide (TMZ)/lomustine (CCNU) combination therapy was superior to TMZ in newly diagnosed MGMT methylated glioblastoma, albeit reporting more frequent hematotoxicity."5.69Patterns, predictors and prognostic relevance of high-grade hematotoxicity after temozolomide or temozolomide-lomustine in the CeTeG/NOA-09 trial. ( Brehmer, S; Bullinger, L; Giordano, FA; Glas, M; Goldbrunner, R; Grauer, O; Hau, P; Herrlinger, U; Kowalski, T; Krex, D; Potthoff, AL; Ringel, F; Sabel, M; Schäfer, N; Schaub, C; Schmidt-Graf, F; Schneider, M; Schnell, O; Seidel, C; Steinbach, JP; Tabatabai, G; Tonn, JC; Tzaridis, T; Vajkoczy, P; Vatter, H; Weller, J; Zeiner, PS; Zeyen, T, 2023)
"The EORTC-26101 study was a randomized phase II and III clinical trial of bevacizumab in combination with lomustine versus lomustine alone in progressive glioblastoma."5.69Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial. ( Bendszus, M; Brandes, AA; Campone, M; Clement, PM; Doerner, L; Dômont, J; Hai, L; Idbaih, A; Ito, J; Kaulen, LD; Kessler, T; Platten, M; Sahm, F; Schrimpf, D; Taphoorn, M; van den Bent, M; von Deimling, A; Wick, A; Wick, W, 2023)
"NOA-18 aims at improving qualified overall survival (qOS) for adult patients with CNS WHO grade 2 and 3 oligodendrogliomas by randomizing between standard chemoradiation with up to six six-weekly cycles with PCV and six six-weekly cycles with lomustine and temozolomide (CETEG) (n = 182 patients per group accrued over 4 years) thereby delaying radiotherapy and adding the chemoradiotherapy concept at progression after initial radiation-free chemotherapy, allowing for effective salvage treatment and delaying potentially deleterious side effects."5.51Improvement of functional outcome for patients with newly diagnosed grade 2 or 3 gliomas with co-deletion of 1p/19q - IMPROVE CODEL: the NOA-18 trial. ( Baumann, L; Bendszus, M; Combs, S; Dormann, A; Haut, T; Kessler, T; Kieser, M; Koch, M; Limprecht, R; Merkle-Lock, J; Pertz, M; Platten, M; Sahm, F; Sander, A; Schlegel, U; Selkrig, N; Walter, S; Wick, A; Wick, W; Winkler, F, 2022)
"Intracranial gliomas are a common malignancy in dogs, and are associated with a poor prognosis due to their aggressive nature and a lack of clinically effective treatments."5.48Survival times in dogs with presumptive intracranial gliomas treated with oral lomustine: A comparative retrospective study (2008-2017). ( Cohen, PW; Dewey, CW; Moirano, SJ; Wright, KZ, 2018)
"Lomustine is a treatment option for patients with high-grade glioma."5.43Toca 511 plus 5-fluorocytosine in combination with lomustine shows chemotoxic and immunotherapeutic activity with no additive toxicity in rodent glioblastoma models. ( Gruber, HE; Huang, TT; Ibañez, CE; Jolly, DJ; Lopez Espinoza, F; Mendoza, D; Robbins, JM; Yagiz, K, 2016)
"Myoinositol (MI) is an organic osmolyte, with intracellular concentration changes depending on the extracellular osmolality."5.43Myoinositol as a Biomarker in Recurrent Glioblastoma Treated with Bevacizumab: A 1H-Magnetic Resonance Spectroscopy Study. ( Bähr, O; Hattingen, E; Pilatus, U; Ronellenfitsch, MW; Steidl, E; Steinbach, JP; Zanella, F, 2016)
" We investigated Depatux-M in combination with temozolomide or as a single agent in a randomized controlled phase II trial in recurrent EGFR amplified glioblastoma."5.34INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma. ( Ansell, P; Brilhante, J; Chinot, O; Clement, PM; Coens, C; De Vos, F; Dey, J; Dubbink, HJ; Eoli, M; Franceschi, E; French, P; Frenel, JS; Golfinopoulos, V; Gorlia, T; Krause, S; Looman, J; Nuyens, S; Sanghera, P; Sepulveda, JM; Smits, M; Spruyt, M; Van Den Bent, M; Walenkamp, A; Weller, M; Whenham, N, 2020)
"Despite somewhat prolonged progression-free survival, treatment with lomustine plus bevacizumab did not confer a survival advantage over treatment with lomustine alone in patients with progressive glioblastoma."5.24Lomustine and Bevacizumab in Progressive Glioblastoma. ( Bendszus, M; Brandes, AA; Bromberg, JC; Campone, M; Clement, PM; Domont, J; Dubois, F; Fabbro, M; Golfinopoulos, V; Gorlia, T; Harting, I; Idbaih, A; Klein, M; Le Rhun, E; Platten, M; Sahm, F; Stupp, R; Taal, W; Taphoorn, M; van den Bent, MJ; von Deimling, A; Weller, M; Wick, W, 2017)
"Adding temozolomide (TMZ) to radiation for patients with newly-diagnosed anaplastic astrocytomas (AAs) is common clinical practice despite the lack of prospective studies demonstrating a survival advantage."5.22The role of temozolomide in the management of patients with newly diagnosed anaplastic astrocytoma: a comparison of survival in the era prior to and following the availability of temozolomide. ( Abuali, I; Grossman, SA; Lu, Y; Strowd, RE; Ye, X, 2016)
"The combination of galunisertib, a transforming growth factor (TGF)-β receptor (R)1 kinase inhibitor, and lomustine was found to have antitumor activity in murine models of glioblastoma."5.22A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma. ( Brandes, AA; Capper, D; Carpentier, AF; Cher, L; Chinot, O; Cleverly, A; Desaiah, D; Guba, SC; Gueorguieva, I; Kesari, S; Lahn, MM; Miles, C; Rodon, J; Sepulveda-Sanchez, JM; Smith, C; Specenier, P; Steinbach, JP; Wheeler, HR; Wick, W, 2016)
"We conducted a randomized, non-comparative, multi center, phase II clinical trial in order to investigate the efficacy of axitinib, an oral small molecule tyrosine kinase inhibitor with high affinity and specificity for the vascular endothelial growth factor receptors, in patients with recurrent glioblastoma following prior treatment with radiation and temozolomide."5.22Randomized phase II study of axitinib versus physicians best alternative choice of therapy in patients with recurrent glioblastoma. ( Bouttens, F; D'Haene, N; Du Four, S; Duerinck, J; Everaert, H; Le Mercier, M; Michotte, A; Neyns, B; Salmon, I; Van Binst, AM; Vandervorst, F; Verschaeve, V, 2016)
"Following maximal surgical resection, newly diagnosed children with nonmetastatic high-grade glioma underwent involved field radiotherapy with concurrent temozolomide."5.22Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children's Oncology Group ACNS0423 study. ( Brat, DJ; Burger, PC; Buxton, A; Cohen, KJ; Eckel, SP; Hamilton, RL; Jakacki, RI; Krailo, MD; Lavey, RS; Pollack, IF; Rosenblum, MK; Zhou, T, 2016)
" This trial evaluated the efficacy of low dose bevacizumab in combination with lomustine (CCNU) compared to standard dose bevacizumab in patients with recurrent glioblastoma."5.22A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma. ( Colen, RR; Conrad, CA; de Groot, JF; Gilbert, MR; Han, X; Liu, DD; Loghin, ME; O'Brien, BJ; Penas-Prado, M; Puduvalli, VK; Tremont-Lukats, I; Weathers, SP; Yung, WKA, 2016)
"Patients with anaplastic oligodendrogliomas (n = 288) who were randomized (EORTC 26951) to radiotherapy (RT) alone or RT plus procarbazine, lomustine, and vincristine (PCV) chemotherapy were analyzed."5.20Joint modeling of longitudinal health-related quality of life data and survival. ( Bottomley, A; Coens, C; Dirven, L; Ediebah, DE; Galindo-Garre, F; Reijneveld, JC; Ringash, J; Taphoorn, MJ; Uitdehaag, BM; van den Bent, MJ; Zikos, E, 2015)
"The BELOB study, a randomised controlled phase 2 trial comparing lomustine, bevacizumab and combined lomustine and bevacizumab in patients with recurrent glioblastoma, showed that the 9-month overall survival rate was most promising in the combination arm."5.20The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: results of the randomised controlled phase 2 BELOB trial. ( Beerepoot, LV; Bottomley, A; Bromberg, JE; de Vos, FY; Dirven, L; Hanse, MC; Otten, A; Reijneveld, JC; Smits, M; Taal, W; Taphoorn, MJ; van den Bent, MJ; van der Holt, B; van der Meer, N; Vos, MJ; Walenkamp, AM, 2015)
"In this side study of the BELOB trial, 141 patients with recurrent glioblastoma were randomised to receive single-agent bevacizumab or lomustine, or bevacizumab plus lomustine."5.20Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial. ( Beerepoot, L; Beije, N; de Vos, FY; Gratama, JW; Hanse, M; Kraan, J; Oosterkamp, HM; Otten, A; Sleijfer, S; Taal, W; van den Bent, MJ; van der Holt, B; van Linde, ME; Vernhout, RM; Walenkamp, AM, 2015)
"The addition of PCV (procarbazine, lomustine, and vincristine) chemotherapy to radiotherapy (RT) for patients with WHO grade 2 glioma improves progression-free survival (PFS)."5.19Effect of the addition of chemotherapy to radiotherapy on cognitive function in patients with low-grade glioma: secondary analysis of RTOG 98-02. ( Barger, GR; Brachman, DG; Brown, PD; Buckner, JC; Gilbert, MR; Hu, C; Mehta, MP; Prabhu, RS; Shaw, EG; Stelzer, KJ; Won, M, 2014)
"The purpose of this prospective phase II/III trial was to study the effect of therapy intensification when combining procarbazine, lomustine, and vincristine (PCV) chemotherapy with a standard course of radiation therapy (RT) on cognitive functioning for patients with World Health Organization grade 2 low-grade gliomas (LGGs)."5.19Patients with primary brain tumors. ( Behrend, SW, 2014)
"We evaluated the prognostic and predictive value of a range of molecular changes in the setting of a randomised trial comparing standard PCV (procarbazine, CCNU (1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea) and vincristine) chemotherapy with the standard temozolomide (TMZ) 5-day (200 mg/m2/day) schedule and a 21-day (100 mg/m2/day) schedule in chemo-naïve, high-grade glioma (non-oligodendroglial tumours; WHO (World Health Organisation) grades III and IV) patients at first progression following radiotherapy."5.19Prognostic and predictive markers in recurrent high grade glioma; results from the BR12 randomised trial. ( Brada, M; Chan, R; Collins, VP; Di, Y; Gabe, R; Ichimura, K; Pearson, D; Stenning, SP; Thompson, LC, 2014)
" Adult patients (≥18 years of age) with a first recurrence of a glioblastoma after temozolomide chemoradiotherapy were randomly allocated by a web-based program to treatment with oral lomustine 110 mg/m(2) once every 6 weeks, intravenous bevacizumab 10 mg/kg once every 2 weeks, or combination treatment with lomustine 110 mg/m(2) every 6 weeks and bevacizumab 10 mg/kg every 2 weeks."5.19Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. ( Beerepoot, LV; Boerman, D; Brandsma, D; Bromberg, JE; Buter, J; de Vos, FY; Dinjens, WN; Dubbink, HJ; Enting, RH; Hanse, MC; Honkoop, AH; Jansen, RL; Oosterkamp, HM; Taal, W; Taphoorn, MJ; van den Bent, MJ; van den Berkmortel, FW; van der Holt, B; van Heuvel, I; Vernhout, RM; Walenkamp, AM, 2014)
"A randomized, phase III, placebo-controlled, partially blinded clinical trial (REGAL [Recent in in Glioblastoma Alone and With Lomustine]) was conducted to determine the efficacy of cediranib, an oral pan-vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor, either as monotherapy or in combination with lomustine versus lomustine in patients with recurrent glioblastoma."5.17Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. ( Ashby, LS; Batchelor, TT; Campone, M; Cher, L; Degroot, J; Gattamaneni, R; Jain, RK; Jürgensmeier, JM; Liu, Q; Mason, W; Mikkelsen, T; Mulholland, P; Nabors, LB; Neyns, B; Payer, F; Phuphanich, S; Rosenthal, M; Sorensen, AG; van den Bent, M; Wick, A; Xu, J, 2013)
"Thirteen patients with temozolomide-refractory anaplastic oligodendroglioma (11 patients) or oligoastrocytoma (2 patients) underwent blood-brain barrier disruption with carboplatin (IA, 200 mg/m(2)/d), etoposide phosphate (IV, 200 mg/m(2)/d), and melphalan (IA, dose escalation) every 4 weeks, for up to 1 year."5.14Intra-arterial chemotherapy with osmotic blood-brain barrier disruption for aggressive oligodendroglial tumors: results of a phase I study. ( Delashaw, JB; Doolittle, ND; Gahramanov, S; Guillaume, DJ; Hedrick, NA; Neuwelt, EA, 2010)
"This phase III open-label study compared the efficacy and safety of enzastaurin versus lomustine in patients with recurrent glioblastoma (WHO grade 4)."5.14Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. ( Carpentier, AF; Chamberlain, MC; Cher, LM; Fine, HA; Hong, S; Liepa, AM; Mason, W; Musib, L; Puduvalli, VK; Thornton, DE; van den Bent, MJ; Weller, M; Wick, W, 2010)
" We determined the effect of IDH1 mutations on progression-free survival and overall survival (OS), and its correlation with other clinical and molecular features in the prospective randomized European Organization for Research and Treatment of Cancer study 26951 on adjuvant procarbazine, 1-(2-chloroethyl)-3-cyclohexyl-l-nitrosourea, and vincristine (PCV) in anaplastic oligodendroglioma."5.14IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. ( Brandes, AA; Dinjens, WN; Dubbink, HJ; Frenay, M; Gorlia, T; Idbaih, A; Kros, JM; Lacombe, D; Marie, Y; Sanson, M; Taphoorn, MJ; Tijssen, CC; van den Bent, MJ; van Marion, R; Wesseling, P, 2010)
"A phase I trial was conducted to determine the maximum tolerated dose (MTD) of temozolomide given in combination with lomustine in newly diagnosed pediatric patients with high-grade gliomas."5.13A phase I trial of temozolomide and lomustine in newly diagnosed high-grade gliomas of childhood. ( Adamson, PC; Blaney, SM; Flom, L; Ingle, AM; Jakacki, RI; Pollack, IF; Prados, MD; Timmerman, R; Yates, A; Zhou, T, 2008)
"The authors administered procarbazine, 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU, lomustine), and vincristine (PCV) to 86 patients with recurrent glioblastoma."5.12PCV chemotherapy for recurrent glioblastoma. ( Dichgans, J; Dietz, K; Fischer, J; Herrlinger, U; Schmidt, F; Weller, M, 2006)
"We previously reported a phase 2 trial of 69 patients with newly diagnosed anaplastic or aggressive oligodendroglioma who were treated with intensive procarbazine, CCNU (lomustine), and vincristine (PCV) followed by high-dose thiotepa with autologous stem cell rescue."5.12High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: long-term follow-up. ( Abrey, LE; Bayer, R; Cairncross, JG; Childs, BH; DeAngelis, LM; Finlay, JL; Forsyth, P; Gardner, S; Hu, W; Kaminer, L; Macdonald, DR; Nimer, SD; Paleologos, N; Peterson, K; Ramsay, DA; Rosenfeld, S; Salzman, D; Smith, AM; Stewart, D; Swinnen, L; Weaver, S, 2006)
"Anaplastic oligodendroglioma (AO) and anaplastic oligoastrocytoma (AOA) are treated with surgery and radiotherapy (RT) at diagnosis, but they also respond to procarbazine, lomustine, and vincristine (PCV), raising the possibility that early chemotherapy will improve survival."5.12Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. ( Berkey, B; Brachman, D; Buckner, J; Cairncross, G; Curran, W; Fink, K; Jenkins, R; Laperierre, N; Mehta, M; Scheithauer, B; Shaw, E; Souhami, L, 2006)
"To evaluate toxicity and efficacy of the combination of lomustine, temozolomide (TMZ) and involved-field radiotherapy in patients with newly diagnosed glioblastoma (GBM)."5.12Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03. ( Bamberg, M; Blaschke, B; Herrlinger, U; Hundsberger, T; Koch, D; Kortmann, RD; Loeser, S; Meyermann, R; Reifenberger, G; Rieger, J; Sommer, C; Steinbach, JP; Tan, TC; Weller, M; Wick, W, 2006)
"Temozolomide is an alkylating agent with activity in the treatment of melanoma metastatic to the brain."5.12A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma. ( Bate, SC; Beirne, DA; Eisen, TG; Gibbens, IM; Gore, ME; Hughes, SA; Larkin, JM; Patel, PM; Thomas, K, 2007)
"Twenty-three patients with recurrent or progressive oligodendrogliomas or oligoastrocytomas after first-line PCV (procarbazine, lomustine, and vincristine) chemotherapy were enrolled in a single-institution Phase II study of second-line carboplatin chemotherapy."5.11Second-line treatment with carboplatin for recurrent or progressive oligodendroglial tumors after PCV (procarbazine, lomustine, and vincristine) chemotherapy: a phase II study. ( Borgognone, M; Costanza, A; Laguzzi, E; Mutani, R; Nobile, M; Rudà, R; Soffietti, R, 2004)
"The authors investigated the results of PCV chemotherapy within a cohort of 24 patients treated within the EORTC study 26971 on temozolomide chemotherapy in recurrent oligodendroglioma."5.11Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas. ( Allgeier, A; Brandes, AA; Enting, RH; Frenay, M; Kros, JM; Menten, J; Stege, EB; Taphoorn, MJ; Tosoni, A; Triebels, VH; van den Bent, MJ; van Heuvel, I, 2004)
"The aim of this study was to compare tolerance of a nitrosurea-based regime with 'standard' therapy of vincristine (VCR) and carboplatin for low-grade gliomas."5.10Tolerance of nitrosurea-based multiagent chemotherapy regime for low-grade pediatric gliomas. ( Hoddes, JA; Lancaster, DL; Michalski, A, 2003)
"To conduct a Phase II study to evaluate the long-term efficacy and safety of high-dose 5'-bromodeoxyuridine (BrdU) and accelerated radiotherapy followed by procarbazine, lomustine (CCNU), and vincristine (PCV) chemotherapy in patients with glioblastoma multiforme."5.09A phase II trial of high-dose bromodeoxyuridine with accelerated fractionation radiotherapy followed by procarbazine, lomustine, and vincristine for glioblastoma multiforme. ( Bruner, JM; Groves, MD; Hess, K; Jaeckle, KA; Kyritsis, AP; Levin, VA; Maor, MH; Meyers, C; Peterson, P; Sawaya, RE; Yung, WK, 1999)
" Here we report our experience with adjuvant postirradiation and preirradiation chemotherapy using procarbazine, lomustine, and vincristine (PCV) in 27 patients with WHO grade II or III oligodendroglioma or oligoastrocytoma."5.09A role for preirradiation PCV chemotherapy for oligodendroglial brain tumors. ( Bamberg, M; Dichgans, J; Grote, EH; Meyermann, R; Schabet, M; Streffer, J; Voigt, K; Weller, M, 2000)
"Although the efficacy of the nitrosourea-based combination chemotherapy procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, and vincristine (PCV) has been previously demonstrated in the setting of anaplastic/intermediate-grade gliomas, the benefit for glioblastoma patients remains unproven."5.09Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme. ( Bruner, JM; Chang, SM; Choucair, A; Flynn, PJ; Gleason, MJ; Hess, KR; Jaeckle, KA; Kyritsis, AP; Levin, VA; Prados, MD; Uhm, JH, 2000)
"To conduct a Phase II one-arm study to evaluate the long-term efficacy and safety of accelerated fractionated radiotherapy combined with intravenous carboplatin for patients with previously untreated glioblastoma multiforme tumors."5.08Phase II study of accelerated fractionation radiation therapy with carboplatin followed by vincristine chemotherapy for the treatment of glioblastoma multiforme. ( Bruner, J; Kyritsis, AP; Leeds, N; Levin, VA; Maor, MH; Rodriguez, L; Sawaya, R; Thall, PF; Woo, S; Yung, WK, 1995)
"There is no benefit to the treatment of high-grade astrocytomas in children with eight-drugs-in-1-day chemotherapy compared with CCNU, vincristine, and prednisone."5.08Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen. Childrens Cancer Group. ( Bertolone, SJ; Boyett, JM; Cherlow, JM; Finlay, JL; Geyer, JR; McGuire, P; Milstein, JM; Tefft, M; Wisoff, JH; Yates, AJ, 1995)
"A prospective phase II study of paclitaxel was performed in adult patients with recurrent hemispheric oligodendrogliomas."5.08Salvage chemotherapy with paclitaxel for recurrent oligodendrogliomas. ( Chamberlain, MC; Kormanik, PA, 1997)
"The regimen of procarbazine, CCNU, and vincristine is active against gliomas."5.08Dose-intensification of procarbazine, CCNU (lomustine), vincristine (PCV) with peripheral blood stem cell support in young patients with gliomas. ( Cornetta, K; Dropcho, E; Heilman, DK; Jakacki, RI; Jamison, C; Macdonald, DR; Mathews, VP; Williams, DA, 1998)
"To examine the rate and duration of response of anaplastic oligodendrogliomas to a dose-escalated combination chemotherapy regimen consisting of procarbazine, lomustine (CCNU), and vincristine (PCV) and to evaluate the side effects of this treatment."5.07Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. ( Buckner, J; Cairncross, G; Cascino, T; Dropcho, E; Fulton, D; Lee, D; Ludwin, S; Macdonald, D; Schold, C; Stewart, D, 1994)
"In a study activated in 1983 and closed in 1987, the Brain Tumor Research Center of the University of California and the Northern California Cancer Center evaluated the effect of bromodeoxyuridine in the treatment of glioblastoma multiforme."5.07Evaluation of bromodeoxyuridine in glioblastoma multiforme: a Northern California Cancer Center Phase II study. ( Ahn, DK; Davis, RL; Flam, MS; Gutin, PH; Levin, VA; Phillips, TL; Prados, MD; Wara, WM; Wilson, CB, 1991)
" The protocol called for a randomized trial that compared the effects of following 60 Gy radiation/oral hydroxyurea treatment with either carmustine (BCNU) or the combination of procarbazine, lomustine (CCNU), and vincristine (PCV) for two histologic strata: glioblastoma multiforme and other anaplastic gliomas."5.06Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. ( Davis, RL; Gutin, PH; Hannigan, J; Levin, VA; Silver, P; Wara, WM; Wilson, CB, 1990)
"The majority of patients with high-risk lower grade gliomas (LGG) are treated with single-agent temozolomide (TMZ) and radiotherapy despite three randomized trials showing a striking overall survival benefit with adjuvant procarbazine, lomustine, and vincristine (PCV) chemotherapy and radiotherapy."5.05Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV. ( Atkins, KM; Dietrich, J; Loeffler, JS; McDuff, SGR; Oh, KS; Shih, HA, 2020)
"The association of radiotherapy and procarbazine, lomustine (CCNU), vincristine chemotherapy in low-grade oligodendrogliomas is definitely superior over radiotherapy alone, and yields median progression-free survival and overall survival values exceeding by far 10 years."5.05Is chemotherapy alone an option as initial treatment for low-grade oligodendrogliomas? ( Rudà, R; Soffietti, R; Touat, M, 2020)
"Forty-three patients with inoperable and/or recurring malignant gliomas and 30 patients with multiple recurring brain metastases were treated with a combination of adriamycine (45 mg/m 2 and 4-dimethyl-epipodophyllotoxin D-thenylidene (VM 26) (60 mg/m 2 for 2 days) and 1-(2-chloroethyl)-3-cyclohexyl-1-nitroso-urea (CCNU) (60 mg/m 2 for 2 days)."5.04Treatment of malignant gliomas and brain metastases in adults using a combination of adriamycine, VM 26, and CCNU. Results of a type II trial. ( Gautier, H; Huguenin, P; Lheritier, J; Mathé, G; Morin, P; Palangie, T; Parrot, R; Poisson, M; Pouillart, P, 1977)
"Forty-three patients with inoperable and/or recurring malignant gliomas, and 30 patients with multiple recurring brain metastases were treated with a combination of adriamycine (45 mg/m2) and 4-dimethyl-epipodophyllotoxin D-thenylidene (VM 26) (60 mg/m2 for 2 days) with 1-(2-chloroethyl) -3-cyclohexyl-1-nitroso-urea (CCNU) (60 mg/m2 for two days)."5.04[Trial treatment of glioblastomas in adults and cerebral metastais by adriamycin, VM 26 and CCNU combination. Result of a type II trial]. ( Buge, A; Gautier, H; Huguenin, P; Lheritier, J; Mathé, G; Morin, P; Parrot, R; Poisson, M; Pouillart, P; Thy, HT, 1976)
"To assess the effectiveness and safety of procarbazine, lomustine, and vincristine (PCV) chemotherapy with other interventions in adults with recurrent high-grade glioma."4.95Procarbazine, lomustine and vincristine for recurrent high-grade glioma. ( Guo, J; Parasramka, S; Rosenfeld, M; Talari, G; Villano, JL, 2017)
"Anaplastic oligodendrogliomas (AOs) are rare brain tumors responsive to chemotherapy with procarbazine, lomustine (CCNU) and vincristine (PCV), especially when harboring 1p19q codeletion."4.91Procarbazine, lomustine and vincristine or temozolomide: which is the better regimen? ( Lassman, AB, 2015)
"The long-term follow-up of the RTOG 9802 trial that compared 54 Gy of radiotherapy (RT) with the same RT followed by adjuvant procarbazine, CCNU, and vincristine (PCV) chemotherapy in high-risk low-grade glioma shows a major increase in survival after adjuvant PCV chemotherapy."4.90Practice changing mature results of RTOG study 9802: another positive PCV trial makes adjuvant chemotherapy part of standard of care in low-grade glioma. ( van den Bent, MJ, 2014)
"The methylhydrazine derivative Procarbazine (PCZ) as monotherapy or in combination with CCNU and vincristine (PCV) was evaluated in a vast number of clinical trials and is still used in patients with high-grade and low-grade gliomas."4.84Procarbazine--a traditional drug in the treatment of malignant gliomas. ( Bogdahn, U; Goerne, R; Hau, P, 2008)
"We report two patients with acute myeloid leukemia (AML) following therapy for malignant glioma; one was a young women treated heavily with alkylating agents for glioblastoma and the other a young man treated with high doses of procarbazine, lomustine, and vincristine (PCV) for anaplastic astrocytoma."4.80Acute leukemia following treatment of malignant glioma. ( Brown, MT; Gockerman, JP; Perry, JR, 1998)
"We evaluated O-(2-[18F]fluoroethyl)-l-tyrosine (FET) PET and MRI for early response assessment in recurrent glioma patients treated with lomustine-based chemotherapy."4.31Prediction of response to lomustine-based chemotherapy in glioma patients at recurrence using MRI and FET PET. ( Bauer, EK; Ceccon, GS; Fink, GR; Galldiks, N; Goldbrunner, R; Kabbasch, C; Langen, KJ; Lohmann, P; Stoffels, G; Tscherpel, C; Werner, JM; Wollring, MM, 2023)
" TTFields therapy is approved for treatment of newly-diagnosed glioblastoma (GBM) concurrent with maintenance temozolomide (TMZ)."4.31Tumor Treating Fields (TTFields) increase the effectiveness of temozolomide and lomustine in glioblastoma cell lines. ( Dor-On, E; Fishman, H; Giladi, M; Haber, A; Kinzel, A; Monin, R; Palti, Y; Weinberg, U, 2023)
" Here we describe the occurrence of pseudoprogression in patients with anaplastic oligodendrogliomas treated with postoperative procarbazine, lomustine and vincristine (PCV) chemotherapy alone."4.31T2-Fluid-attenuated inversion recovery (FLAIR) pseudoprogression in patients with anaplastic oligodendrogliomas treated with procarbazine, lomustine and vincristine (PCV) chemotherapy alone. ( Boutet, C; Carpentier, C; Dehais, C; Di Stefano, AL; Ducray, F; Esparragosa Vazquez, I; Figarella-Branger, D; Forest, F; Larrieu-Ciron, D; Meyronet, D; Ndiaye, M; Picart, T; Rivoirard, R; Seyve, A; Vassal, F; Younan, N, 2023)
"In the randomized CeTeG/NOA-09 trial, lomustine/temozolomide (CCNU/TMZ) was superior to TMZ therapy regarding overall survival (OS) in MGMT promotor-methylated glioblastoma."4.31Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analyses. ( Duffy, C; Galldiks, N; Glas, M; Goldbrunner, R; Grauer, O; Hattingen, E; Hau, P; Herrlinger, U; Krex, D; Nitsch, L; Paech, D; Potthoff, AL; Radbruch, A; Schäfer, N; Schaub, C; Schlegel, U; Schneider, M; Seidel, C; Steinbach, JP; Stummer, W; Tabatabai, G; Tzaridis, T; Weller, J; Zeiner, PS; Zeyen, T, 2023)
"Glioblastomas (GBM) often acquire resistance against temozolomide (TMZ) after continuous treatment and recur as TMZ-resistant GBM (TMZ-R-GBM)."4.02Lomustine and nimustine exert efficient antitumor effects against glioblastoma models with acquired temozolomide resistance. ( Fujii, T; Ichimura, K; Kawauchi, D; Kobayashi, T; Kondo, A; Nakano, T; Narita, Y; Sasaki, N; Satomi, K; Takahashi, M; Tomiyama, A; Uchida, E; Wada, K; Yamamuro, S; Yoshino, A, 2021)
"IDH-mutant anaplastic astrocytomas (AAs) are chemosensitive tumors for which the best choice of adjuvant chemotherapy between procarbazine, lomustine, and vincristine (PCV) or temozolomide (TMZ) after radiotherapy (RT) remains unclear."4.02Radiotherapy Plus Procarbazine, Lomustine, and Vincristine Versus Radiotherapy Plus Temozolomide for IDH-Mutant Anaplastic Astrocytoma: A Retrospective Multicenter Analysis of the French POLA Cohort. ( Bronniman, C; Carpentier, C; Ciron, DL; Dehais, C; Ducray, F; Esteyrie, V; Figarella-Branger, D; Martin, E; Moyal, EC; Network, P; Pouessel, D; Uro-Coste, E, 2021)
"Following optimal local therapy, adjuvant Procarbazine, Lomustine and Vincristine (PCV) improves overall survival (OS) in low-grade glioma (LGG)."4.02One year of procarbazine lomustine and vincristine is poorly tolerated in low grade glioma: a real world experience in a national neuro-oncology centre. ( Aslam, R; Breathnach, OS; Coyne, Z; Grogan, L; Hennessy, BT; Hennessy, MA; Keogh, RJ; Morris, PG, 2021)
"Patients (n = 142) with molecularly defined oligodendroglioma (WHO 2016) were assigned to four cohorts: W&S, wait-and-scan after stereotactic biopsy (n = 59); RES, surgical resection only (n = 27); TMZ, temozolomide after biopsy (n = 26) or PCV (n = 30) after biopsy."4.02PCV chemotherapy alone for WHO grade 2 oligodendroglioma: prolonged disease control with low risk of malignant progression. ( Egensperger, R; Karschnia, P; Katzendobler, S; Lietke, S; Suchorska, B; Thon, N; Tonn, JC; Weller, J; Weller, M, 2021)
"In the EF-14 trial for newly diagnosed glioblastoma (ndGBM) patients addition of Tumour Treating Fields (TTFields) to temozolomide treatment resulted in a significantly improved overall survival (OS)."3.96Tumour Treating Fields (TTFields) in combination with lomustine and temozolomide in patients with newly diagnosed glioblastoma. ( Blau, T; Deuschl, C; Glas, M; Herrlinger, U; Kebir, S; Keyvani, K; Kleinschnitz, C; Lazaridis, L; Oster, C; Pierscianek, D; Schäfer, N; Scheffler, B; Schmidt, T; Stuschke, M; Sure, U; Teuber-Hanselmann, S; Tzaridis, T; Weller, J, 2020)
"Systematic evaluation of the effectiveness and safety of combined procarbazine, lomustine, and vincristine for treating recurrent high-grade glioma."3.96A comparative study of the effectiveness and safety of combined procarbazine, lomustine, and vincristine as a therapeutic method for recurrent high-grade glioma: A protocol for systematic review and meta-analysis. ( Cai, Y; Jiang, YG; Jiang, ZH; Tan, ZG; Wang, M, 2020)
"Imaging necrosis on MRI scans was assessed and compared to outcome measures of the European Organisation for Research and Treatment of Cancer 26101 phase III trial that compared single-agent lomustine with lomustine plus bevacizumab in patients with progressive glioblastoma."3.91Imaging necrosis during treatment is associated with worse survival in EORTC 26101 study. ( Bendszus, M; Brandes, AA; Bromberg, JEC; Campone, M; Clement, PM; Domont, J; Fabbro, M; Golfinopoulos, V; Gorlia, T; Harting, I; Idbaih, A; Kickingereder, P; Le Rhun, E; Nowosielski, M; Platten, M; Sahm, F; Taal, W; Taphoorn, MJB; van den Bent, MJ; Weller, M; Wick, W, 2019)
"Radiotherapy with procarbazine, lomustine, and vincristine (PCV) improves overall survival in patients with anaplastic oligodendroglioma 1p19q codeleted."3.88Radiotherapy plus temozolomide or PCV in patients with anaplastic oligodendroglioma 1p19q codeleted. ( Castro-Martinez, E; Gonzalez-Aguilar, A; Guerrero-Juarez, V; Gutierrez-Aceves, A; Hernandez-Hernandez, A; Lopez-Martinez, M; Peiro-Osuna, RP; Reyes-Moreno, I; Santos-Zambrano, J, 2018)
"The addition of procarbazine, lomustine, vincristine (PCV) chemotherapy to radiotherapy (RT) for patients with high-risk (≥40 y old or subtotally resected) low-grade glioma (LGG) results in an absolute median survival benefit of over 5 years."3.85Cost-effectiveness of radiation and chemotherapy for high-risk low-grade glioma. ( Bendavid, E; Chang, DT; Chin, AL; Durkee, BY; Harris, JP; Kim, H; Kumar, KA; Maruyama, S; Owens, DK; Pitt, A; Pollom, EL; Qian, Y; Soltys, SG, 2017)
"Taken together, these data suggest a potential role for a combination therapy of lomustine and DHA for the treatment of glioblastomas."3.81Enhanced anticancer properties of lomustine in conjunction with docosahexaenoic acid in glioblastoma cell lines. ( Cohen-Gadol, AA; Harvey, KA; Pollok, K; Saaddatzadeh, MR; Siddiqui, RA; Wang, H; Xu, Z, 2015)
"While procarbazine with 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (PC) added to vincristine (PCV) was proven beneficial in the treatment of co-deleted anaplastic oligodendroglioma (AO), the question of whether PC alone is sufficient is important, as vincristine adds toxicity with uncertain benefit."3.81PC or PCV, That Is the Question: Primary Anaplastic Oligodendroglial Tumors Treated with Procarbazine and CCNU With and Without Vincristine. ( De Groot, J; Liu, D; Shonka, N; Smith, L; Webre, C, 2015)
"We previously developed a mathematical model capturing tumor size dynamics of adult low-grade gliomas (LGGs) before and after treatment either with PCV (Procarbazine, CCNU, and Vincristine) chemotherapy alone or with radiotherapy (RT) alone."3.81Increasing the Time Interval between PCV Chemotherapy Cycles as a Strategy to Improve Duration of Response in Low-Grade Gliomas: Results from a Model-Based Clinical Trial Simulation. ( Ducray, F; Honnorat, J; Mazzocco, P; Ribba, B, 2015)
"In this retrospective study, we identified adult patients with histologically confirmed glioblastoma (WHO grade IV) who were treated with lomustine or carmustine in combination with bevacizumab as a second or third regimen after failing an alternative initial bevacizumab-containing regimen."3.80Retrospective study of carmustine or lomustine with bevacizumab in recurrent glioblastoma patients who have failed prior bevacizumab. ( Alexander, BM; Beroukhim, R; Doherty, L; Hempfling, K; Huang, RY; LaFrankie, D; Lee, EQ; Nayak, L; Norden, AD; Rahman, R; Rai, A; Reardon, DA; Rifenburg, J; Rinne, ML; Ruland, S; Wen, PY, 2014)
" This has changed with the long-term follow-up analysis of the EORTC and RTOG trials on procarbazine, lomustine, and vincristine (PCV) chemotherapy in anaplastic oligodendroglioma."3.79How to use molecular markers when caring for a patient with brain cancer: 1P/19Q as a predictive and prognostic marker in the neuro-oncology clinic. ( van den Bent, MJ, 2013)
" The validated method has been successfully applied to a pharmacokinetic study of thermosensitive liposome-encapsulated lomustine containing iohexol and lomustine solution after intravenous administration to C6 glioma rats."3.77HPLC method validation for the quantification of lomustine to study pharmacokinetics of thermosensitive liposome-encapsulated lomustine containing iohexol for CT imaging in C6 glioma rats. ( Derendorf, H; Gao, J; Li, M; Liu, C; Yu, F; Zeng, Y; Zhang, B; Zhuang, L, 2011)
" Among these tumors, a high percentage of low-grade oligodendrogliomas (ODG) are sensitive to chemotherapy with procarbazine, CCNU, and vincristine (PCV)."3.73Semi-quantification of methionine uptake and flair signal for the evaluation of chemotherapy in low-grade oligodendroglioma. ( Branle, F; De Witte, O; Goldman, S; Sadeghi, N; Tang, BN; Wikler, D, 2005)
"We have reported that carmustine (BCNU) and cisplatin administered before, during, and after radiotherapy did not improve the survival of patients with high-grade astrocytomas and were associated with more serious toxicities than radiotherapy plus BCNU."3.73Combination chemotherapy with carmustine and cisplatin followed by procarbazine, lomustine, and vincristine for adult high-grade astrocytoma. ( Jung, SM; Liau, CT; Tseng, CK; Wei, KC, 2005)
"Accidentally, we observed a complete response (CR) in a patient undergoing chemotherapy with bleomycin, vincristine or Oncovin, CCNU or lomustine, dacarbazine (BOLD) regimen for metastatic melanoma including brain metastases, who was also treated with G-CSF to manage a concomitant leukopenia."3.73Complete remission of brain metastases in three patients with stage IV melanoma treated with BOLD and G-CSF. ( Bonaccorsi, P; Borroni, RG; Bottoni, U; Calvieri, S; Clerico, R; Devirgiliis, V; Panasiti, V; Trasimeni, G, 2005)
"To re-evaluate the cost effectiveness and median overall survival (OS) achieved in patients with recurrent malignant gliomas treated with temozolomide in British Columbia, as compared to previous lomustine use in the same patient population based on updated outcomes data."3.73Re-evaluation of the cost effectiveness of temozolomide for malignant gliomas in British Columbia. ( Mabasa, VH; Taylor, SC, 2006)
"We report the long-term follow-up, 71 months, of seven patients treated by procarbazine, lomustine and vincristine (PCV) therapy for a symptomatic low-grade oligodendrogliomatous tumor."3.73[Long-term outcome in patients with symptomatic low-grade oligodendrogliomatous tumors treated by cytotoxic agents]. ( Cartalat-Carel, S; Catenoix, H; Chapuis, F; Honnorat, J; Nighoghossian, N; Trouillas, P, 2006)
"We collected 6 case-reports of symptomatric non removable low grade fibrillary astrocytoma of adults treated with a procarbazine-CCNU-vincristine chemotherapy regimen."3.72[Neoadjuvant chemotherapy for symptomatic non operable grade II fibrillary astrocytoma in adults]. ( Alchaar, H; Bleuse, A; Bondiau, PY; Bourg, V; Brunetto, JL; Chanalet, S; Chatel, M; Courdi, A; Darcourt, J; Fauchon, F; Fontaine, D; Frénay, M; Grellier, P; Guibert, F; Lanteri-Minet, M; Lebrun, C; Lonjon, M; Michiels, JF; Paquis, P; Paquis, V; Ramaioli, A; Rasendrarijao, D; Vandenbos, F, 2004)
" In glioblastomas (histological grade 4, n = 257) the same chemotherapy was evaluated versus two cycles 4 weeks apart of 160 mg lomustine (CCNU) orally instead of BCNU, combined with vincristine and procarbazine (PCV) versus no chemotherapy."3.70A retrospective study of the value of chemotherapy as adjuvant therapy to surgery and radiotherapy in grade 3 and 4 gliomas. ( Gundersen, S; Lote, K; Watne, K, 1998)
"The aim of this study was to evaluate the toxicity, response, and survival of patients with relapsed high-grade gliomas after radiation therapy (RT) combined with lomustine (CCNU)."3.70Reirradiation and lomustine in patients with relapsed high-grade gliomas. ( Arcicasa, M; Bidoli, E; Dedkov, A; Gigante, M; Roncadin, M; Trovò, MG, 1999)
"The authors reviewed the results of neoadjuvant (preradiation) procarbazine, CCNU, and vincristine chemotherapy for anaplastic oligodendrogliomas because, increasingly, chemotherapy is prescribed before radiation for oligodendroglial neoplasms."3.70Neoadjuvant procarbazine, CCNU, and vincristine for anaplastic and aggressive oligodendroglioma. ( Cairncross, JG; Macdonald, DR; Paleologos, NA; Vick, NA, 1999)
"We treated 54 patients, newly diagnosed for glioblastoma, with systemic chemotherapy (carmustine (BCNU) 100 mg/m2 and cisplatin 90 mg/m2 every 6 weeks) and radiotherapy soon after surgery."3.70Locally delivered chemotherapy and repeated surgery can improve survival in glioblastoma patients. ( Boiardi, A; Broggi, G; Eoli, M; Pozzi, A; Salmaggi, A; Silvani, A, 1999)
"Carmustine and lomustine are nitrosourea antitumor chemotherapeutic agents which were used to determine whether or not they could affect arylamine N-acetyltransferase (NAT) activity and DNA-2-aminofluorene adducts in rat glial tumor cell line (C6 glioma)."3.70Effects of carmustine and lomustine on arylamine N-acetyltransferase activity and 2-aminofluorene-DNA adducts in rat glial tumor cells. ( Hung, CF, 2000)
"The aim of this study was to examine the range of sensitivity of a panel of short-term cultures derived from different types of malignant childhood brain tumours including medulloblastoma, ependymoma and glioblastoma multiforme to three cytotoxic drugs, lomustine (CCNU), vincristine (VCR) and procarbazine (PCB)."3.70Chemosensitivity in childhood brain tumours in vitro: evidence of differential sensitivity to lomustine (CCNU) and vincristine. ( Darling, JL; Harding, B; Harkness, W; Hayward, R; Lewandowicz, GM; Thomas, DG, 2000)
"To report a lomustine overdose in a patient with anaplastic astrocytoma."3.69Multiorgan failure associated with lomustine overdose. ( Moreb, J; Myers, L; Trent, KC, 1995)
"We report a patient who developed aplastic anemia after three courses of cyclohexylchloroethylnitrousurea (CCNU), procarbazine and oncovine administered after craniotomy and irradiation for brain astrocytoma."3.69Aplastic anemia induced by cyclohexylchloroethylnitrousurea. ( Elis, A; Lishner, M; Ravid, M; Savin, H, 1994)
"We administered chemotherapy in standard and intensified formulations of procarbazine, lomustine (CCNU), and vincristine to nine symptomatic patients with low-grade oligodendroglioma."3.69Low-grade oligodendroglioma responds to chemotherapy. ( DeAngelis, LM; Krol, GS; Mason, WP, 1996)
"Our results indicate that chemotherapy with a combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea is active for patients with recurrent anaplastic gliomas and glioblastomas not previously treated with nitrosourea-based chemotherapy but is inactive for patients with glioblastomas previously treated with chemotherapy."3.69Combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas. ( Bruner, J; Flowers, A; Gleason, MJ; Ictech, SE; Jaeckle, KA; Kyritsis, AP; Levin, VA; Yung, WK, 1996)
"Effective chemotherapy using PCV (procarbazine, lomustine and vincristine) has been documented in anaplastic oligodendrogliomas and oligoastrocytomas."3.69[Assessment of procarbazine, vincristine and lomustine association (PCV protocol) in oligodendroglioma and mixed glioma]. ( Bouffet, E; Bret, P; Helfre, S; Jouvet, A; Mertens, P; Mornex, F; Sindou, M; Thiesse, P, 1997)
"Twenty-eight evaluable children with the diagnosis of brain stem glioma were treated with 5-fluorouracil and CCNU before posterior fossa irradiation (5500 rads); during irradiation, the children received hydroxyurea and misonidazole."3.675-Fluorouracil and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) followed by hydroxyurea, misonidazole, and irradiation for brain stem gliomas: a pilot study of the Brain Tumor Research Center and the Childrens Cancer Group. ( Allen, J; Edwards, MS; Levin, VA; Ortega, J; Vestnys, P; Wara, WM, 1984)
"Twenty-one patients with recurrent malignant central nervous system gliomas were treated with a combination of 5-fluorouracil, CCNU, hydroxyurea, and 6-mercaptopurine."3.67Treatment of recurrent brain stem gliomas and other central nervous system tumors with 5-fluorouracil, CCNU, hydroxyurea, and 6-mercaptopurine. ( Edwards, MS; Fulton, D; Levin, V; Prados, M; Rodriguez, LA; Silver, P, 1988)
"Fourteen consecutive melanoma patients with evaluable metastatic disease were treated with combination chemotherapy including procarbazine, vincristine and lomustine (POC)."3.67Metastatic malignant melanoma treated with procarbazine, vincristine and lomustine (POC). ( Ardizzoni, A; Grimaldi, A; Repetto, L; Rosso, R; Sertoli, MR, 1987)
"One hundred and seventeen patients with cerebral glioma (Kernohan grades III and IV) were treated with adjuvant chemotherapy using procarbazine (PCB), CCNU and vincristine (VCR) following whole head irradiation."3.67Assay of anti-cancer drugs in tissue culture: relationship of relapse free interval (RFI) and in vitro chemosensitivity in patients with malignant cerebral glioma. ( Bozek, T; Capra, LG; Collins, CD; Darling, JL; Godlee, JN; Mooney, C; Mott, TJ; Paul, EA; Thomas, DG; Tobias, JS, 1985)
"A patient is presented who developed nephrotoxicity after therapy with lomustine (CCNU) for astrocytoma of the brain."3.67Nephrotoxicity of lomustine. A case report and literature review. ( Ellis, ME; Kuperminc, M; Weiss, RB, 1985)
"Twenty consecutive patients with supratentorial Grade III and IV astrocytomas were treated with postoperative radiotherapy, and a simultaneous induction chemotherapy with 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU), procarbazine, bleomycin, and maintenance chemotherapy with CCNU."3.66Radiotherapy combined with procarbazine, bleomycin, and CCNU in the treatment of high-grade supratentorial astrocytomas. ( Greiner, RH; Markwalder, H; Seiler, RW; Zimmerman, A, 1978)
"A patient with a mixed malignant glioma metastatic to the bones and lungs failed to respond to two different broad-spectrum combination chemotherapy regimens which included Adriamycin, methotrexate, cyclophosphamide, CCNU and cis-dichlorodiammineplatinum(II)."3.66Combination chemotherapy for extracranial metastases of a primary malignant cerebral neoplasm. ( Oster, MW, 1979)
"Seven patients were treated with a combination of intraventricular methotrexate (MTX) and oral CCNU after resection and whole CNS irradiation of medulloblastomas."3.66Adjuvant chemotherapy with intraventricular methotrexate and CCNU after surgery and radiotherapy of medulloblastomas. ( Imbach, P; Seiler, RW; Vassella, F; Wagner, HP, 1978)
"Seventeen patients with recurrent medulloblastoma were treated with a combination of three drugs: procarbazine, CCNU, and vincristine (PCV)."3.66Chemotherapy of recurrent medulloblastoma with combined procarbazine, CCNU, and vincristine. ( Crafts, DC; Edwards, MS; Levin, VA; Pischer, TL; Wilson, CB, 1978)
"Forty-three patients with inoperable or recurring malignant gliomas, and 30 patients with multiple recurring brain metastases were treated with a combination of Adriamycin (45 mg/m2) and 4-dimethyl-epipodophyllotoxin D-thenylidene (VM 26) (60 mg/m2 for 2 days) with 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) (60 mg/m2 for 2 days)."3.65Treatment of malignant gliomas and brain metastases in adults with a combination of adriamycin, VM 26, and CCNU. Results of a phase II trail. ( Gauthier, H; Huguenin, P; Lheritier, J; Mathe, G; Morin, P; Parrot, R; Poisson, M; Pouillart, P; Thy, TH, 1976)
"Axitinib is a small molecule tyrosine kinase inhibitor with high affinity and specificity for the family of vascular endothelial growth factor receptors."2.87Randomized phase II trial comparing axitinib with the combination of axitinib and lomustine in patients with recurrent glioblastoma. ( Andre, C; Bouttens, F; Chaskis, C; D'Haene, N; Du Four, S; Duerinck, J; Le Mercier, M; Michotte, A; Neyns, B; Rogiers, A; Salmon, I; Van Fraeyenhove, F; Verschaeve, V, 2018)
"The prognosis of patients with anaplastic oligodendrogliomas (AOD) and oligoastrocytomas (AOA) is variable."2.78New clinical, pathological and molecular prognostic models and calculators in patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European Organisation for Research and Treatment of Cancer Brai ( Bernsen, HJ; Brandes, AA; Delattre, JY; Frénay, M; Gorlia, T; Kouwenhoven, MC; Kros, JM; Lacombe, D; Taphoorn, MJ; Tijssen, CC; van den Bent, MJ, 2013)
"Anaplastic oligodendroglioma are chemotherapy-sensitive tumors."2.78Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. ( Allgeier, A; Bernsen, HJ; Brandes, AA; Delattre, JY; Dinjens, WN; Enting, RH; Frenay, M; French, PJ; Gorlia, T; Grisold, W; Hoang-Xuan, K; Kouwenhoven, MC; Kros, JM; Lacombe, D; Sipos, L; Taphoorn, MJ; Tijssen, CC; van den Bent, MJ; Vecht, CJ, 2013)
"Intrinsic subtypes are highly prognostic in EORTC 26951 and improve outcome prediction when combined with other prognostic factors."2.78Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EORTC stu ( de Rooi, J; den Dunnen, WF; Eilers, PH; Erdem-Eraslan, L; French, PJ; Gorlia, T; Gravendeel, LA; Idbaih, A; Kros, JM; Sillevis Smitt, PA; Spliet, WG; Teepen, JL; van den Bent, MJ; Wesseling, P, 2013)
" The safety component reported here, which also investigated pharmacokinetics and preliminary clinical activity, required expansion and is therefore considered a phase I part to establish a recommended dosing regimen of the combination of CCNU (90-110 mg/m(2)) and dasatinib (100-200 mg daily)."2.77EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma. ( Allgeier, A; Brandes, AA; Franceschi, E; Gorlia, T; Hegi, M; Lacombe, D; Laigle Donadey, F; Lhermitte, B; Strauss, LC; Stupp, R; van den Bent, MJ; van Herpen, C, 2012)
"RT alone for anaplastic oligodendroglioma."2.75Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for pure and mixed anaplastic oligodendrogliomas: radiation therapy oncology group trial 9402. ( Brachman, D; Buckner, J; Cairncross, G; Curran, W; Fink, K; Jenkins, R; Laperriere, N; Mehta, M; Scheithauer, B; Shaw, E; Souhami, L; Wang, M, 2010)
"AOA tumors with necrosis are to be considered WHO grade IV tumors (GBM)."2.74Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951. ( Allgeier, A; Brandes, AA; Bromberg, JE; Gorlia, T; Grisold, W; Ibdaih, A; Kouwenhoven, MC; Kros, JM; Lacombe, D; Mirimanoff, R; Mokhtari, K; Sipos, L; Teepen, JL; van den Bent, MJ; van Duinen, SG; Vandenbos, F; Vecht, CJ; Wesseling, P, 2009)
"Based on studies relating to anaplastic oligodendroglioma (OG) chemosensitivity and benefit of time to progression or overall survival, chemotherapy for pure OG has been proposed."2.73Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas with PCV chemotherapy. ( Bourg, V; Chanalet, S; Fauchon, F; Fontaine, D; Frenay, M; Lebrun, C; Lonjon, M; Paquis, P; Ramaioli, A; Vandenbos, F, 2007)
"Adult patients with anaplastic oligodendrogliomas received RT alone or RT plus PCV chemotherapy."2.73Health-related quality of life in patients treated for anaplastic oligodendroglioma with adjuvant chemotherapy: results of a European Organisation for Research and Treatment of Cancer randomized clinical trial. ( Allgeier, A; Bernsen, HJ; Bottomley, A; Brandes, AA; Coens, C; Delattre, JY; Frénay, M; Lacombe, D; Mauer, ME; Sillevis Smitt, PA; Taphoorn, MJ; Tijssen, CC; van den Bent, MJ, 2007)
"Anaplastic oligodendrogliomas are more responsive to chemotherapy than high-grade astrocytomas."2.72Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer p ( Allgeier, A; Bernsen, HJ; Brandes, AA; Carpentier, AF; Frenay, M; Gorlia, T; Grisold, W; Haaxma-Reiche, H; Kros, JM; Lacombe, D; Sanson, M; Sipos, L; Taphoorn, MJ; Tijssen, CC; van den Bent, MJ; van Kouwenhoven, MC; Vecht, CJ, 2006)
"Temozolomide was in general well tolerated; the most frequent side-effects were hematological."2.71Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. ( Baron, B; Boogerd, W; Bravo Marques, J; Chinot, O; De Beule, N; Kros, JM; Taphoorn, MJ; van den Bent, MJ; van der Rijt, CC; Vecht, CJ, 2003)
"Anaplastic oligodendroglioma is a chemosensitive glial neoplasm."2.71High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma. ( Abrey, LE; Bayer, R; Cairncross, JG; Childs, BH; DeAngelis, LM; Finlay, JL; Forsyth, P; Gardner, S; Hu, W; Kaminer, L; Macdonald, DR; Nimer, SD; Paleologos, N; Peterson, K; Ramsey, DA; Rosenfeld, S; Salzman, D; Smith, AM; Stewart, D; Swinnen, L; Weaver, S, 2003)
"Because of the diffuse nature of gliomatosis cerebri (GC), surgery is not suitable, and large field radiotherapy carries the risk of severe toxicity."2.71Initial chemotherapy in gliomatosis cerebri. ( Carpentier, A; Cartalat-Carel, S; Chinot, O; Cougnard, J; Delattre, JY; Djafari, L; Duffau, H; Gervais, H; Hoang-Xuan, K; Honnorat, J; Laigle, F; Mokhtari, K; Napolitano, M; Sanson, M; Taillandier, L; Taillibert, S, 2004)
"Histologically, 69 had anaplastic astrocytoma; 14, anaplastic oligoastrocytoma; and 7, anaplastic oligodendroglioma."2.70Phase II study of accelerated fractionation radiation therapy with carboplatin followed by PCV chemotherapy for the treatment of anaplastic gliomas. ( Bruner, J; Chang, E; Gleason, MJ; Hess, KR; Ictech, SA; Kyritsis, A; Leeds, N; Levin, VA; Maor, MH; Meyers, CA; Yung, WK, 2002)
"Estimated 4-year survival for the anaplastic astrocytoma (AA) stratum (n = 116) is 46%."2.68Radiation therapy and bromodeoxyuridine chemotherapy followed by procarbazine, lomustine, and vincristine for the treatment of anaplastic gliomas. ( Davis, RL; Gutin, PH; Lamborn, K; Levin, VA; Phillips, TL; Prados, MR; Wara, WM; Wilson, CB, 1995)
"Nine patients had brain metastases, and seven patients were systemically pretreated."2.68Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD) plus interferon alpha for metastatic melanoma: a multicentre phase II study. ( de Mulder, PH; Jansen, RL; Muller, EW; Punt, CJ; van Herpen, CM; Vreugdenhil, G, 1997)
"Those treated for glioblastoma multiforme had a mean Karnofsky Performance Score of 86% (range 60-100%) at 1 month and 75% (range 60-100%) at 24 months."2.67External irradiation followed by an interstitial high activity iodine-125 implant "boost" in the initial treatment of malignant gliomas: NCOG study 6G-82-2. ( Gutin, PH; Larson, DA; Leibel, SA; Levin, VA; Phillips, TL; Prados, MD; Silver, P; Sneed, PK; Wara, WM; Weaver, KA, 1991)
" Nevertheless, regimen B resulted in significantly more leukopenic patients, septicemic episodes, and blood transfusions, and the dosage of etoposide was more often reduced in arm B than in arm A."2.67Combination chemotherapy of limited-stage small-cell lung cancer. A controlled trial on 221 patients comparing two alternating regimens. ( Dombernowsky, P; Hansen, HH; Hansen, M; Hirsch, FR; Osterlind, K; Pedersen, AG; Sörenson, S, 1991)
"Glioblastomas are the most common malignant primary intrinsic brain tumors."2.66How did lomustine become standard of care in recurrent glioblastoma? ( Le Rhun, E; Weller, M, 2020)
" Nor did the analysis of life quality and of changes in clinical performance show any benefit in supplementing surgery and radiation therapy with CCNU chemotherapy at the dosage used."2.66Quality of survival of patients with brain gliomas treated with postoperative CCNU and radiation therapy. ( Bendarzewska, B; Bielawski, A; Dabrowska, A; Gościński, I; Lopatkiewicz, J; Markiewicz, P; Peszyński, J; Szymona, J; Trojanowski, T; Turowski, K, 1989)
"Misonidazole 1."2.66Combined modality treatment of operated astrocytomas grade 3 and 4. A prospective and randomized study of misonidazole and radiotherapy with two different radiation schedules and subsequent CCNU chemotherapy. Stage II of a prospective multicenter trial of ( Ganz, JC; Hagen, S; Hatlevoll, R; Kristiansen, K; Lindegaard, KF; Mella, O; Nesbakken, R; Ringkjöb, R; Rosengren, B; Torvik, A, 1985)
"Thirty-one patients with metastatic brain tumors were treated with Radiotherapy (RT) and CCNU or with RT, CCNU and Levamisole (LMS) in a randomized clinical trial."2.65Radio-chemo-immunotherapy (CCNU plus levamisole) for treatment of metastatic brain tumors. A pilot study. ( Knerich, R; Paoletti, P; Pavesi, L; Preti, P; Robustelli della Cuna, G, 1984)
" On the other side, dosage and the interval between cycles of chemotherapy appear to be a determining factor in the activity, but the limits are very narrow."2.64[A study of the use of sequential chemotherapy in 176 cases of glioblastoma (author's transl)]. ( Buge, A; Poisson, M; Pouillart, P, 1978)
"Brain metastasis occurred in 0/14 patients in the PCI and 4/15 in the non-PCI (P less than or equal to ."2.64Prophylactic cranial irradiation in small cell carcinoma of the lung. A randomized study. ( Cooper, MR; Ferree, C; Jackson, DV; Muss, HB; Richards, F; Spurr, CL; White, DR, 1977)
"Glioblastomas are rich in blood vessels (i."2.58Anti-angiogenic therapy for high-grade glioma. ( Ameratunga, M; Grant, R; Khasraw, M; Pavlakis, N; Simes, J; Wheeler, H, 2018)
"Gliomas are the most frequent primary brain tumors."2.50[Management of gliomas]. ( Chapet, S; Lévy, S; Mazeron, JJ, 2014)
" Alternative dosing regimens, such as 1-week on/1-week off, or 3-week on/1-week off, that deliver more prolonged exposure have been observed to result in higher cumulative doses than the standard 5-day regimen and may deplete tumor-derived O6-methylguanine-DNA methyltransferase (MGMT) in tumor cells, thus sensitizing tumor cells to the effects of TMZ."2.45[Treatment of glioma with temozolomide]. ( Nishikawa, R, 2009)
"The incidence of oligodendroglioma is increasing, most likely due to its improved recognition."2.42Oligodendroglioma and anaplastic oligodendroglioma: clinical features, treatment, and prognosis. ( Engelhard, HH; Mundt, A; Stelea, A, 2003)
"Procarbazine was stopped after 2 cycles because of the development of a rash."2.42The role of PCV chemotherapy in the treatment of central neurocytoma: illustration of a case and review of the literature. ( Berger, MS; Chang, SM; Schmidt, MH; Uyehara-Lock, JH; von Koch, CS, 2003)
"Because oligodendroglioma are infiltrative tumors, the Mac Donald's response criteria, usually used for solid and contrast-enhanced tumors, seem not to be adapted."2.41PCV chemotherapy for oligodendroglioma: response analyzed on T2 weighted-MRI. ( Diabira, S; Gamelin, E; Jadaud, E; Menei, P; Rousselet, MC; Soulier, P, 2001)
" Since no epidemiological data in man are available, extrapolation of animal data to man are important as well as dose-response studies in risk evaluations."2.37Carcinogenic N-nitroso compounds and their environmental significance. ( Preussmann, R, 1984)
"Temozolomide-based treatment was administered to 64 of 68 (94."1.72Early Postoperative Treatment versus Initial Observation in CNS WHO Grade 2 and 3 Oligodendroglioma: Clinical Outcomes and DNA Methylation Patterns. ( Aichholzer, M; Berghoff, AS; Dieckmann, K; Furtner, J; Goldberger, S; Hatziioannou, T; Heller, G; Leibetseder, A; Mair, MJ; Pichler, J; Preusser, M; Puhr, R; Tomasich, E; von Oertzen, T; Weis, S; Widhalm, G; Wöhrer, A, 2022)
"Glioblastoma is a malignant primary brain tumor that affects approximately 250,000 new patients per year worldwide."1.72Current therapeutic options for glioblastoma and future perspectives. ( Aquilanti, E; Wen, PY, 2022)
"Intracranial gliomas are a common malignancy in dogs, and are associated with a poor prognosis due to their aggressive nature and a lack of clinically effective treatments."1.48Survival times in dogs with presumptive intracranial gliomas treated with oral lomustine: A comparative retrospective study (2008-2017). ( Cohen, PW; Dewey, CW; Moirano, SJ; Wright, KZ, 2018)
"The study included 26 patients with anaplastic astrocytoma and 37 patients with glioblastoma; all patients were aged ≤18 years."1.43High-grade glioma in children and adolescents: a single-center experience. ( Akalan, N; Akyuz, C; Cengiz, M; Eren, G; Gurkaynak, M; Ozyigit, G; Varan, A; Yazici, G; Yüce, D; Zorlu, F, 2016)
"Mice were dosed with either intravenous lomustine Molecular Envelope Technology (MET) nanoparticles (13 mg kg(-1)) or ethanolic lomustine (6."1.43Lomustine Nanoparticles Enable Both Bone Marrow Sparing and High Brain Drug Levels - A Strategy for Brain Cancer Treatments. ( Chooi, KW; Fisusi, FA; Garrett, N; Lalatsa, K; Moger, J; Okubanjo, O; Satchi-Fainaro, R; Schätzlein, AG; Serrano, D; Siew, A; Stapleton, P; Summers, I; Uchegbu, IF, 2016)
"Lomustine is a treatment option for patients with high-grade glioma."1.43Toca 511 plus 5-fluorocytosine in combination with lomustine shows chemotoxic and immunotherapeutic activity with no additive toxicity in rodent glioblastoma models. ( Gruber, HE; Huang, TT; Ibañez, CE; Jolly, DJ; Lopez Espinoza, F; Mendoza, D; Robbins, JM; Yagiz, K, 2016)
"Lomustine was administered, but 1 year after surgery, the dog exhibited cluster seizures and died."1.43Case of a miniature dachshund with a primitive neuroectodermal tumor confined to the forebrain region treated with a combination of surgery and chemotherapy. ( Matsunaga, S; Nakamoto, Y; Ozawa, T; Uchida, K; Yamada, A, 2016)
"Myoinositol (MI) is an organic osmolyte, with intracellular concentration changes depending on the extracellular osmolality."1.43Myoinositol as a Biomarker in Recurrent Glioblastoma Treated with Bevacizumab: A 1H-Magnetic Resonance Spectroscopy Study. ( Bähr, O; Hattingen, E; Pilatus, U; Ronellenfitsch, MW; Steidl, E; Steinbach, JP; Zanella, F, 2016)
"Our results of combined treatment of brain metastases are presented and available approaches to brain irradiation and chemotherapy are discussed."1.37[Brain metastasis in breast cancer]. ( Ivanov, VG; Korytova, LI; Masliukova, EA; Meshechkin, AV; Zhabuna, RM, 2011)
"Malignant gliomas are the most common primary intrinsic brain tumors and are highly lethal."1.35Nitrosoureas inhibit the stathmin-mediated migration and invasion of malignant glioma cells. ( Choi, Y; Liang, XJ; Park, JK; Sackett, DL, 2008)
"12 months."1.35[Clinical features and combined treatment of the central nervous system in Hodgkin's disease]. ( Filatova, LV; Gershanovich, ML, 2008)
"Identification of synchronous brain tumors prompted genetic testing for predisposition to malignancy."1.35De novo germline TP53 mutation presenting with synchronous malignancies of the central nervous system. ( Brat, DJ; Esiashvili, N; Janss, AJ; Schniederjan, MJ; Shehata, B, 2009)
"Epilepsy was the most important risk factor for disability."1.32Long-term sequelae in children treated for brain tumors: impairments, disability, and handicap. ( Jereb, B; Macedoni-Luksic, M; Todorovski, L, 2003)
"We describe a case of anaplastic astrocytoma in a 14-year-old boy arising at the site of a dysembryoplastic neuroepithelial tumor (DNT) 3 years after combined radiation and chemotherapy."1.32Malignant transformation of a dysembryoplastic neuroepithelial tumor after radiation and chemotherapy. ( Mena, H; Rushing, EJ; Thompson, LD, 2003)
"Secondary anaplastic oligodendroglioma patients were younger than patients with de novo anaplastic oligodendrogliomas."1.32Long-term outcome of oligodendrogliomas. ( Bourg, V; Chanalet, S; Chatel, M; Fontaine, D; Frenay, M; Lebrun, C; Lonjon, M; Michiels, JF; Paquis, P; Ramaioli, A; Vandenbos, F, 2004)
"Several protocols for the adjuvant treatment of glioblastoma multiforme (GBM) are currently being evaluated."1.31Distinct radiochemotherapy protocols differentially influence cellular proliferation and expression of p53 and Bcl-2 in glioblastoma multiforme relapses in vivo. ( Deininger, MH; Grote, E; Meyermann, R; Wickboldt, J, 2000)
"Oligodendroglioma is a rare central nervous system tumor which may occur in pure or mixed histology."1.30Radiation and chemotherapy improve outcome in oligodendroglioma. ( Allison, RR; Barry, T; Schulsinger, A; Shin, KH; Vongtama, V, 1997)
"Intracranial Hodgkin's disease is very rare and is often a terminal event."1.30Intracranial Hodgkin's disease in two patients with familial Hodgkin's disease. ( Agarwal, V; Ashigbi, MY; Bello, J; Venkatraj, U; Wiernik, PH, 1997)
"004), the elimination half-life was 35% shorter (12."1.30Cytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors. ( Joensuu, H; Kivistö, KT; Mäenpää, H; Neuvonen, PJ; Villikka, K, 1999)
"The rate of brain metastases was significantly lower in patients treated with methotrexate and nitrosurea containing schedules and PCI, compared to those who were treated with other schedules (irrespective of PCI)."1.29Consolidative thoracic radiotherapy and prophylactic cranial irradiation in limited disease small cell lung cancer. ( de Jonge, A; Karim, AB; Meyer, OW; Njo, KH; Slotman, BJ, 1993)
"Malignant oligodendrogliomas have been shown to be responsive to chemotherapy."1.28The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with PCV chemotherapy. ( Glass, J; Gruber, ML; Hochberg, FH; Louis, DN; Rattner, B; Smith, D, 1992)
"Procarbazine was ineffective."1.28The chemotherapeutic response of a murine (VM) model of human glioma. ( Bradford, R; Darling, JL; Thomas, DG, 1990)
"12 patients with brain tumors were treated with a combination of procarbazine, CCNU (bis-2-chloroethyl-3-cyclohexyl-1-nitrosourea) and vincristine."1.27Procarbazine, CCNU and vincristine (PCV) combination chemotherapy for brain tumors. ( Biran, S; Brufman, G; Catane, R; Halpern, J; Sulkes, A, 1984)
" The shapes of the dose-response curves indicated complete cross-resistance between BCNU and CCNU, i."1.27In vitro analysis of BCNU-sensitivity in human malignant gliomas. II. Cross-resistance studies with cisplatinum and nitrosoureas. ( Bricolo, A; Della Corte, V; Gerosa, MA; Licata, C; Marcon, C; Rosenblum, ML; Stevanoni, G; Tridente, G, 1986)
"The disease appeared to be a diffuse encephalopathy frequently affecting the higher cortical functions."1.27Neurologic dysfunction in patients treated for small cell carcinoma of the lung: a clinical and radiological study. ( Chak, LY; Cox, RS; Kushlan, PD; Porzig, KJ; Sikic, BI; Wasserstein, P; Zatz, LM, 1986)
" The radiation dose ranged from 3000 to 4650 rad and the oral CCNU dosage from 300 mg to 1050 mg."1.27Sudden onset of blindness in patients treated with oral CCNU and low-dose cranial irradiation. ( Kleinschmidt-Demasters, BK; Perez, GM; Wilson, WB, 1987)
"5 g/M2 every six weeks, with dosage adjustments for myelotoxicity."1.27Misonidazole and CCNU chemotherapy for recurrent primary brain tumor. ( Fulton, DS; McKinnon, S; Tanasichuk, H; Urtasun, RC, 1987)
"Malignant oligodendroglioma is a uniquely chemosensitive glial tumor."1.27Successful chemotherapy for recurrent malignant oligodendroglioma. ( Cairncross, JG; Macdonald, DR, 1988)
"Bone marrow myelofibrosis may be another delayed treatment effect of this class of drugs."1.27Myelofibrosis following treatment with a nitrosourea for malignant glioma. ( Fehir, KM; McKenney, SA, 1986)
"Six of them had tumor metastasis with in 6 months after the initial treatment(s)."1.27[Brain tumors in infants and children--factors affecting prognosis, (Part-3). Mode of metastasis and prognosis in medulloblastoma]. ( Matsumoto, S; Oi, S; Raimondi, AJ, 1985)
"A dose-response relation for the cytotoxic activity of chloroethylnitrosourea cancer chemotherapeutic agents in cell culture has been developed."1.26Quantitative dose-response relations for the cytotoxic activity of chloroethylnitrosoureas in cell culture. ( Deen, DF; Weinkam, RJ, 1982)
"Three cases of pseudocysts following surgery and chemotherapy for glioblastomas are reported."1.26Cerebral pseudocysts following chemotherapy of glioblastomas. ( Philippon, J; Poisson, M; Racadot, J; Sichez, JP; van Effenterre, R, 1977)
" The depression of platelets and white blood cells was mild after a single dosage of 40 mg/kg CCNU which recovered on about the 6th day."1.26Brain tumor chemotherapy using a rat glioma model. ( Mennel, HD; Tamura, M; Zülch, KJ, 1979)
"34 patients operated on for malignant gliomas were successively treated by combination chemotherapy with VM26 and CCNU and conventional radiation therapy with an average dosage of 5,800 Rads, six months after surgery."1.26Malignant gliomas treated after surgery by combination chemotherapy and delayed radiation therapy. Part II. Tolerance to irradiation after chemotherapy. ( Bataini, JP; Hauw, JJ; Mashaly, R; Metzger, J; Pertuiset, BF; Poisson, M; Pouillart, P, 1979)
"Three patients developed CNS metastasis while on treatment."1.26Adriamycin and 1-(2-chlorethyl)-3-cyclohexyl-1-nitrosourea (CCNU) in the treatment of metastatic breast cancer. ( Blumenschein, GR; Burgess, MA; Buzdar, AU; Hortobagyi, GN; Tashima, CK; Waterfield, WC, 1978)
"Pretreatment with phenytoin, sodium methylprednisolone succinate and dexamethasone had little or no effect."1.26The effect of phenobarbital pretreatment on the antitumor activity of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) and 1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidyl-1-nitrosourea (PCNU), and on the plasma p ( Byrd, A; Finn, A; Levin, VA; Stearns, J; Weinkam, RJ, 1979)
" However, with certain dosage schedules such as every 2 hr for 5 injections daily on 2 consecutive days, i."1.26Chemotherapy of an experimental glioma with nitrosoureas. ( Day, A; Liberman, L; Ng, R; Tator, CH, 1977)
"Untreated meningeal carcinomatosis is a uniformly fatal type of metastatic disease presenting with many protean signs and symptoms."1.26Meningeal carcinomatosis. Case report and review of the literature. ( Bender, J; Bramlet, D; Giliberti, J, 1976)
" In the first phase, 14 patients (Group A) with progressive neurologic dysfunction following primary treatment were treated with DTIC alone (8 patients) or in combination with CCNU or methyl CCNU (6 patients) and evaluated for change in neurologic status."1.25Treatment of grade III and IV astrocytoma with dimethyl triazeno imidazole carboxamide (DTIC, NSC-45388) alone and in combination with CCNU (NSC-79037) or methyl CCNU (MeCCNU, NSC-95441). ( Baxter, D; Cunningham, TJ; Horton, J; Nelson, L; Olson, KB; Rosenbaum, C; Sponzo, RW; Taylor, SG, 1975)

Research

Studies (488)

TimeframeStudies, this research(%)All Research%
pre-1990176 (36.07)18.7374
1990's78 (15.98)18.2507
2000's101 (20.70)29.6817
2010's98 (20.08)24.3611
2020's35 (7.17)2.80

Authors

AuthorsStudies
Yamamuro, S1
Takahashi, M1
Satomi, K1
Sasaki, N1
Kobayashi, T2
Uchida, E1
Kawauchi, D1
Nakano, T1
Fujii, T1
Narita, Y1
Kondo, A1
Wada, K1
Yoshino, A1
Ichimura, K2
Tomiyama, A1
McBain, C1
Lawrie, TA1
Rogozińska, E1
Kernohan, A1
Robinson, T1
Jefferies, S1
Lavogina, D1
Laasfeld, T1
Vardja, M1
Lust, H1
Jaal, J1
Wick, A4
Sander, A1
Koch, M1
Bendszus, M5
Combs, S1
Haut, T1
Dormann, A1
Walter, S1
Pertz, M1
Merkle-Lock, J1
Selkrig, N1
Limprecht, R1
Baumann, L1
Kieser, M1
Sahm, F5
Schlegel, U4
Winkler, F2
Platten, M8
Wick, W16
Kessler, T3
Mair, MJ1
Leibetseder, A1
Heller, G1
Puhr, R1
Tomasich, E1
Goldberger, S1
Hatziioannou, T1
Wöhrer, A1
Widhalm, G1
Dieckmann, K3
Aichholzer, M1
Weis, S1
von Oertzen, T1
Furtner, J1
Pichler, J1
Preusser, M4
Berghoff, AS1
Aquilanti, E1
Wen, PY5
Wollring, MM1
Werner, JM2
Bauer, EK2
Tscherpel, C2
Ceccon, GS1
Lohmann, P2
Stoffels, G2
Kabbasch, C2
Goldbrunner, R4
Fink, GR2
Langen, KJ3
Galldiks, N3
Le Rhun, E6
Oppong, FB3
van den Bent, M10
Brandes, AA18
Taphoorn, MJ15
Idbaih, A10
Clement, PM7
Golfinopoulos, V6
Gorlia, T17
Weller, M21
Weller, J6
Schäfer, N6
Schaub, C4
Tzaridis, T4
Zeyen, T2
Schneider, M3
Potthoff, AL2
Giordano, FA1
Steinbach, JP6
Zeiner, PS2
Kowalski, T1
Sabel, M2
Hau, P5
Krex, D4
Grauer, O3
Schnell, O2
Tabatabai, G2
Ringel, F1
Schmidt-Graf, F2
Brehmer, S1
Tonn, JC3
Bullinger, L1
Vajkoczy, P1
Glas, M6
Vatter, H2
Herrlinger, U9
Seidel, C3
Ellingson, BM1
Chang, SM3
Vogelbaum, MA2
Li, G1
Li, S1
Kim, J1
Youssef, G1
Lassman, AB3
Gilbert, MR7
de Groot, JF2
Galanis, E1
Cloughesy, TF3
Fishman, H1
Monin, R1
Dor-On, E1
Kinzel, A1
Haber, A1
Giladi, M1
Weinberg, U1
Palti, Y1
Esparragosa Vazquez, I1
Ndiaye, M1
Di Stefano, AL1
Younan, N1
Larrieu-Ciron, D1
Seyve, A1
Picart, T1
Meyronet, D2
Boutet, C1
Vassal, F1
Carpentier, C3
Figarella-Branger, D2
Dehais, C2
Forest, F1
Rivoirard, R1
Ducray, F8
Schrimpf, D1
Doerner, L1
Hai, L1
Kaulen, LD1
Ito, J1
Taphoorn, M3
Dômont, J3
Campone, M4
von Deimling, A4
Paech, D1
Duffy, C1
Nitsch, L1
Stummer, W1
Hattingen, E2
Radbruch, A1
Krugman, J1
Patel, K1
Cantor, A1
Snuderl, M1
Cooper, B1
Zan, E1
Radmanesh, A1
Hidalgo, ET1
Nicolaides, T1
McDuff, SGR1
Dietrich, J1
Atkins, KM1
Oh, KS1
Loeffler, JS2
Shih, HA1
Mukherjee, S1
Wood, J1
Liaquat, I1
Stapleton, SR1
Martin, AJ1
Eoli, M3
Sepulveda, JM1
Smits, M3
Walenkamp, A2
Frenel, JS1
Franceschi, E3
Chinot, O4
De Vos, F1
Whenham, N1
Sanghera, P1
Dubbink, HJ4
French, P2
Looman, J1
Dey, J1
Krause, S1
Ansell, P1
Nuyens, S1
Spruyt, M1
Brilhante, J1
Coens, C3
Lazaridis, L1
Teuber-Hanselmann, S1
Blau, T1
Schmidt, T1
Oster, C1
Pierscianek, D1
Keyvani, K1
Kleinschnitz, C1
Stuschke, M1
Scheffler, B1
Deuschl, C1
Sure, U1
Kebir, S2
Lobbous, M1
Nabors, LB2
Indraccolo, S1
De Salvo, GL1
Verza, M1
Caccese, M1
Esposito, G1
Piga, I1
Del Bianco, P1
Pizzi, M1
Gardiman, MP1
Rudà, R3
Ibrahim, T1
Rizzato, S1
Lolli, I1
Zagonel, V1
Lombardi, G1
Raswoli, M1
Nobre, L1
Hawkins, C1
Bartels, UK1
Tabori, U1
Bouffet, E3
Alrohaibani, A1
Swetnam, LA1
Andeen, NK1
Kickingereder, P2
Brugnara, G1
Hansen, MB1
Nowosielski, M2
Pflüger, I1
Schell, M1
Isensee, F1
Foltyn, M1
Neuberger, U1
Heiland, S1
Maier-Hein, KH1
Østergaard, L1
van den Bent, MJ29
Cai, Y1
Jiang, YG1
Wang, M5
Jiang, ZH1
Tan, ZG1
Touat, M1
Soffietti, R2
Seidel, S1
Coch, C1
Fimmers, R1
Pietsch, T3
Reifenberger, G4
Felsberg, J3
Petrecca, K1
Walbert, T2
Butowski, N1
Salacz, M1
Perry, J1
Damek, D1
Bota, D1
Bettegowda, C1
Zhu, JJ1
Iwamoto, F1
Placantonakis, D1
Kim, L2
Elder, B1
Kaptain, G1
Cachia, D1
Moshel, Y1
Brem, S2
Piccioni, D1
Landolfi, J1
Chen, CC1
Gruber, H1
Rao, AR1
Hogan, D1
Accomando, W1
Ostertag, D1
Montellano, TT1
Kheoh, T1
Kabbinavar, F1
Esteyrie, V1
Martin, E1
Uro-Coste, E1
Bronniman, C1
Pouessel, D1
Ciron, DL1
Moyal, EC1
Network, P1
Keogh, RJ1
Aslam, R1
Hennessy, MA1
Coyne, Z1
Hennessy, BT1
Breathnach, OS1
Grogan, L1
Morris, PG1
Katzendobler, S1
Karschnia, P1
Lietke, S1
Egensperger, R1
Thon, N1
Suchorska, B1
Ceccon, G1
Baues, C1
Celik, E1
Marnitz, S1
Gielen, GH1
Lin, P1
Jiang, H1
Zhao, YJ1
Pang, JS1
Liao, W1
He, Y1
Lin, ZY1
Yang, H1
Castro, M1
Pampana, A1
Alam, A1
Parashar, R1
Rajagopalan, S1
Lala, DA1
Roy, KGG1
Basu, S1
Prakash, A1
Nair, P1
Joseph, V1
Agarwal, A1
G, P1
Behura, L1
Kulkarni, S1
Choudhary, NR1
Kapoor, S1
Qian, Y1
Maruyama, S1
Kim, H2
Pollom, EL1
Kumar, KA1
Chin, AL1
Harris, JP1
Chang, DT1
Pitt, A1
Bendavid, E1
Owens, DK1
Durkee, BY1
Soltys, SG1
Parasramka, S1
Talari, G1
Rosenfeld, M1
Guo, J1
Villano, JL2
Belcher, SM1
Burton, CC1
Cookman, CJ1
Kirby, M1
Miranda, GL1
Saeed, FO1
Wray, KE1
Duerinck, J3
Du Four, S3
Bouttens, F2
Andre, C1
Verschaeve, V2
Van Fraeyenhove, F1
Chaskis, C1
D'Haene, N2
Le Mercier, M2
Rogiers, A1
Michotte, A3
Salmon, I2
Neyns, B4
Harting, I2
Taal, W9
Stupp, R5
Fabbro, M2
Dubois, F1
Bromberg, JC1
Klein, M1
Staberg, M2
Rasmussen, RD2
Michaelsen, SR2
Pedersen, H1
Jensen, KE1
Villingshøj, M2
Skjoth-Rasmussen, J1
Brennum, J1
Vitting-Seerup, K1
Poulsen, HS2
Hamerlik, P2
Moirano, SJ1
Dewey, CW1
Wright, KZ1
Cohen, PW1
Grube, S1
Ewald, C1
Kögler, C1
Lawson McLean, A1
Kalff, R1
Walter, J1
Rodrigues-Junior, DM1
Biassi, TP1
Carlin, V1
Buri, MV1
Torrecilhas, AC1
Bortoluci, KR1
Vettore, AL1
Gonzalez-Aguilar, A1
Reyes-Moreno, I1
Peiro-Osuna, RP1
Hernandez-Hernandez, A1
Gutierrez-Aceves, A1
Santos-Zambrano, J1
Guerrero-Juarez, V1
Lopez-Martinez, M1
Castro-Martinez, E1
Ameratunga, M1
Pavlakis, N2
Wheeler, H2
Grant, R2
Simes, J1
Khasraw, M2
Lukas, RV1
Hegi, ME1
Killock, D1
Norden, AD2
Korytowsky, B1
You, M1
Kim Le, T1
Dastani, H1
Bobiak, S1
Singh, P1
Bromberg, JEC1
Taphoorn, MJB1
Lee, EQ2
Nayak, L2
Reardon, DA2
Rosenfeld, MR1
Delattre, JY6
Kros, JM16
Kouwenhoven, MC3
Bernsen, HJ4
Frénay, M10
Tijssen, CC6
Lacombe, D8
Roth, P3
Batchelor, TT1
Mulholland, P1
Mason, W2
Mikkelsen, T2
Phuphanich, S2
Ashby, LS2
Degroot, J1
Gattamaneni, R1
Cher, L2
Rosenthal, M1
Payer, F1
Jürgensmeier, JM1
Jain, RK1
Sorensen, AG1
Xu, J1
Liu, Q1
Prabhu, RS1
Won, M2
Shaw, EG4
Hu, C1
Brachman, DG2
Buckner, JC6
Stelzer, KJ1
Barger, GR2
Brown, PD3
Mehta, MP4
Kaloshi, G2
Rroji, A2
Petrela, M2
Cairncross, JG14
Jenkins, RB2
Giannini, C1
Fink, KL1
Souhami, L4
Laperriere, NJ1
Huse, JT1
Curran, WJ4
Behrend, SW1
Tonder, M1
Eisele, G1
Weiss, T1
Hofer, S2
Seystahl, K1
Valavanis, A1
Collins, VP1
Di, Y1
Pearson, D1
Chan, R1
Thompson, LC1
Gabe, R1
Brada, M1
Stenning, SP2
Rahman, R1
Hempfling, K1
Rinne, ML1
Beroukhim, R1
Doherty, L1
Ruland, S1
Rai, A1
Rifenburg, J1
LaFrankie, D1
Alexander, BM1
Huang, RY1
Oosterkamp, HM3
Walenkamp, AM3
Beerepoot, LV4
Hanse, MC3
Buter, J3
Honkoop, AH2
Boerman, D1
de Vos, FY3
Dinjens, WN5
Enting, RH4
van den Berkmortel, FW1
Jansen, RL2
Brandsma, D1
Bromberg, JE4
van Heuvel, I4
Vernhout, RM4
van der Holt, B5
Villanueva, MT2
Lévy, S1
Chapet, S1
Mazeron, JJ2
Ameratunga, MS1
Raza, S1
Firwana, B1
Doll, DC1
Ediebah, DE1
Galindo-Garre, F1
Uitdehaag, BM2
Ringash, J1
Reijneveld, JC2
Dirven, L2
Zikos, E1
Bottomley, A3
van der Rijt, CC2
Sillevis Smitt, PA6
Wertenbroek, AA1
Harvey, KA1
Xu, Z1
Saaddatzadeh, MR1
Wang, H1
Pollok, K1
Cohen-Gadol, AA1
Siddiqui, RA1
Chamberlain, MC7
Wong, ET1
Lok, E1
Swanson, KD1
Dixit, S1
Hingorani, M1
Schiff, D2
van der Meer, N1
Vos, MJ2
Otten, A2
Levin, VA25
Beije, N1
Kraan, J1
Beerepoot, L1
Hanse, M2
van Linde, ME1
Gratama, JW1
Sleijfer, S1
Roci, E1
Carvalho, BF1
Fernandes, AC1
Almeida, DS1
Sampaio, LV1
Costa, A1
Caeiro, C1
Osório, L1
Castro, L1
Linhares, P1
Damasceno, M1
Vaz, RC1
Webre, C1
Shonka, N1
Smith, L1
Liu, D1
De Groot, J1
Sander, W1
Van Binst, AM2
Everaert, H2
Heiland, DH1
Masalha, W1
Franco, P1
Machein, MR1
Weyerbrock, A1
Yazici, G1
Zorlu, F1
Cengiz, M1
Ozyigit, G1
Eren, G1
Yüce, D1
Varan, A2
Akyuz, C2
Akalan, N2
Gurkaynak, M1
Strowd, RE1
Abuali, I1
Ye, X1
Lu, Y1
Grossman, SA1
Erdem-Eraslan, L2
Hoogstrate, Y1
Naz-Khan, H1
Stubbs, A1
van der Spek, P1
Böttcher, R1
Gao, Y1
de Wit, M1
French, PJ3
Mazzocco, P1
Honnorat, J4
Ribba, B1
Carpentier, AF3
Kesari, S1
Sepulveda-Sanchez, JM1
Wheeler, HR1
Capper, D1
Specenier, P1
Rodon, J1
Cleverly, A1
Smith, C1
Gueorguieva, I1
Miles, C1
Guba, SC1
Desaiah, D1
Lahn, MM1
Fisusi, FA1
Siew, A1
Chooi, KW1
Okubanjo, O1
Garrett, N1
Lalatsa, K1
Serrano, D1
Summers, I1
Moger, J1
Stapleton, P1
Satchi-Fainaro, R1
Schätzlein, AG1
Uchegbu, IF1
Vandervorst, F1
Jakacki, RI5
Cohen, KJ1
Buxton, A1
Krailo, MD1
Burger, PC2
Rosenblum, MK2
Brat, DJ2
Hamilton, RL1
Eckel, SP1
Zhou, T3
Lavey, RS1
Pollack, IF4
Pugh, SL1
Chakravarti, A1
Coons, S1
Ricci, P1
Bullard, D1
Stelzer, K1
Brachman, D4
Suh, JH1
Schultz, CJ1
Bahary, JP1
Fisher, BJ3
Murtha, AD1
Bell, EH1
Gramatzki, D1
Rushing, EJ2
Hentschel, B1
Westphal, M1
Simon, M2
Yagiz, K1
Huang, TT1
Lopez Espinoza, F1
Mendoza, D1
Ibañez, CE1
Gruber, HE1
Jolly, DJ1
Robbins, JM1
Combs, SE1
Meyer, B1
Weathers, SP1
Han, X1
Liu, DD1
Conrad, CA2
Loghin, ME1
O'Brien, BJ1
Penas-Prado, M1
Puduvalli, VK3
Tremont-Lukats, I1
Colen, RR1
Yung, WKA1
Nakamoto, Y1
Yamada, A1
Uchida, K1
Matsunaga, S1
Ozawa, T1
Steidl, E1
Pilatus, U1
Zanella, F1
Ronellenfitsch, MW1
Bähr, O1
Gahrmann, R1
Vos, M1
de Groot, JC1
Flach, ZH1
Jasperse, B1
Goerne, R1
Bogdahn, U1
Liang, XJ1
Choi, Y1
Sackett, DL1
Park, JK1
Baumert, BG1
Rasch, K1
Wiewrodt, D1
Kartashev, AV1
Vinogradov, VM1
Fewer, D1
Wilson, CB12
Boldrey, EB3
Enot, JK1
Filatova, LV1
Gershanovich, ML2
Ibdaih, A2
Mokhtari, K5
van Duinen, SG1
Teepen, JL2
Wesseling, P4
Vandenbos, F4
Grisold, W6
Sipos, L3
Mirimanoff, R1
Vecht, CJ4
Allgeier, A6
Yang, SH2
Hong, YK2
Jeun, SS2
Kim, IS1
Hong, JT1
Sung, JH1
Son, BC1
Lee, SW1
Kim, MC2
Lee, KS2
Vesper, J1
Graf, E1
Wille, C1
Tilgner, J1
Trippel, M1
Nikkhah, G1
Ostertag, C1
Nakamura, M1
Shimada, K1
Nakase, H1
Konishi, N1
Nishikawa, R1
Schniederjan, MJ1
Shehata, B1
Esiashvili, N1
Janss, AJ1
Cairncross, G5
Shaw, E3
Jenkins, R4
Scheithauer, B2
Buckner, J4
Fink, K3
Laperriere, N2
Mehta, M3
Curran, W3
DeAngelis, LM5
Sanson, M7
van der Lee-Haarloo, CR1
Hegi, M2
Jeuken, JW1
Hartmann, C1
Engel, C1
Stoffels, M1
Stockhammer, F1
Sabel, MC1
Koeppen, S1
Ketter, R1
Meyermann, R4
Rapp, M1
Meisner, C1
Kortmann, RD2
Wiestler, OD1
Ernemann, U1
Bamberg, M4
Guillaume, DJ1
Doolittle, ND1
Gahramanov, S1
Hedrick, NA1
Delashaw, JB1
Neuwelt, EA1
Cher, LM1
Hong, S1
Musib, L1
Liepa, AM1
Thornton, DE1
Fine, HA2
Marie, Y1
van Marion, R1
Agha, CA1
Ibrahim, S1
Hassan, A1
Elias, DA1
Fathallah-Shaykh, HM1
Peyre, M1
Cartalat-Carel, S3
Ricard, D1
Jouvet, A4
Pallud, J1
Guyotat, J2
Jouanneau, E2
Sunyach, MP2
Frappaz, D2
Groves, MD2
Yung, WK7
Bobustuc, GC1
Colman, H1
Hsu, SH1
Bekele, BN1
Qiao, W1
Kong, DS1
Kim, ST1
Lee, JI1
Suh, YL1
Lim, DH1
Kim, WS1
Kwon, KH1
Park, K1
Kim, JH1
Nam, DH1
Dalmasso, C1
Kouwenhoven, M1
Jeuken, J1
Teepen, J1
Broët, P1
Delattre, O1
Hoang-Xuan, K4
Zhuang, L1
Gao, J1
Zeng, Y1
Yu, F1
Zhang, B1
Li, M1
Derendorf, H1
Liu, C1
Iwamoto, FM1
Aldape, KD1
Rivera, AL1
Eichler, AF1
Louis, DN4
Paleologos, NA2
Roldán, GB1
Ligon, KL1
Robins, HI1
Rocque, BG1
Mason, WP2
Weaver, SA1
Green, RM1
Kamar, FG1
Abrey, LE4
Jhanwar, SC1
Panageas, KS1
Korytova, LI1
Meshechkin, AV1
Zhabuna, RM1
Masliukova, EA1
Ivanov, VG1
Vauleon, E1
Mesbah, H1
Gedouin, D1
Lecouillard, I1
Louvel, G1
Hamlat, A1
Riffaud, L1
Carsin, B1
Quillien, V1
Audrain, O1
Lesimple, T1
Ater, JL1
Holmes, E1
Mazewski, CM1
Booth, TN1
Freyer, DR1
Lazarus, KH1
Packer, RJ5
Prados, M3
Sposto, R3
Vezina, G1
Wisoff, JH2
Stuplich, M1
Hadizadeh, DR1
Kuchelmeister, K1
Scorzin, J1
Filss, C1
Mack, F1
Schüller, H1
Urbach, H1
Van Meervenne, S1
Verhoeven, PS1
de Vos, J1
Gielen, IM1
Polis, I1
Van Ham, LM1
Viaccoz, A1
Lekoubou, A1
Printz, C1
Szabo, D1
Saveraid, TC1
Rodenas, S1
van Herpen, C1
Laigle Donadey, F1
Lhermitte, B1
Strauss, LC1
Dignam, JJ1
Zhang, QE1
DeGroot, JF1
Hunsberger, S1
Gravendeel, LA1
de Rooi, J1
Eilers, PH1
Spliet, WG1
den Dunnen, WF1
Murphy, C1
Pickles, T1
Knowling, M1
Thiesse, B1
Zander, T1
Nettekoven, W1
Kraus, JA1
Pels, H1
Ko, YD1
Vetter, H1
Klockgether, T1
Baker, MJ1
Daniels, S1
Sherman, B1
Gesme, D1
O'Fallon, JR1
Hammack, JE1
Stafford, S1
Hawkins, R1
Scheithauer, BW1
Erickson, BJ1
Levitt, R1
Louis, E1
Keime-Guibert, F1
Macedoni-Luksic, M1
Jereb, B1
Todorovski, L1
Piribauer, M3
Fazeny-Dörner, B2
Rössler, K2
Ungersböck, K2
Czech, T2
Killer, M2
Birner, P1
Prayer, D2
Hainfellner, J1
Muhm, M2
Marosi, C4
Nieder, C1
Looijenga, LH2
Langenberg, K1
Dinjens, W1
Graveland, W1
Uytdewilligen, L1
Barkhof, F1
Heimans, JJ3
Baayen, HC1
Boogerd, W3
Castelijns, JA1
Elkhuizen, PH1
Postma, TJ2
Bravo Marques, J1
De Beule, N1
Baron, B1
Pommier, P1
Martel Lafay, I1
Ginestet, G1
Sindou, M3
Bret, P2
Carrie, C1
Gyries, A1
Budinsky, A1
Baumgartner, G1
Veitl, M1
Lancaster, DL1
Hoddes, JA1
Michalski, A1
Thompson, LD1
Mena, H1
Fouladi, M1
Hunt, DL1
Dueckers, G1
Becker, LE1
Yates, AJ3
Gilles, FH1
Davis, RL5
Boyett, JM5
Finlay, JL7
Engelhard, HH1
Stelea, A1
Mundt, A1
Khil'ko, VA1
Khachatrian, VA1
Shuleshova, NV1
von Koch, CS1
Schmidt, MH1
Uyehara-Lock, JH1
Berger, MS1
Lichy, MP1
Bachert, P1
Henze, M1
Lichy, CM1
Debus, J1
Schlemmer, HP1
Childs, BH2
Paleologos, N4
Kaminer, L3
Rosenfeld, S3
Salzman, D3
Gardner, S2
Peterson, K3
Hu, W3
Swinnen, L3
Bayer, R3
Forsyth, P4
Stewart, D5
Smith, AM2
Macdonald, DR8
Weaver, S2
Ramsey, DA1
Nimer, SD2
Nobile, M1
Borgognone, M1
Costanza, A1
Laguzzi, E1
Mutani, R1
Prados, MD9
Seiferheld, W1
Sandler, HM1
Phillips, T2
Schultz, C2
Urtasun, R3
Davis, R3
Gutin, P3
Cascino, TL2
Greenberg, HS2
Lebrun, C3
Fontaine, D3
Ramaioli, A3
Chanalet, S3
Lonjon, M3
Michiels, JF2
Bourg, V3
Paquis, P3
Chatel, M2
Alchaar, H1
Bleuse, A1
Bondiau, PY1
Brunetto, JL1
Courdi, A1
Darcourt, J1
Fauchon, F2
Guibert, F1
Grellier, P1
Lanteri-Minet, M1
Paquis, V1
Rasendrarijao, D1
Taillibert, S1
Napolitano, M1
Djafari, L1
Cougnard, J1
Gervais, H1
Laigle, F1
Carpentier, A1
Taillandier, L1
Duffau, H1
de Wit, MC1
de Bruin, HG2
Eijkenboom, W1
Triebels, VH1
Menten, J1
Tosoni, A1
Stege, EB1
Teng, LH1
Gui, QP1
Xuan, Q1
Lu, DH1
Stege, EM1
van der Rijt, CD1
Smitt, PA1
Tang, BN1
Sadeghi, N1
Branle, F1
De Witte, O1
Wikler, D1
Goldman, S1
Liau, CT1
Wei, KC1
Tseng, CK1
Jung, SM1
Nomura, K1
Oberndorfer, S1
Lahrmann, H1
Hitzenberger, P1
Bottoni, U1
Bonaccorsi, P1
Devirgiliis, V1
Panasiti, V1
Borroni, RG1
Trasimeni, G1
Clerico, R1
Calvieri, S1
Tafuto, S1
Muto, P1
Tortoriello, A1
Pisano, A1
Comella, P1
Formato, R1
Quattrin, S1
Iaffaioli, RV1
Ty, AU1
See, SJ1
Rao, JP1
Khoo, JB1
Wong, MC1
Yimam, MA1
Bui, T1
Ho, RJ2
Jones, R1
Kirkup, M1
Guglani, S1
Hopkins, K1
Schmidt, F1
Fischer, J2
Dietz, K1
Dichgans, J3
Ramsay, DA2
Cornetta, K2
Croop, J1
Dropcho, E3
Abonour, R1
Kieran, MW1
Kreissman, S1
Reeves, L1
Erickson, LC1
Williams, DA2
Walker, C2
Haylock, B2
Husband, D2
Joyce, KA2
Fildes, D2
Jenkinson, MD2
Smith, T2
Broome, J2
du Plessis, DG2
Warnke, PC2
Lang, FF1
Berkey, B1
Laperierre, N1
Haaxma-Reiche, H1
van Kouwenhoven, MC1
Faber, V1
Thödtmann, R1
Piccirilli, M1
Landi, A1
Salvati, M1
Rieger, J1
Koch, D1
Loeser, S1
Blaschke, B1
Hundsberger, T1
Tan, TC1
Sommer, C1
Mabasa, VH1
Taylor, SC1
Kopitzki, K1
Prosser, J1
Vinjamuri, S1
Atahan, L1
Söylemezoglu, F1
Selek, U1
Yalçin, B1
Kutluk, T1
Büyükpamukçu, M1
Catenoix, H1
Chapuis, F1
Nighoghossian, N1
Trouillas, P1
Larkin, JM1
Hughes, SA1
Beirne, DA1
Patel, PM1
Gibbens, IM1
Bate, SC1
Thomas, K1
Eisen, TG1
Gore, ME1
Yoon, SC1
Kim, BS1
Lee, YS1
Lee, TK1
Park, CK1
Mauer, ME1
Wolff, JE1
Berrak, S1
Koontz Webb, SE1
Zhang, M1
Choi, JD1
Powers, CJ1
Vredenburgh, JJ1
Friedman, AH1
Sampson, JH1
Kobiakov, GL1
Mohile, NA1
Raizer, JJ1
Kewalramani, T1
Yates, A1
Blaney, SM1
Timmerman, R1
Ingle, AM1
Flom, L1
Adamson, PC1
Edwards, MS4
Wara, WM6
Allen, J1
Ortega, J2
Vestnys, P1
Eyre, HJ2
Quagliana, JM2
Eltringham, JR2
Frank, J1
O'Bryan, RM1
McDonald, B1
Rivkin, SE1
Stridsklev, IC1
Hagen, S2
Klepp, O1
Kessinger, A1
Gropp, C1
Havemann, K1
Seiler, RW9
Bleehen, NM3
Osieka, R1
Glatte, P1
Pannenbäcker, R1
Schmidt, CG2
Cianfriglia, F1
Pompili, A2
Riccio, A2
Grassi, A1
Zimmermann, A2
Markwalder, H4
Jellinger, K2
Volc, D2
Podreka, I2
Böck, F1
Schuster, H1
Alth, G1
Kogelnik, HD1
Pomodanov, AP1
Sosnov, IuD1
Perevodchikova, NI2
Dvoĭrin, VV1
Assekritova, IV1
Aisner, J1
Whitacre, M1
Van Echo, DA1
Wiernik, PH2
Smyth, JF1
Ford, HT1
Conte, PF1
Giaccone, G1
Musella, R1
Calciati, A1
Robustelli della Cuna, G3
Paoletti, P9
Bernardo, G1
Knerich, R6
Butti, G2
Cuzzoni, Q1
Kostron, H1
Barrere, M1
Fanjaud, G1
Larrue, V1
Geraud, G1
Bes, A1
Jacque, C1
Kujas, M1
Raoul, M1
Baumann, N1
Poisson, M10
Afra, D2
Kocsis, B2
Dobay, J1
Eckhardt, S2
Seydel, HG2
Creech, R1
Pagano, M1
Salazar, O1
Rubin, P1
Concannon, J1
Carbone, P1
Mohuiddin, M1
Perez, C1
Matthews, M1
Mikhina, ZP1
Glekov, IV1
Voĭnarevich, AO1
Ausekar, BV1
Pavesi, L1
Preti, P1
Preussmann, R1
Fingert, HJ1
Hochberg, FH3
Oredsson, SM1
Deen, DF4
Marton, LJ2
Brufman, G1
Halpern, J1
Sulkes, A1
Catane, R1
Biran, S1
Wheeler, KT3
Wallen, CA2
Wolf, KL1
Siemann, DW1
Shapiro, WR3
Weiss, RB2
Issell, BF1
Muller, PJ3
Tator, CH5
Bloom, ML1
Hildebrand, J6
Badjou, R1
Collard-Ronge, E1
Delforge, A1
Malarme, M1
Spiro, T1
Sztern, B1
Vandensteene, A1
Stryckmans, PA1
Hansen, HH2
Dombernowsky, P2
Hirsch, FR2
Hansen, M2
Rygård, J1
Vestnys, PS1
Weinkam, RJ2
Ilsen, HW1
Petrovici, IN1
Mennel, HD4
Zülch, KJ2
Szymas, J1
Vats, TS1
Trueworthy, RC1
Langston, CM1
Huang, Q1
Flament, H1
Vollmer, R1
Weiss, R1
Schacht, RG1
Feiner, HD1
Gallo, GR1
Lieberman, A1
Baldwin, DS1
Bloom, M1
Chaurasiya, J1
Mohanty, S1
Prasad, GC1
Berglund, J1
Thuning, CA1
Bakir, NA1
Warren, J1
Jandolo, B1
Fontana, M1
Li, J1
Li, L1
Kang, S1
Açikgöz, S1
Bingol, F1
offin, S1
Açikgöz, B1
Cohen, BH1
Zeltzer, PM2
Geyer, JR5
Allen, JC4
McGuire-Cullen, P1
Milstein, JM3
Rorke, LB4
Stanley, P2
Trent, KC1
Myers, L1
Moreb, J1
Eisenhauer, EA1
Maor, MH3
Thall, PF1
Bruner, J3
Sawaya, R1
Kyritsis, AP5
Leeds, N2
Woo, S1
Rodriguez, L1
Shrieve, DC1
Coleman, CN1
Turski, PA1
Sobol, RE1
Fakhrai, H1
Shawler, D1
Gjerset, R1
Dorigo, O1
Carson, C1
Khaleghi, T1
Koziol, J1
Shiftan, TA1
Royston, I1
Prados, MR1
Gutin, PH8
Phillips, TL4
Lamborn, K3
Albright, AL1
Stevens, KR1
Wisoff, J1
Schramm, CM1
Donahue, BR1
Haas, F1
Bertolone, SJ1
McGuire, P1
Cherlow, JM1
Tefft, M1
Macdonald, D3
Ludwin, S1
Lee, D1
Cascino, T1
Fulton, D2
Schold, C1
Slotman, BJ1
Njo, KH1
de Jonge, A1
Meyer, OW1
Karim, AB1
Elis, A1
Lishner, M1
Savin, H1
Ravid, M1
Goldwein, JW1
Radcliffe, J1
Sutton, LN3
Lange, B1
D'Angio, GJ1
Crowley, JJ1
Townsend, JJ1
Morantz, RA1
Schulman, SF1
al-Sarraf, M1
Krol, GS1
Ilveskoski, I1
Saarinen, UM1
Wiklund, T1
Perkkiö, M1
Salmi, TT1
Lanning, M1
Mäkipernaa, A1
Pihko, H1
Evans, AE4
Anderson, JR1
Lefkowitz-Boudreaux, IB1
Thornton, AF1
Harsh, GR1
Patel, H1
Finkelstein, D1
Schlegel, J1
Stumm, G1
Ruschoff, J1
Jaeckle, KA5
Gleason, MJ3
Ictech, SE1
Flowers, A1
Rabbitt, J2
Kaba, SE1
Hess, K2
Mercier, R1
Dakhil, S1
Allison, RR1
Schulsinger, A1
Vongtama, V1
Barry, T1
Shin, KH1
Ashigbi, MY1
Venkatraj, U1
Agarwal, V1
Bello, J1
Colleoni, M1
Graiff, C1
Nelli, P1
Vicario, G1
Sgarbossa, G1
Pancheri, F1
Manente, P1
Punt, CJ2
van Herpen, CM1
Vreugdenhil, G1
Muller, EW1
de Mulder, PH1
Hayat, K1
Jones, B1
Bisbrown, G1
Baria, K1
Pigott, T1
El-Deredy, W1
Ashmore, SM1
Branston, NM1
Darling, JL7
Williams, SR1
Thomas, DG5
Kormanik, PA1
Mornex, F1
Thiesse, P2
Mertens, P1
Helfre, S1
van Groeningen, CJ2
Witjes, RJ1
Weerts, JG1
Kralendonk, JH1
Bauman, GS2
Abele, M1
Leonhardt, M1
Urban, C1
Benesch, M1
Pakisch, B1
Lackner, H1
Kerbl, R1
Schwinger, W1
Oberbauer, R1
Pronk, LC1
Krouwer, HG1
Zonnenberg, BA1
Twijnstra, A1
Jamison, C1
Mathews, VP1
Heilman, DK1
Perry, JR1
Brown, MT1
Gockerman, JP1
Gundersen, S1
Lote, K1
Watne, K1
Celik, I1
Erman, M1
Kars, A1
Tekuzman, G1
Arcicasa, M1
Roncadin, M1
Bidoli, E1
Dedkov, A1
Gigante, M1
Trovò, MG1
Sankar, A1
Meyers, C1
Sawaya, RE1
Bruner, JM2
Peterson, P1
Vick, NA1
Jeremic, B2
Shibamoto, Y1
Gruijicic, D1
Milicic, B1
Stojanovic, M1
Nikolic, N1
Dagovic, A1
Aleksandrovic, J1
Scott, C1
Sandler, H1
Villikka, K1
Kivistö, KT1
Mäenpää, H1
Joensuu, H1
Neuvonen, PJ1
Källén, K1
Geijer, B1
Malmström, P1
Andersson, AM1
Holtås, S1
Ryding, E1
Rosén, I1
Streffer, J1
Schabet, M1
Grote, EH1
Voigt, K1
Boiardi, A2
Pozzi, A1
Salmaggi, A1
Broggi, G1
Silvani, A1
Hung, CF1
Lewandowicz, GM1
Harding, B1
Harkness, W1
Hayward, R1
Uhm, JH1
Choucair, A1
Flynn, PJ1
Hess, KR2
Deininger, MH1
Grote, E1
Wickboldt, J1
Lesser, GJ1
Wara, W3
Edwards, M1
Malec, M1
Ramsay, D1
Smith, A1
Bethune, CR1
Geyer, RJ1
Spence, AM1
Noël, G1
Röhn, TA1
Wagenknecht, B1
Roth, W1
Naumann, U1
Gulbins, E1
Krammer, PH1
Walczak, H1
Maleniak, TC1
Lowenstein, PR1
Castro, MG1
Qin, D2
Ou, G2
Mo, H2
Song, Y1
Kang, G1
Hu, Y1
Gu, X1
Diabira, S1
Rousselet, MC1
Gamelin, E1
Soulier, P1
Jadaud, E1
Menei, P1
Kyritsis, A1
Meyers, CA1
Ictech, SA1
Chang, E1
Kochi, M1
Ushio, Y1
Croteau, D1
Gangji, D1
Nouwynck, C1
Machin, D1
Greiner, RH1
Zimmerman, A1
Walker, MD5
Taylor, SG1
Nelson, L1
Baxter, D1
Rosenbaum, C1
Sponzo, RW1
Cunningham, TJ1
Olson, KB1
Horton, J1
Reagan, TJ1
Bisel, HF1
Childs, DS1
Layton, DD1
Rhoton, AL1
Taylor, WF1
Drafts, D1
Enot, KJ2
Pouillart, P8
Mathé, G4
Huguenin, P5
M'orin, P1
Buge, A4
Palangie, T3
Parrot, R4
Philippon, J1
van Effenterre, R1
Racadot, J1
Sichez, JP1
Ertel, IJ2
Boesel, C2
Williams, CJ1
Heiss, WD2
Turnheim, M1
Mamoli, B1
Monfardini, S2
Brambilla, C2
Solero, CL2
Vaghi, A2
Valagussa, P2
Morello, G2
Bonadonna, G2
Paillas, JE2
Prince, MA1
Hassoun, J1
Pellet, W2
Peragut, JC1
Bleher, EA1
Creech, RH1
Mietlowski, WL1
Perez, CA1
Costanza, M1
Buechler, M1
Munzenreider, J1
Emami, B1
Mukherji, B1
Shucart, W1
Scott, M1
Nathanson, L1
Rudders, R1
Stein, B1
Post, K1
Piro, A1
Kung, FH1
Nythan, WL1
Cuttner, J1
Falkson, G1
Lanzkowsky, P1
Del Duca, V1
Nawabi, IU1
Koch, K1
Pluess, H1
Freeman, A1
Burgert, EO1
Leone, LA1
Ruymann, F1
Patterson, RB1
Degnan, T1
Hakami, N1
Pajak, TF1
Holland, J1
Lheritier, J3
Gautier, H3
Morin, P4
Garrett, MJ2
Hughes, HJ2
Freedman, LS2
Strada, MR1
Schulz, U1
Lapukins, Z1
Baldini, M1
Princi, L1
Hasegawa, H1
Posner, JB1
Tamura, M1
Vassella, F2
Oster, MW1
Bataini, JP2
Mashaly, R2
Pertuiset, BF2
Metzger, J2
Hauw, JJ1
Williams, ME1
Jackson, DV1
Richards, F1
Cooper, MR1
Ferree, C1
Muss, HB1
White, DR1
Spurr, CL1
Imbach, P1
Wagner, HP1
Hilton, J3
Fumagalli, R3
Weiss, JF1
Pezzotta, S3
Racca, AR2
Crafts, DC2
Townsend, J1
Waterfield, WC1
Tashima, CK1
Hortobagyi, GN1
Blumenschein, GR1
Buzdar, AU1
Burgess, MA1
Pischer, TL1
Waldbaur, H1
Kuschnir, H1
Engelmann, U1
Schmidt, H1
Schmack, B1
Ward, HW1
Bloom, HJ1
Neidhardt, MK1
Loubrieu, G1
Elie, A1
Ribadeau Dumas, JL1
Kabra, PA1
Freeman-Dove, MA1
Stearns, J1
Byrd, A1
Finn, A1
Pollet, JF1
D'Estienne d'Orves, JF1
Thy, HT1
Ommaya, AK1
Ziegler, JL1
Magrath, IT1
Bluming, AZ1
Day, A1
Ng, R1
Liberman, L1
Terheggen, HG1
Fein, VJ1
Allan, AE1
Rottman, A1
Brihaye, J2
Weir, B1
Band, P1
Blain, G1
Mclean, D1
Wilson, F1
Mielke, B2
Grace, M1
Bramlet, D1
Giliberti, J1
Bender, J1
Brisman, R1
Housepian, EM1
Chang, C1
Duffy, P1
Balis, E1
Young, DF1
Maker, HS1
Syed, H1
Whetsell, W1
Lehrer, GM1
Thy, TH1
Gauthier, H1
Wasserman, TH1
Slavik, M1
Carter, SK1
Kumar, AR1
Levin, V2
Powell, M1
Ryall, RD1
Wagenknecht, L1
Michel, J1
Kenis, Y1
Jovanovic, D1
Djuric, LJ1
Jevremovic, S1
Mijatovic, LJ1
Fulton, DS2
Urtasun, RC2
Scott-Brown, I1
Johnson, ES1
Curry, B1
Huyser-Wierenga, D1
Hanson, J1
Feldstein, M1
Sneed, PK2
Weaver, KA2
Larson, DA2
Pyrich, M2
Gościński, I3
Krzyszkowski, T2
Hildebrand, JG1
Massin, F1
Coudert, B1
Foucher, P1
Lombard, JN1
Reybet-Degat, O1
Jeannin, L1
Camus, P1
Israel, L1
Breau, JL1
Morere, JF1
Boaziz, C1
Glass, J1
Gruber, ML1
Smith, D1
Rattner, B1
Leibel, SA1
Silver, P3
Ahn, DK1
Flam, MS1
Wong, KH1
Osterlind, K1
Sörenson, S1
Pedersen, AG1
Ogilvy-Stuart, AL1
Shalet, SM3
Gattamaneni, HR1
Fulton, LM1
Steinberg, HS1
Hannigan, J1
Arena, G1
Abbondandolo, A1
Rossi, O1
Gentile, SL1
Bruzzone, E1
Francaviglia, N1
Capellini, C1
Bradford, R1
Trojanowski, T3
Turowski, K3
Peszyński, J3
Koźniewska, H1
Gaetani, P1
Assietti, R1
Gaspar, LE1
Jenkin, RD2
Boesel, CP1
Venes, JL1
Ortega, JA1
Hammond, D1
Constantinovici, A1
Cristescu, AM1
Markiewicz, P1
Bielawski, A2
Bendarzewska, B1
Szymona, J1
Dabrowska, A1
Lopatkiewicz, J1
Clayton, PE2
Price, DA2
Jones, PH1
Livesey, EA2
Brook, CG2
Friedman, HS1
Schold, SC1
Djang, WT1
Kurtzberg, J1
Longee, DC1
Halperin, EC1
Falletta, JM1
Coleman, RE1
Oakes, WJ1
McDermott, M1
Krouwer, D1
Wilson, C2
Evans, CG1
Bodell, WJ1
Tokuda, K1
Doane-Setzer, P1
Smith, MT1
Lichter, AS1
Bunn, PA1
Ihde, DC1
Cohen, MH1
Makuch, RW1
Carney, DN1
Johnston-Early, A1
Minna, JD1
Glatstein, E1
Kapp, JP1
Vance, RB1
Steinbok, P1
Dolman, CL1
Goldie, JH1
Hatlevoll, R1
Lindegaard, KF1
Kristiansen, K1
Nesbakken, R1
Torvik, A1
Ganz, JC1
Mella, O1
Rosengren, B1
Ringkjöb, R1
Müller, H1
Brock, M1
Ernst, H1
Gerosa, MA1
Rosenblum, ML1
Stevanoni, G1
Licata, C1
Della Corte, V1
Marcon, C1
Bricolo, A1
Tridente, G1
Chak, LY1
Zatz, LM1
Wasserstein, P1
Cox, RS1
Kushlan, PD1
Porzig, KJ1
Sikic, BI1
Wilson, WB1
Perez, GM1
Kleinschmidt-Demasters, BK1
McKinnon, S1
Tanasichuk, H1
Pendergrass, TW1
Mulne, AF1
Kosnik, EJ1
Morris, JD1
Heideman, RL1
Ruymann, FB1
Stuntz, JT1
Bleyer, WA1
Kamiński, S1
Reinfus, M1
Leszczyk, C1
Campbell, RH1
Siegel, KR2
D'Angio, G1
Bunin, GR1
Schut, L2
Lefkowitz, IB1
Bruce, DA1
Retsas, S1
Gershuny, AR1
Rodriguez, LA1
Arkhipov, AI1
Vilenskiĭ, BS1
Chastagner, P1
Olive, D1
Philip, T1
Zucker, JM1
Czorny, A1
Lapras, C1
Brunat-Mentigny, M1
Carcavilla, LI1
Gómez Perún, J1
Alberdi, J1
Eiras, J1
Arana, T1
Pisón, J1
Linfoot, PA1
Gray, JW1
Dean, PN1
Hoag, G1
Sima, AA1
Rozdilsky, B1
McKenney, SA1
Fehir, KM1
Kerpel-Fronius, S1
Hellwig, D1
Simon, H1
Ertel, I1
Evans, A1
Hittle, R1
Anderson, J1
Sulis, E1
Floris, C1
Chessa, A1
Desogus, A1
Muggiano, A1
Tedde, A1
Turno, R1
Repetto, L1
Grimaldi, A1
Ardizzoni, A1
Sertoli, MR1
Rosso, R1
Roberts, JT1
Paul, EA1
Mott, TJ1
Godlee, JN1
Tobias, JS1
Capra, LG1
Collins, CD1
Mooney, C1
Bozek, T1
Ellis, ME1
Kuperminc, M1
Oi, S1
Matsumoto, S1
Raimondi, AJ1

Clinical Trials (27)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Improvement of Functional Outcome for Patients With Newly Diagnosed Grade II or III Glioma With Co-deletion of 1p/19q - IMPROVE CODEL: the NOA-18 Trial[NCT05331521]Phase 3406 participants (Anticipated)Interventional2021-04-07Recruiting
INTELLANCE-2: ABT-414 Alone or ABT-414 Plus Temozolomide Versus Lomustine or Temozolomide for Recurrent Glioblastoma: A Randomized Phase 2 Study of the EORTC Brain Tumor Group[NCT02343406]Phase 2266 participants (Actual)Interventional2015-02-17Completed
Phase III Trial of CCNU/Temozolomide (TMZ) Combination Therapy vs. Standard TMZ Therapy for Newly Diagnosed MGMT-methylated Glioblastoma Patients[NCT01149109]Phase 3141 participants (Actual)Interventional2010-10-31Completed
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma[NCT02414165]Phase 2/Phase 3403 participants (Actual)Interventional2015-11-30Terminated (stopped due to Sponsor Decision)
Phase III Trial Exploring the Combination of Bevacizumab and Lomustine in Patients With First Recurrence of a Glioblastoma[NCT01290939]Phase 3592 participants (Actual)Interventional2011-10-31Completed
Evaluation of ex Vivo Drug Combination Optimization Platform in Recurrent High Grade Astrocytic Glioma[NCT05532397]10 participants (Anticipated)Interventional2023-02-17Recruiting
A Phase III, Randomised, Parallel Group, Multi-Centre Study in Recurrent Glioblastoma Patients to Compare the Efficacy of Cediranib [RECENTIN™, AZD2171] Monotherapy and the Combination of Cediranib With Lomustine to the Efficacy of Lomustine Alone[NCT00777153]Phase 3423 participants (Actual)Interventional2008-10-31Completed
Precoce Medical Care by the Mobil Support for Patients With Glioblastoma Receiving Specific Medical Oncology Treatment[NCT04516733]35 participants (Actual)Interventional2019-05-10Completed
A Phase II Study of Observation in Favorable Low-Grade Glioma and a Phase II Study of Radiation With or Without PCV Chemotherapy in Unfavorable Low-Grade Glioma[NCT00003375]Phase 2/Phase 3370 participants (Actual)Interventional1998-10-31Completed
Phase II Study of Bevacizumab and Nimustine in Patients With Recurrent High Grade Glioma[NCT02698280]Phase 223 participants (Actual)Interventional2015-07-31Completed
Temozolomide Plus Bevacizumab Chemotherapy in Supratentorial Glioblastoma in 70 Years and Older Patients With an Impaired Functional Status (KPS<70)[NCT02898012]Phase 270 participants (Actual)Interventional2010-10-31Completed
A Phase 2 Study of LY2157299 Monohydrate Monotherapy or LY2157299 Monohydrate Plus Lomustine Therapy Compared to Lomustine Monotherapy in Patients With Recurrent Glioblastoma[NCT01582269]Phase 2180 participants (Anticipated)Interventional2012-04-26Active, not recruiting
PHASE III STUDY OF ADJUVANT PROCARBAZINE, CCNU AND VINCRISTINE CHEMOTHERAPY IN PATIENTS WITH HIGHLY ANAPLASTIC OLIGODENDROGLIOMA[NCT00002840]Phase 3350 participants (Anticipated)Interventional1996-08-31Completed
Phase III Intergroup Randomized Comparison of Radiation Alone vs. Pre-Radiation Chemotherapy for Pure and Mixed Anaplastic Oligodendrogliomas[NCT00002569]Phase 3299 participants (Actual)Interventional1994-07-31Completed
Randomized Phase 3 Open Label Study - Enzastaurin vs. Lomustine in Glioblastoma[NCT00295815]Phase 3397 participants (Actual)Interventional2006-01-31Completed
Chemotherapy for Progressive Low Grade Astrocytoma in Children Less Than Ten Years Old[NCT00002944]Phase 3428 participants (Actual)Interventional1997-04-30Completed
A Prospective Cohort to Study the Effect of Postoperative Upfront Temozolomide Chemotherapy on IDH Mutational Low Grade Gliomas in Eloquent Areas[NCT02209428]Phase 254 participants (Actual)Interventional2014-06-30Active, not recruiting
PHASE II STUDY OF PREIRRADIATION PCV CHEMOTHERAPY IN PATIENTS WITH SUPRATENTORIAL LOW-GRADE GLIOMAS[NCT00002806]Phase 243 participants (Actual)Interventional1996-07-31Completed
Second Line Chemotherapy With Temozolomide in Recurrent Oligodendroglial Tumors After PCV-Chemotherapy[NCT00003304]Phase 229 participants (Anticipated)Interventional1998-04-30Completed
A Phase I Trial of Enzastaurin (LY317615) in Combination With Carboplatin in Adults With Recurrent Gliomas[NCT01445119]Phase 158 participants (Actual)Interventional2007-01-31Completed
A Phase I Study of Temozolomide and CCNU in Pediatric Patients With Newly Diagnosed Incompletely Resected Non-Brainstem High-Grade Gliomas[NCT00006024]Phase 132 participants (Actual)Interventional2000-11-30Completed
Phase II, Single Arm, Open Label Clinical Trial With Irinotecan in Combination With Cisplatin in Pediatric Patients With Unfavorable Prognosis Gliomas[NCT01574092]Phase 239 participants (Actual)Interventional2009-11-30Completed
A Phase I Trial of Lenalidomide and Radiotherapy in Children With Diffuse Intrinsic Pontine Gliomas and High-grade Gliomas[NCT01222754]Phase 129 participants (Actual)Interventional2010-11-23Completed
A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-Ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors[NCT00994071]Phase 19 participants (Actual)Interventional2009-09-22Completed
Does Varenicline Influence Alcohol Consumption in Alcohol Dependent Individuals?[NCT00846859]Phase 2162 participants (Actual)Interventional2009-03-31Completed
A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas[NCT01837862]Phase 1/Phase 236 participants (Anticipated)Interventional2013-10-22Recruiting
A Prospective National Study to Molecularly and Genetically Characterize Human Gliomas: The Glioma Molecular Diagnostic Initiative[NCT00031538]674 participants (Actual)Observational2002-03-01Terminated
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Adult Study: Objective Response Rate (ORR)

The objective response rate (ORR) included best overall responses - complete response (CR) and partial response (PR) - assessed by the independent review committee per response assessment in neurooncology criteria (RANO) criteria from the date of randomization until disease progression or death, whichever came first. All objective responses (CR and PR) must be have been confirmed by repeat MRI 4 weeks after the first time when CR or PR is identified. Any subject who did not meet CR or PR including those who did not have post-baseline radiological assessments was considered a nonresponder. (NCT02343406)
Timeframe: Every 8 weeks at each assessment of disease, up to 28 months

Interventionpercentage of participants (Number)
ABT-414/Temozolomide14.3
ABT-414_adult7.7
Control (Temozolomide/Lomustine)4.4

Pediatric Study: Area Under the Concentration-time Curve (AUC) Observed for ABT-414

AUC is a measure of how long and how much drug is present in the body after dosing. The AUC of depatuxizumab mafodotin (ABT-414) in the pediatric population was measured following treatment to confirm that this was comparable to adults, and that the dosing levels are appropriate for a pediatric population. (NCT02343406)
Timeframe: Samples collected Cycle 1 Days 1, 2,3,5,8,15; Cycle 2 Day 1; Cycle 3 Day 1; Cycle 5 Day 1; Day 1 of every two cycles starting with Cycle 5; and 35 days after the last dose

Interventionµg*h/mL (Mean)
ABT-414_ Pediatric3170

Pediatric Study: Area Under the Concentration-time-curve (AUC) Observed for Unconjugated Cys-mcMMAF

AUC is a measure of how long and how much drug or drug metabolite is present in the body after dosing. The AUC of Cys-mcMMAF, a toxic metabolite of depatuxizumab mafodotin, in the pediatric population was measured following treatment to confirm that this was comparable to adults, and that the dosing levels are appropriate for a pediatric population. (NCT02343406)
Timeframe: Samples collected Cycle 1 Days 1, 2, 3, 5, 8

Interventionng*h/mL (Mean)
ABT-414_ Pediatric14.1

Pediatric Study: Half-life (t1/2) Observed for ABT-414

Half-life is the calculated time it takes for half of the drug to leave the body. (NCT02343406)
Timeframe: Samples collected Cycle 1 Days 1, 2,3,5,8,15; Cycle 2 Day 1; Cycle 3 Day 1; Cycle 5 Day 1; Day 1 of every two cycles starting with Cycle 5; and 35 days after the last dose

Interventiondays (Mean)
ABT-414_ Pediatric9.0

Pediatric Study: Half-life (t1/2) Observed for Cys-mcMMAF

Half-life is the calculated time it takes for half of the drug or drug metabolite to leave the body. CysmcMMAF is a toxic metabolite of depatuxizumab mafodotin. (NCT02343406)
Timeframe: Samples collected Cycle 1 Days 1, 2, 3, 5, 8

Interventiondays (Mean)
ABT-414_ Pediatric11.2

Pediatric Study: Maximum Observed Plasma Concentration (Cmax) of Cys-mcMMAF

Cmax is the peak concentration that a drug or drug metabolite achieves in a specified compartment after the drug has been administrated and before administration of a second dose. Cys-mcMMAF is a toxic metabolite of depatuxizumab mafodotin. (NCT02343406)
Timeframe: Samples collected Cycle 1 Days 1, 2, 3, 5, 8

Interventionng/mL (Mean)
ABT-414_ Pediatric0.272

Pediatric Study: Maximum Observed Serum Concentration (Cmax) of ABT-414

Cmax is the peak concentration that a drug achieves in a specified compartment after the drug has been administrated and before administration of a second dose. (NCT02343406)
Timeframe: Samples collected Cycle 1 Days 1, 2,3,5,8,15; Cycle 2 Day 1; Cycle 3 Day 1; Cycle 5 Day 1; Day 1 of every two cycles starting with Cycle 5; and 35 days after the last dose

Interventionµg/mL (Mean)
ABT-414_ Pediatric31.4

Pediatric Study: Percentage of Participants With Adverse Events From the First Visit Until 49 Days After the Last Dose of Study Drug

The severity of each adverse event was rated according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE Version 4.0) (NCT02343406)
Timeframe: From participant's first visit until 49 days after the participant's last dose of study drug, up to 63 weeks

Interventionpercentage of participants (Number)
ABT-414_ Pediatric100

Adult Study: Overall Survival (OS)

Overall Survival (OS) was defined as time from randomization to death due to any cause, regardless of whether the event occurred on or off study drug (depatuxizumab mafodotin/temozolomide/lomustine). (NCT02343406)
Timeframe: From the date of randomization up to the date of participant's death; participants who completed treatment were to be assessed every 12 weeks, up to 28 months.

,,
Interventionmonths (Number)
25th quartile50th quartile75th quartile
ABT-414_adult4.67.915.5
ABT-414/Temozolomide5.79.616.9
Control (Temozolomide/Lomustine)4.98.212.6

Adult Study: Overall Survival in the Subgroup With Epidermal Growth Factor Receptor (EGFRvIII) Mutation

Overall Survival (OS) was defined as time from randomization to death due to any cause, regardless of whether the event occurred on or off study drug (depatuxizumab mafodotin/temozolomide/lomustine) for all randomized participants that had the Epidermal Growth Factor Receptor (EGFRvIII) mutation. (NCT02343406)
Timeframe: From the date of randomization up to the date of participant's death; participants who completed treatment were to be assessed every 12 weeks, up to 28 months

,,
Interventionmonths (Number)
25th quartile50th quartile75th quartile
ABT-414_adult5.08.413.9
ABT-414/Temozolomide6.39.414.4
Control (Temozolomide/Lomustine)4.77.512.4

Adult Study: Progression-Free Survival (PFS)

Progression-free survival was assessed per response assessment in neuro-oncology criteria (RANO) criteria and assessed by an independent review committee and was defined as the length of time during and after the treatment of a disease, that the participant lived with the disease but did not get worse. (NCT02343406)
Timeframe: Measured every 8 weeks from date of randomization until the date of first objective progression or subject's death, whichever occurred first, up to 2 years

,,
Interventionmonths (Number)
25th quartile50th quartile75th quartile
ABT-414_adult1.51.93.5
ABT-414/Temozolomide1.82.74.9
Control (Temozolomide/Lomustine)1.61.94.2

Alive and Progression Free Rate at 6 Months (APF6)

Proportion of patients alive and progression free at 6 months (based on central review) as estimated from Kaplan-Meier techniques. Values are percentages. (NCT00777153)
Timeframe: 6 Months

Intervention% of patients alive and progression free (Number)
Cediranib 30mg16.2
Cediranib 20mg + Lomustine 100mg34.5
Lomustine 100mg24.5

Daily Steroid Dose

The mean steroid dosage prior to treatment will be considered as the patient's baseline. The percent change in average daily steroid dosage from baseline is calculated by following formula: PC = (md - bm)/bm*100; where PC is the percent change in average daily steroid dosage from baseline; md the mean daily steroid dosage recorded from the first day of therapy to progression; and bm the baseline mean. (NCT00777153)
Timeframe: Baseline to the date of first documented progression or date of death or study discontinuation, whichever came first, assed up to 2014-April-25

Interventionpercentage of change (Number)
Cediranib 30mg-17.6
Cediranib 20mg + Lomustine 110mg-1.8
Lomustine 110mg36.6

Overall Survival (OS)

Number of months from randomisation to the date of death from any cause (NCT00777153)
Timeframe: Baseline through to date of death up to 25th April 2010

InterventionMonths (Median)
Cediranib 30mg8.0
Cediranib 20mg + Lomustine 110mg9.4
Lomustine 110mg9.8

Progression Free Survival (PFS)

"For patients with measurable disease at entry (at least one lesion that has a shortest diameter~≥10 mm at baseline on 2 axial slices), PFS will be defined as the earliest time that:~The sum of the products of the largest perpendicular diameters of contrast enhancement for all lesions has increased by a greater than or equal to 25% in comparison to the nadir scan as long as the shortest diameter is ≥15 mm. If the dose of steroids has been reduced within the 10 days prior to the scan being conducted, progression will be based on a follow-up scan performed after the dose of steroids has been stabilized for 10 days.~The patient has died from any cause.~A new lesion is detected that is outside the original tumor volume and has a shortest diameter ≥10 mm." (NCT00777153)
Timeframe: Baseline at 6 weeks and then every 6 weeks to discontinuation

InterventionDays (Median)
Cediranib 30mg92
Cediranib 20mg+ Lomustine 110mg125
Lomustine 110mg82

Response Rate

"An individual visit response of PR was defined as a greater than or equal to 50% reduction in the sum of the products of the largest perpendicular diameters of contrast enhancement for all lesions compared to baseline as long as the steroid dose has not been increased within the previous 10 days and no new lesions are present.~An individual visit response of CR was defined as the complete disappearance of all tumor on MRI scan." (NCT00777153)
Timeframe: Baseline at 6 weeks and then every 6 weeks to discontinuation

InterventionParticipants (Number)
Cediranib 30mg18
Cediranib 20mg + Lomustine 110mg21
Lomustine 110mg5

Steroid Free Days

Number of days known not to have used any steroids prior to progression (NCT00777153)
Timeframe: Baseline to the date of first documented progression or date of death or study discontinuation, whichever came first, assessed up to 2014-April-25

InterventionDays (Mean)
Cediranib 30mg75.8
Cediranib 20mg + Lomustine 119mg74.8
Lomustine 110mg92.3

Reviews

47 reviews available for lomustine and Benign Neoplasms, Brain

ArticleYear
Treatment options for progression or recurrence of glioblastoma: a network meta-analysis.
    The Cochrane database of systematic reviews, 2021, 05-04, Volume: 5

    Topics: Brain Neoplasms; Glioblastoma; Humans; Lomustine; Neoplasm Recurrence, Local; Network Meta-Analysis

2021
Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between objective response rate and median overall survival.
    Neuro-oncology, 2023, 06-02, Volume: 25, Issue:6

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Brain Neoplasms; Glioblastoma; Humans; Lomustine; Ne

2023
Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV.
    Cancer medicine, 2020, Volume: 9, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Chemoradiotherapy, Adjuvant;

2020
How did lomustine become standard of care in recurrent glioblastoma?
    Cancer treatment reviews, 2020, Volume: 87

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Glioblastoma; Humans; Lomustine; Ne

2020
Is chemotherapy alone an option as initial treatment for low-grade oligodendrogliomas?
    Current opinion in neurology, 2020, Volume: 33, Issue:6

    Topics: Antineoplastic Agents; Brain Neoplasms; Humans; Lomustine; Oligodendroglioma; Temozolomide; Treatmen

2020
Procarbazine, lomustine and vincristine for recurrent high-grade glioma.
    The Cochrane database of systematic reviews, 2017, 07-26, Volume: 7

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cytarabine; Dacarbazine; Dis

2017
Anti-angiogenic therapy for high-grade glioma.
    The Cochrane database of systematic reviews, 2018, 11-22, Volume: 11

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brai

2018
[Management of gliomas].
    Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2014, Volume: 18, Issue:5-6

    Topics: Age Factors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Co

2014
Antiangiogenic therapy for high-grade glioma.
    The Cochrane database of systematic reviews, 2014, Sep-22, Issue:9

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brai

2014
Practice changing mature results of RTOG study 9802: another positive PCV trial makes adjuvant chemotherapy part of standard of care in low-grade glioma.
    Neuro-oncology, 2014, Volume: 16, Issue:12

    Topics: Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Clinical Trials, Phase III as T

2014
Low-grade gliomas.
    Continuum (Minneapolis, Minn.), 2015, Volume: 21, Issue:2 Neuro-on

    Topics: Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression;

2015
Procarbazine, lomustine and vincristine or temozolomide: which is the better regimen?
    CNS oncology, 2015, Volume: 4, Issue:5

    Topics: Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Humans; Lomustine; Ol

2015
Procarbazine--a traditional drug in the treatment of malignant gliomas.
    Current medicinal chemistry, 2008, Volume: 15, Issue:14

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cli

2008
[Clinicopathological diagnosis of gliomas by genotype analysis].
    Brain and nerve = Shinkei kenkyu no shinpo, 2009, Volume: 61, Issue:7

    Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms;

2009
[Treatment of glioma with temozolomide].
    Brain and nerve = Shinkei kenkyu no shinpo, 2009, Volume: 61, Issue:7

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Pro

2009
Chemotherapy for diffuse low-grade gliomas in adults.
    Revue neurologique, 2011, Volume: 167, Issue:10

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Chemother

2011
Chemotherapy in low-grade gliomas.
    Current opinion in oncology, 2012, Volume: 24, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Clinical Trials

2012
Integrated phase II/III clinical trials in oncology: a case study.
    Clinical trials (London, England), 2012, Volume: 9, Issue:6

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto

2012
Conformal irradiation for pure and mixed oligodendroglioma: the experience of Centre Leon Berard Lyon.
    International journal of radiation oncology, biology, physics, 2003, May-01, Volume: 56, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brain Damage, Chronic; Brain Injuries

2003
Oligodendroglioma and anaplastic oligodendroglioma: clinical features, treatment, and prognosis.
    Surgical neurology, 2003, Volume: 60, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine

2003
The role of PCV chemotherapy in the treatment of central neurocytoma: illustration of a case and review of the literature.
    Surgical neurology, 2003, Volume: 60, Issue:6

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Female; Humans; Lomusti

2003
Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression.
    Neurology, 2004, Aug-10, Volume: 63, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Artifacts; Astrocytoma; Brain Edema; Brain Neoplasms

2004
[The molecular genetics of oligodendroglioma].
    Zhonghua bing li xue za zhi = Chinese journal of pathology, 2004, Volume: 33, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chromosomes, Human, Pair 1; Chromos

2004
[Brief review of the neuro oncology for recent three decades in Japan].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain; Brain Neoplasms; Humans;

2005
Anaplastic oligodendroglioma and oligoastrocytoma.
    Neurologic clinics, 2007, Volume: 25, Issue:4

    Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brai

2007
[Clinical significance of mustoforan in management of malignant glioma].
    Voprosy onkologii, 2007, Volume: 53, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Astrocytoma; Blood-Brain Barr

2007
High dose chemotherapy with autologous bone marrow rescue for high grade gliomas of the brain: a potential for improvement in therapeutic results.
    Neurosurgery, 1984, Volume: 15, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Brain Neoplasms; Carmus

1984
Management of small cell cancer: radiotherapy.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 1984, Volume: 92

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Small Cell; Combined Mod

1984
Carcinogenic N-nitroso compounds and their environmental significance.
    Die Naturwissenschaften, 1984, Volume: 71, Issue:1

    Topics: Alkylation; Animals; Brain Neoplasms; Carcinogens; Carcinogens, Environmental; Carmustine; Dimethyln

1984
Treatment of neuroectodermal brain tumors.
    Annals of neurology, 1982, Volume: 12, Issue:3

    Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Astrocytoma; Blood-Brain Barrier; Brain Neoplasms;

1982
The nitrosoureas: carmustine (BCNU) and lomustine (CCNU).
    Cancer treatment reviews, 1982, Volume: 9, Issue:4

    Topics: Bone Marrow; Brain Neoplasms; Carmustine; Drug Therapy, Combination; Gastrointestinal Neoplasms; Hod

1982
Aggressive oligodendroglioma: a chemosensitive tumor.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 1994, Volume: 135

    Topics: Alkylating Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Ad

1994
Acute leukemia following treatment of malignant glioma.
    Journal of neuro-oncology, 1998, Volume: 40, Issue:1

    Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Fatal Outcome

1998
Chemotherapy of low-grade gliomas.
    Seminars in radiation oncology, 2001, Volume: 11, Issue:2

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Chi

2001
Multidisciplinary management of adult anaplastic oligodendrogliomas and anaplastic mixed oligo-astrocytomas.
    Seminars in radiation oncology, 2001, Volume: 11, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Therapy; G

2001
PCV chemotherapy for oligodendroglioma: response analyzed on T2 weighted-MRI.
    Journal of neuro-oncology, 2001, Volume: 55, Issue:1

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined M

2001
[Chemo-radiotherapy for malignant brain tumors].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Central Nervous System

2002
Adults with newly diagnosed high-grade gliomas.
    Current treatment options in oncology, 2001, Volume: 2, Issue:6

    Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Antioxidan

2001
Immunotherapy of gliomas: a review.
    Advances in neurology, 1976, Volume: 15

    Topics: Adult; Animals; Azaguanine; BCG Vaccine; Brain; Brain Neoplasms; Child; Disease Models, Animal; Glio

1976
A pharmacologic basis for brain tumor chemotherapy.
    Seminars in oncology, 1975, Volume: 2, Issue:1

    Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Division; Doxorubicin; Drug Interactions; Huma

1975
Chemotherapy: the agents in current use.
    Seminars in oncology, 1975, Volume: 2, Issue:1

    Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Dacarbazine; Drug Therapy, Combination; Glioma;

1975
Clinical comparison of the nitrosoureas.
    Cancer, 1975, Volume: 36, Issue:4

    Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Carmustine; Chemical Phenomena; C

1975
[Nitrosourea-induced lung diseases].
    Revue des maladies respiratoires, 1992, Volume: 9, Issue:6

    Topics: Adult; Brain Neoplasms; Carmustine; Child; Drug Therapy, Combination; Female; Humans; Iatrogenic Dis

1992
Aggressive oligodendroglioma: a chemosensitive tumor.
    Neurosurgery, 1992, Volume: 31, Issue:1

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Crani

1992
Preliminary study of lomustine in the treatment of intracranial masses in dogs following localization by imaging techniques.
    Seminars in veterinary medicine and surgery (small animal), 1990, Volume: 5, Issue:4

    Topics: Animals; Brain Neoplasms; Dog Diseases; Dogs; Lomustine; Magnetic Resonance Imaging; Tomography, X-R

1990
The role of radiation therapy in the treatment of small cell lung cancer.
    Cancer, 1985, May-01, Volume: 55, Issue:9 Suppl

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Small Cell; Clinical Tri

1985
Chemotherapy of primary brain tumors.
    Neurologic clinics, 1985, Volume: 3, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Brain Stem; Child; Efl

1985

Trials

149 trials available for lomustine and Benign Neoplasms, Brain

ArticleYear
Improvement of functional outcome for patients with newly diagnosed grade 2 or 3 gliomas with co-deletion of 1p/19q - IMPROVE CODEL: the NOA-18 trial.
    BMC cancer, 2022, Jun-13, Volume: 22, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Humans; Lomustine; Neoplasm

2022
Thrombocytopenia limits the feasibility of salvage lomustine chemotherapy in recurrent glioblastoma: a secondary analysis of EORTC 26101.
    European journal of cancer (Oxford, England : 1990), 2023, Volume: 178

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Feasibility Studies; G

2023
Thrombocytopenia limits the feasibility of salvage lomustine chemotherapy in recurrent glioblastoma: a secondary analysis of EORTC 26101.
    European journal of cancer (Oxford, England : 1990), 2023, Volume: 178

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Feasibility Studies; G

2023
Thrombocytopenia limits the feasibility of salvage lomustine chemotherapy in recurrent glioblastoma: a secondary analysis of EORTC 26101.
    European journal of cancer (Oxford, England : 1990), 2023, Volume: 178

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Feasibility Studies; G

2023
Thrombocytopenia limits the feasibility of salvage lomustine chemotherapy in recurrent glioblastoma: a secondary analysis of EORTC 26101.
    European journal of cancer (Oxford, England : 1990), 2023, Volume: 178

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Feasibility Studies; G

2023
Thrombocytopenia limits the feasibility of salvage lomustine chemotherapy in recurrent glioblastoma: a secondary analysis of EORTC 26101.
    European journal of cancer (Oxford, England : 1990), 2023, Volume: 178

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Feasibility Studies; G

2023
Thrombocytopenia limits the feasibility of salvage lomustine chemotherapy in recurrent glioblastoma: a secondary analysis of EORTC 26101.
    European journal of cancer (Oxford, England : 1990), 2023, Volume: 178

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Feasibility Studies; G

2023
Thrombocytopenia limits the feasibility of salvage lomustine chemotherapy in recurrent glioblastoma: a secondary analysis of EORTC 26101.
    European journal of cancer (Oxford, England : 1990), 2023, Volume: 178

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Feasibility Studies; G

2023
Thrombocytopenia limits the feasibility of salvage lomustine chemotherapy in recurrent glioblastoma: a secondary analysis of EORTC 26101.
    European journal of cancer (Oxford, England : 1990), 2023, Volume: 178

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Feasibility Studies; G

2023
Thrombocytopenia limits the feasibility of salvage lomustine chemotherapy in recurrent glioblastoma: a secondary analysis of EORTC 26101.
    European journal of cancer (Oxford, England : 1990), 2023, Volume: 178

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Feasibility Studies; G

2023
Patterns, predictors and prognostic relevance of high-grade hematotoxicity after temozolomide or temozolomide-lomustine in the CeTeG/NOA-09 trial.
    Journal of neuro-oncology, 2023, Volume: 161, Issue:1

    Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Lomus

2023
Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2023, 10-02, Volume: 29, Issue:19

    Topics: Bevacizumab; Biomarkers; Brain Neoplasms; DNA Methylation; DNA Modification Methylases; DNA Repair E

2023
INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma.
    Neuro-oncology, 2020, 05-15, Volume: 22, Issue:5

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Brain Neoplasms; ErbB Receptor

2020
Phosphorylated Acetyl-CoA Carboxylase Is Associated with Clinical Benefit with Regorafenib in Relapsed Glioblastoma: REGOMA Trial Biomarker Analysis.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 09-01, Volume: 26, Issue:17

    Topics: Acetyl-CoA Carboxylase; Biomarkers, Tumor; Brain; Brain Neoplasms; Chemotherapy, Adjuvant; Female; G

2020
Noninvasive Characterization of Tumor Angiogenesis and Oxygenation in Bevacizumab-treated Recurrent Glioblastoma by Using Dynamic Susceptibility MRI: Secondary Analysis of the European Organization for Research and Treatment of Cancer 26101 Trial.
    Radiology, 2020, Volume: 297, Issue:1

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasms; Contrast M

2020
MGMT promoter methylation analysis for allocating combined CCNU/TMZ chemotherapy: Lessons learned from the CeTeG/NOA-09 trial.
    International journal of cancer, 2021, 04-01, Volume: 148, Issue:7

    Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor

2021
Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma: A Randomized Clinical Trial.
    JAMA oncology, 2020, 12-01, Volume: 6, Issue:12

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neop

2020
Randomized phase II trial comparing axitinib with the combination of axitinib and lomustine in patients with recurrent glioblastoma.
    Journal of neuro-oncology, 2018, Volume: 136, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating

2018
Lomustine and Bevacizumab in Progressive Glioblastoma.
    The New England journal of medicine, 2017, 11-16, Volume: 377, Issue:20

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemother

2017
Lomustine and Bevacizumab in Progressive Glioblastoma.
    The New England journal of medicine, 2017, 11-16, Volume: 377, Issue:20

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemother

2017
Lomustine and Bevacizumab in Progressive Glioblastoma.
    The New England journal of medicine, 2017, 11-16, Volume: 377, Issue:20

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemother

2017
Lomustine and Bevacizumab in Progressive Glioblastoma.
    The New England journal of medicine, 2017, 11-16, Volume: 377, Issue:20

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemother

2017
New clinical, pathological and molecular prognostic models and calculators in patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European Organisation for Research and Treatment of Cancer Brai
    European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:16

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Biomarkers, Tu

2013
Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Sep-10, Volume: 31, Issue:26

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Female; Follow-Up Studies; Glioblas

2013
Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Sep-10, Volume: 31, Issue:26

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Female; Follow-Up Studies; Glioblas

2013
Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Sep-10, Volume: 31, Issue:26

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Female; Follow-Up Studies; Glioblas

2013
Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Sep-10, Volume: 31, Issue:26

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Female; Follow-Up Studies; Glioblas

2013
Effect of the addition of chemotherapy to radiotherapy on cognitive function in patients with low-grade glioma: secondary analysis of RTOG 98-02.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Feb-20, Volume: 32, Issue:6

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy, Adjuvant;

2014
Upfront chemotherapy with CCNU alone for adults' low-grade gliomas: a clinical analysis.
    Journal of neuro-oncology, 2014, Volume: 117, Issue:2

    Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Disease-Free Survival; Female

2014
Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Mar-10, Volume: 32, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Chi-Square Distr

2014
Patients with primary brain tumors.
    Oncology nursing forum, 2014, Volume: 41, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Che

2014
Prognostic and predictive markers in recurrent high grade glioma; results from the BR12 randomised trial.
    Acta neuropathologica communications, 2014, Jun-20, Volume: 2

    Topics: Antineoplastic Agents; Brain Neoplasms; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Dac

2014
Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.
    The Lancet. Oncology, 2014, Volume: 15, Issue:9

    Topics: Administration, Oral; Adolescent; Adult; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neopl

2014
Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.
    The Lancet. Oncology, 2014, Volume: 15, Issue:9

    Topics: Administration, Oral; Adolescent; Adult; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neopl

2014
Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.
    The Lancet. Oncology, 2014, Volume: 15, Issue:9

    Topics: Administration, Oral; Adolescent; Adult; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neopl

2014
Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.
    The Lancet. Oncology, 2014, Volume: 15, Issue:9

    Topics: Administration, Oral; Adolescent; Adult; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neopl

2014
Joint modeling of longitudinal health-related quality of life data and survival.
    Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 2015, Volume: 24, Issue:4

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Female; Hu

2015
The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: results of the randomised controlled phase 2 BELOB trial.
    European journal of cancer (Oxford, England : 1990), 2015, Volume: 51, Issue:10

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che

2015
Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial.
    British journal of cancer, 2015, Jul-14, Volume: 113, Issue:2

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antigens, CD; Antineoplastic Combined Chemotherapy P

2015
Sunitinib Malate plus Lomustine for Patients with Temozolomide-refractory Recurrent Anaplastic or Low-grade Glioma.
    Anticancer research, 2015, Volume: 35, Issue:10

    Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neop

2015
The role of temozolomide in the management of patients with newly diagnosed anaplastic astrocytoma: a comparison of survival in the era prior to and following the availability of temozolomide.
    Journal of neuro-oncology, 2016, Volume: 127, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Dacarbazin

2016
Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial.
    Cancer research, 2016, Feb-01, Volume: 76, Issue:3

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; B

2016
A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma.
    Neuro-oncology, 2016, Volume: 18, Issue:8

    Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Disease-Free Survival; Drug Therapy, Combination

2016
Randomized phase II study of axitinib versus physicians best alternative choice of therapy in patients with recurrent glioblastoma.
    Journal of neuro-oncology, 2016, Volume: 128, Issue:1

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Axitinib; Bevacizumab; Brai

2016
Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children's Oncology Group ACNS0423 study.
    Neuro-oncology, 2016, Volume: 18, Issue:10

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Chil

2016
Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma.
    The New England journal of medicine, 2016, Apr-07, Volume: 374, Issue:14

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Combined Modali

2016
[Not Available].
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2016, Volume: 192, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Chemoradiotherapy; Dis

2016
A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma.
    Journal of neuro-oncology, 2016, Volume: 129, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Dose-Response Relationship, Drug;

2016
Comparison of 2D (RANO) and volumetric methods for assessment of recurrent glioblastoma treated with bevacizumab-a report from the BELOB trial.
    Neuro-oncology, 2017, 06-01, Volume: 19, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Contrast Media; Gliobl

2017
[Postoperative chemoradiotherapy for cerebral glioblastoma].
    Voprosy onkologii, 2008, Volume: 54, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemothera

2008
Phase II study of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU; NSC-79037) in the treatment of brain tumors.
    Cancer chemotherapy reports, 1972, Volume: 56, Issue:3

    Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Brain Neoplasms; Humans; Lomustine; Neoplas

1972
Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951.
    Neuro-oncology, 2009, Volume: 11, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Cell Proliferation; Ch

2009
Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for pure and mixed anaplastic oligodendrogliomas: radiation therapy oncology group trial 9402.
    International journal of radiation oncology, biology, physics, 2010, Jul-01, Volume: 77, Issue:3

    Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cognition; Combined Mo

2010
MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Dec-10, Volume: 27, Issue:35

    Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Chemotherapy, Adjuvant

2009
NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Dec-10, Volume: 27, Issue:35

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai

2009
Intra-arterial chemotherapy with osmotic blood-brain barrier disruption for aggressive oligodendroglial tumors: results of a phase I study.
    Neurosurgery, 2010, Volume: 66, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Carbopl

2010
Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Mar-01, Volume: 28, Issue:7

    Topics: Adult; Aged; Brain Neoplasms; Female; Glioblastoma; Humans; Indoles; Lomustine; Male; Middle Aged; N

2010
IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Mar-01, Volume: 16, Issue:5

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined M

2010
Impact of adjuvant chemotherapy for gliomatosis cerebri.
    BMC cancer, 2010, Aug-13, Volume: 10

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine

2010
Genomic aberrations associated with outcome in anaplastic oligodendroglial tumors treated within the EORTC phase III trial 26951.
    Journal of neuro-oncology, 2011, Volume: 103, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Chr

2011
Alpha-internexin expression predicts outcome in anaplastic oligodendroglial tumors and may positively impact the efficacy of chemotherapy: European organization for research and treatment of cancer trial 26951.
    Cancer, 2011, Jul-01, Volume: 117, Issue:13

    Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Combined

2011
Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children's Oncology Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jul-20, Volume: 30, Issue:21

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Central Nervous System

2012
Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Jan-20, Volume: 31, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Disease-Fre

2013
Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Jan-20, Volume: 31, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Chromosomes, Hum

2013
EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma.
    Neuro-oncology, 2012, Volume: 14, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dasatinib; Disease-Fre

2012
Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EORTC stu
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Jan-20, Volume: 31, Issue:3

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemothera

2013
Concurrent modified PCV chemotherapy and radiotherapy in newly diagnosed grade IV astrocytoma.
    Journal of neuro-oncology, 2002, Volume: 57, Issue:3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Combined Modali

2002
Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Jan-15, Volume: 21, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Chromosome Aber

2003
Feasibility and toxicity of CCNU therapy in elderly patients with glioblastoma multiforme.
    Anti-cancer drugs, 2003, Volume: 14, Issue:2

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Disease Progression; Fe

2003
Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2003, Volume: 14, Issue:4

    Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neop

2003
Tolerance of nitrosurea-based multiagent chemotherapy regime for low-grade pediatric gliomas.
    Journal of neuro-oncology, 2003, Volume: 63, Issue:3

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Child; Chi

2003
Outcome of children with centrally reviewed low-grade gliomas treated with chemotherapy with or without radiotherapy on Children's Cancer Group high-grade glioma study CCG-945.
    Cancer, 2003, Sep-15, Volume: 98, Issue:6

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Pr

2003
High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma.
    Journal of neuro-oncology, 2003, Volume: 65, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combin

2003
Second-line treatment with carboplatin for recurrent or progressive oligodendroglial tumors after PCV (procarbazine, lomustine, and vincristine) chemotherapy: a phase II study.
    Cancer, 2004, Feb-15, Volume: 100, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms;

2004
Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404.
    International journal of radiation oncology, biology, physics, 2004, Mar-15, Volume: 58, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Bromodeoxyuridine; Che

2004
Initial chemotherapy in gliomatosis cerebri.
    Neurology, 2004, Jul-27, Volume: 63, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combin

2004
Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression.
    Neurology, 2004, Aug-10, Volume: 63, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Artifacts; Astrocytoma; Brain Edema; Brain Neoplasms

2004
Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas.
    Neurology, 2004, Sep-14, Volume: 63, Issue:5

    Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Astrocytom

2004
Phase I study of temozolomide and lomustine in the treatment of high grade malignant glioma.
    Frontiers in bioscience : a journal and virtual library, 2006, Jan-01, Volume: 11

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai

2006
Oligodendroglial tumor chemotherapy using "decreased-dose-intensity" PCV: a Singapore experience.
    Neurology, 2006, Jan-24, Volume: 66, Issue:2

    Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic;

2006
PCV chemotherapy for recurrent glioblastoma.
    Neurology, 2006, Feb-28, Volume: 66, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease Progression; D

2006
High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: long-term follow-up.
    Neuro-oncology, 2006, Volume: 8, Issue:2

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brai

2006
A pilot study of dose-intensified procarbazine, CCNU, vincristine for poor prognosis brain tumors utilizing fibronectin-assisted, retroviral-mediated modification of CD34+ peripheral blood cells with O6-methylguanine DNA methyltransferase.
    Cancer gene therapy, 2006, Volume: 13, Issue:9

    Topics: Adolescent; Adult; Antigens, CD34; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto

2006
Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jun-20, Volume: 24, Issue:18

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant

2006
Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer p
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jun-20, Volume: 24, Issue:18

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant

2006
Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Sep-20, Volume: 24, Issue:27

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms;

2006
A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma.
    British journal of cancer, 2007, Jan-15, Volume: 96, Issue:1

    Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarb

2007
Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas with PCV chemotherapy.
    European journal of neurology, 2007, Volume: 14, Issue:4

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease Progression; Disease

2007
Health-related quality of life in patients treated for anaplastic oligodendroglioma with adjuvant chemotherapy: results of a European Organisation for Research and Treatment of Cancer randomized clinical trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Dec-20, Volume: 25, Issue:36

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Mo

2007
A phase II study of intensified chemotherapy alone as initial treatment for newly diagnosed anaplastic oligodendroglioma: an interim analysis.
    Journal of neuro-oncology, 2008, Volume: 89, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Busulfan; Combi

2008
A phase I trial of temozolomide and lomustine in newly diagnosed high-grade gliomas of childhood.
    Neuro-oncology, 2008, Volume: 10, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols

2008
Randomized comparisons of radiotherapy and CCNU versus radiotherapy, CCNU plus procarbazine for the treatment of malignant gliomas following surgery. A Southwest Oncology Group Report.
    Journal of neuro-oncology, 1983, Volume: 1, Issue:3

    Topics: Brain Neoplasms; Combined Modality Therapy; Drug Therapy, Combination; Female; Glioblastoma; Humans;

1983
CCNU-chemotherapy of hemispheric supratentorial glioblastoma multiforme.
    Cancer, 1980, Mar-15, Volume: 45, Issue:6

    Topics: Adolescent; Adult; Aged; Bone Marrow; Brain Neoplasms; Clinical Trials as Topic; Female; Glioblastom

1980
Adjuvant chemotherapy with VM 26 and CCNU after operation and radiotherapy of high-grade supratentorial astrocytomas.
    Surgical neurology, 1980, Volume: 13, Issue:1

    Topics: Adult; Aged; Brain Neoplasms; Drug Therapy, Combination; Female; Glioblastoma; Humans; Lomustine; Ma

1980
Combination chemotherapy for small cell carcinoma of the lung: continuous versus alternating non-cross-resistant combinations.
    Cancer treatment reports, 1982, Volume: 66, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Small Cell; Cyclophosphamide; Doxoru

1982
Combined radiotherapy and chemotherapy with dibromodulcitol and CCNU in the postoperative treatment of malignant gliomas.
    Journal of neurosurgery, 1983, Volume: 59, Issue:1

    Topics: Brain Neoplasms; Drug Therapy, Combination; Glioblastoma; Humans; Lomustine; Mitolactol; Nitrosourea

1983
Combined modality treatment of regional small cell undifferentiated carcinoma of the lung: a cooperative study of the RTOG and ECOG.
    International journal of radiation oncology, biology, physics, 1983, Volume: 9, Issue:8

    Topics: Brain Neoplasms; Carcinoma, Small Cell; Clinical Trials as Topic; Cyclophosphamide; Female; Humans;

1983
Radio-chemo-immunotherapy (CCNU plus levamisole) for treatment of metastatic brain tumors. A pilot study.
    Journal of neuro-oncology, 1984, Volume: 2, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Therapy; Humans;

1984
Treatment of neuroectodermal brain tumors.
    Annals of neurology, 1982, Volume: 12, Issue:3

    Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Astrocytoma; Blood-Brain Barrier; Brain Neoplasms;

1982
Prophylactic irradiation in bronchogenic small cell anaplastic carcinoma. A comparative trial of localized versus extensive radiotherapy including prophylactic brain irradiation in patients receiving combination chemotherapy.
    Cancer, 1980, Jul-15, Volume: 46, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Bronchogenic; Clinical Trials as Top

1980
Evaluation of CCNU, VM-26 plus CCNU, and procarbazine in supratentorial brain gliomas. Final evaluation of a randomized study. European Organization for Research on Treatment of Cancer (EORTC) Brain Tumor Group.
    Journal of neurosurgery, 1981, Volume: 55, Issue:1

    Topics: Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Drug Therapy, Combination; Female;

1981
Primary intracranial gliomas: clinical studies and treatment regimens of the Brain Tumor Research Center, University of California, San Francisco, 1977-1979.
    Cancer treatment reports, 1981, Volume: 65 Suppl 2

    Topics: Antineoplastic Agents; Brain Neoplasms; California; Carmustine; Clinical Trials as Topic; Drug Thera

1981
A review of studies of the EORTC brain tumor group.
    Cancer treatment reports, 1981, Volume: 65 Suppl 2

    Topics: Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Dexamethasone; Drug Administration

1981
[VM-26 plus CCNU in the prevention of brain metastasis in lung cancer patients].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 1995, Volume: 17, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcin

1995
Prognostic factors and treatment results for supratentorial primitive neuroectodermal tumors in children using radiation and chemotherapy: a Childrens Cancer Group randomized trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Preschool; Combined M

1995
Phase II study of accelerated fractionation radiation therapy with carboplatin followed by vincristine chemotherapy for the treatment of glioblastoma multiforme.
    International journal of radiation oncology, biology, physics, 1995, Sep-30, Volume: 33, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Chemother

1995
Pre-irradiation chemotherapy in children with high-grade astrocytoma: tumor response to two cycles of the '8-drugs-in-1-day' regimen. A Childrens Cancer Group study, CCG-945.
    Journal of neuro-oncology, 1994, Volume: 21, Issue:3

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Che

1994
Radiation therapy and bromodeoxyuridine chemotherapy followed by procarbazine, lomustine, and vincristine for the treatment of anaplastic gliomas.
    International journal of radiation oncology, biology, physics, 1995, Apr-30, Volume: 32, Issue:1

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasm

1995
Survival and prognostic factors following radiation and/or chemotherapy for primitive neuroectodermal tumors of the pineal region in infants and children: a report of the Childrens Cancer Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:6

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Pr

1995
Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen. Childrens Cancer Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:1

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Che

1995
Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1994, Volume: 12, Issue:10

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Canada; Ce

1994
Results of a pilot study of low-dose craniospinal radiation therapy plus chemotherapy for children younger than 5 years with primitive neuroectodermal tumors.
    Cancer, 1993, Apr-15, Volume: 71, Issue:8

    Topics: Brain Neoplasms; Chemotherapy, Adjuvant; Child, Preschool; Cisplatin; Cranial Fossa, Posterior; Cran

1993
A randomized trial of radiotherapy versus radiotherapy plus CCNU for incompletely resected low-grade gliomas: a Southwest Oncology Group study.
    Journal of neurosurgery, 1993, Volume: 78, Issue:6

    Topics: Adult; Aged; Brain Neoplasms; Combined Modality Therapy; Female; Glioma; Humans; Lomustine; Male; Mi

1993
Ototoxicity in children with malignant brain tumors treated with the "8 in 1" chemotherapy protocol.
    Medical and pediatric oncology, 1996, Volume: 27, Issue:1

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant;

1996
Adjuvant chemotherapy of childhood posterior fossa ependymoma: cranio-spinal irradiation with or without adjuvant CCNU, vincristine, and prednisone: a Childrens Cancer Group study.
    Medical and pediatric oncology, 1996, Volume: 27, Issue:1

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant;

1996
Treatment of pediatric low-grade gliomas with a nitrosourea-based multiagent chemotherapy regimen.
    Journal of neuro-oncology, 1997, Volume: 32, Issue:3

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Preschool

1997
TPDC-FuHu chemotherapy for the treatment of recurrent metastatic brain tumors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:3

    Topics: Adenocarcinoma; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neop

1997
Activity of combination chemotherapy in brain metastases from breast and lung adenocarcinoma.
    American journal of clinical oncology, 1997, Volume: 20, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phyt

1997
Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD) plus interferon alpha for metastatic melanoma: a multicentre phase II study.
    British journal of cancer, 1997, Volume: 76, Issue:2

    Topics: Abdominal Neoplasms; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoc

1997
Salvage chemotherapy with paclitaxel for recurrent oligodendrogliomas.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:12

    Topics: Adult; Alopecia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols;

1997
Synchronous radiochemotherapy in unfavorable brain tumors of children and young adults.
    Journal of neuro-oncology, 1998, Volume: 39, Issue:1

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Che

1998
Dose-intensification of procarbazine, CCNU (lomustine), vincristine (PCV) with peripheral blood stem cell support in young patients with gliomas.
    Medical and pediatric oncology, 1998, Volume: 31, Issue:6

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Pr

1998
A phase II trial of high-dose bromodeoxyuridine with accelerated fractionation radiotherapy followed by procarbazine, lomustine, and vincristine for glioblastoma multiforme.
    International journal of radiation oncology, biology, physics, 1999, Aug-01, Volume: 45, Issue:1

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Brain

1999
Combined treatment modality for anaplastic oligodendroglioma: a phase II study.
    Journal of neuro-oncology, 1999, Volume: 43, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Therapy; D

1999
A phase 3 randomized study of radiotherapy plus procarbazine, CCNU, and vincristine (PCV) with or without BUdR for the treatment of anaplastic astrocytoma: a preliminary report of RTOG 9404.
    International journal of radiation oncology, biology, physics, 1999, Dec-01, Volume: 45, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Bromodeoxyuridine; Che

1999
Quantitative 201Tl SPET imaging in the follow-up of treatment for brain tumour: a sensitive tool for the early identification of response to chemotherapy?
    Nuclear medicine communications, 2000, Volume: 21, Issue:3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Female; Follow-

2000
A role for preirradiation PCV chemotherapy for oligodendroglial brain tumors.
    Journal of neurology, 2000, Volume: 247, Issue:4

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antin

2000
Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2000, Volume: 6, Issue:10

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin;

2000
Phase II study of 6-thioguanine, procarbazine, dibromodulcitol, lomustine, and vincristine chemotherapy with radiotherapy for treating malignant glioma in children.
    Neuro-oncology, 2000, Volume: 2, Issue:1

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Pr

2000
[Therapeutic effect on glioblastoma of chemotherapy on the basis of brain irradiation].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2001, Volume: 23, Issue:2

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Carmustine; Chil

2001
Phase II study of accelerated fractionation radiation therapy with carboplatin followed by PCV chemotherapy for the treatment of anaplastic gliomas.
    International journal of radiation oncology, biology, physics, 2002, May-01, Volume: 53, Issue:1

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasm

2002
Enhancement of bone marrow toxicity of VM-26-CCNU combination by bleomycin.
    Cancer treatment reports, 1977, Volume: 61, Issue:9

    Topics: Adult; Aged; Bleomycin; Bone Marrow; Brain Neoplasms; Clinical Trials as Topic; Drug Therapy, Combin

1977
Chemotherapy: adjuvant to surgery and radiation therapy.
    Seminars in oncology, 1975, Volume: 2, Issue:1

    Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Fluorouracil; Glioma;

1975
Controlled study of CCNU and radiation therapy in malignant astrocytoma.
    Journal of neurosurgery, 1976, Volume: 44, Issue:2

    Topics: Adult; Aged; Brain Neoplasms; Digestive System; Drug Evaluation; Glioblastoma; Hematopoiesis; Humans

1976
Controlled study with BCNU vs. CCNU as adjuvant chemotherapy following surgery plus radiotherapy for glioblastoma multiforme.
    Cancer clinical trials, 1979,Spring, Volume: 2, Issue:1

    Topics: Brain Neoplasms; Carmustine; Clinical Trials as Topic; Female; Glioblastoma; Humans; Lomustine; Male

1979
Preliminary report of a cooperative randomized study for the treatment of localized small cell lung carcinoma.
    International journal of radiation oncology, biology, physics, 1979, Volume: 5, Issue:9

    Topics: Bone Marrow; Brain Neoplasms; Carcinoma, Small Cell; Clinical Trials as Topic; Cyclophosphamide; Dru

1979
Radiation plus adjuvant CCNU (1-[2-chloroethyl]-3-cyclohexyl-1-nitrosourea) vs CCNU, hpydroxyurea and vincristine in the treatment of malignant glioma.
    International journal of radiation oncology, biology, physics, 1979, Volume: 5, Issue:9

    Topics: Adolescent; Adult; Aged; Bone Marrow; Brain Neoplasms; Clinical Trials as Topic; Drug Therapy, Combi

1979
Vincristine, prednisone and L-asparaginase in the induction of remission in children with acute lymphoblastic leukemia following relapse.
    Cancer, 1978, Volume: 41, Issue:2

    Topics: Adolescent; Adult; Antineoplastic Agents; Asparaginase; Bone Marrow; Brain Neoplasms; Carmustine; Ch

1978
Treatment of malignant gliomas and brain metastases in adults using a combination of adriamycine, VM 26, and CCNU. Results of a type II trial.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 1977, Issue:62

    Topics: Adult; Aged; Brain Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Doxorubicin; Drug Therapy,

1977
A comparison of radiotherapy alone with radiotherapy and CCNU in cerebral glioma.
    Clinical oncology, 1978, Volume: 4, Issue:1

    Topics: Adult; Age Factors; Aged; Brain Neoplasms; Clinical Trials as Topic; Evaluation Studies as Topic; Fe

1978
Multidisciplinary treatment for central nervous system tumours with nitrosourea compounds.
    Acta neurochirurgica, 1978, Volume: 41, Issue:4

    Topics: Adolescent; Adult; Aged; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Female; Humans; Lomu

1978
Effect of CCNU on survival rate of objective remission and duration of free interval in patients with malignant brain glioma--final evaluation. E.O.R.T.C. Brain Tumor Group.
    European journal of cancer, 1978, Volume: 14, Issue:8

    Topics: Brain Neoplasms; Clinical Trials as Topic; Female; Glioma; Humans; Lomustine; Male; Neoplasm Recurre

1978
[A study of the use of sequential chemotherapy in 176 cases of glioblastoma (author's transl)].
    Revue neurologique, 1978, Volume: 134, Issue:5

    Topics: Adult; Brain Neoplasms; Clinical Trials as Topic; Doxorubicin; Drug Therapy, Combination; Follow-Up

1978
[Combined postoperative therapy of glial brain tumors. Initial results of the pilot study].
    Strahlentherapie. Sonderbande, 1978, Volume: 75

    Topics: Astrocytoma; Brain Neoplasms; Clinical Trials as Topic; Cobalt Radioisotopes; Glioma; Humans; Lomust

1978
Prophylactic cranial irradiation in small cell carcinoma of the lung. A randomized study.
    JAMA, 1977, Jun-20, Volume: 237, Issue:25

    Topics: Adult; Aged; Brain; Brain Neoplasms; Carcinoma; Cyclophosphamide; Doxorubicin; Drug Therapy, Combina

1977
[Letter: Chemotherapy of operated malignant brain gliomas using a combination of VM 26 and CCNU].
    La Nouvelle presse medicale, 1976, Feb-14, Volume: 5, Issue:7

    Topics: Brain Neoplasms; Clinical Trials as Topic; Drug Therapy, Combination; Follow-Up Studies; Glioma; Hum

1976
[Trial treatment of glioblastomas in adults and cerebral metastais by adriamycin, VM 26 and CCNU combination. Result of a type II trial].
    La Nouvelle presse medicale, 1976, Jun-19, Volume: 5, Issue:25

    Topics: Adult; Aged; Brain Neoplasms; Clinical Trials as Topic; Doxorubicin; Drug Evaluation; Drug Therapy,

1976
Radiotherapy and CCNU in the treatment of high-grade supratentorial astrocytomas.
    Journal of neurosurgery, 1976, Volume: 45, Issue:2

    Topics: Astrocytoma; Brain Neoplasms; Drug Evaluation; Female; Humans; Lomustine; Male; Nitrosourea Compound

1976
Adjuvant nitrosourea therapy for glioblastoma.
    Archives of neurology, 1976, Volume: 33, Issue:11

    Topics: Adolescent; Adult; Aged; Brain Neoplasms; Carmustine; Child; Child, Preschool; Drug Evaluation; Fema

1976
Effect of CCNU on survival, rate of objective remission and duration of free interval in patients with malignant brain glioma--first evaluation.
    European journal of cancer, 1976, Volume: 12, Issue:1

    Topics: Brain Neoplasms; Dexamethasone; Glioma; Humans; Lomustine; Neoplasm Recurrence, Local; Nitrosourea C

1976
Advantage of post-radiotherapy chemotherapy with CCNU, procarbazine, and vincristine (mPCV) over chemotherapy with VM-26 and CCNU for malignant gliomas.
    Journal of chemotherapy (Florence, Italy), 1992, Volume: 4, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Combined

1992
Increasing radiation dose intensity using hyperfractionation in patients with malignant glioma. Final report of a prospective phase I-II dose response study.
    Journal of neuro-oncology, 1992, Volume: 14, Issue:1

    Topics: Adolescent; Adult; Age Factors; Aged; Astrocytoma; Brain; Brain Neoplasms; Cobalt Radioisotopes; Com

1992
[Chemotherapy of malignant glioma. Results of studies of the EORTC group of brain tumors].
    Revue neurologique, 1992, Volume: 148, Issue:6-7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Combined Modality Therap

1992
External irradiation followed by an interstitial high activity iodine-125 implant "boost" in the initial treatment of malignant gliomas: NCOG study 6G-82-2.
    International journal of radiation oncology, biology, physics, 1991, Volume: 21, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Brain Neoplasms; Combine

1991
Evaluation of bromodeoxyuridine in glioblastoma multiforme: a Northern California Cancer Center Phase II study.
    International journal of radiation oncology, biology, physics, 1991, Volume: 21, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Bro

1991
Combination chemotherapy of limited-stage small-cell lung cancer. A controlled trial on 221 patients comparing two alternating regimens.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1991, Volume: 2, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Small Cell;

1991
Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report.
    International journal of radiation oncology, biology, physics, 1990, Volume: 18, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined M

1990
A randomized study of CCNU with and without benznidazole in the treatment of recurrent grades 3 and 4 astrocytoma. Report to the Medical Research Council by the Brain Tumor Working Party.
    International journal of radiation oncology, biology, physics, 1989, Volume: 16, Issue:4

    Topics: Adolescent; Adult; Brain Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Double-Blin

1989
The effectiveness of chemotherapy for treatment of high grade astrocytoma in children: results of a randomized trial. A report from the Childrens Cancer Study Group.
    Journal of neuro-oncology, 1989, Volume: 7, Issue:2

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Chi

1989
Quality of survival of patients with brain gliomas treated with postoperative CCNU and radiation therapy.
    Journal of neurosurgery, 1989, Volume: 70, Issue:1

    Topics: Adolescent; Adult; Aged; Brain Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Disab

1989
The role of radiation therapy in the treatment of small cell lung cancer.
    Cancer, 1985, May-01, Volume: 55, Issue:9 Suppl

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Small Cell; Clinical Tri

1985
Combined modality treatment of operated astrocytomas grade 3 and 4. A prospective and randomized study of misonidazole and radiotherapy with two different radiation schedules and subsequent CCNU chemotherapy. Stage II of a prospective multicenter trial of
    Cancer, 1985, Jul-01, Volume: 56, Issue:1

    Topics: Actuarial Analysis; Adult; Aged; Brain Neoplasms; Clinical Trials as Topic; Combined Modality Therap

1985
Long-term survival and recurrence-free interval in combined surgical, radio- and chemotherapy of malignant brain gliomas.
    Clinical neurology and neurosurgery, 1985, Volume: 87, Issue:3

    Topics: Adolescent; Adult; Aged; Brain Neoplasms; Child; Child, Preschool; Clinical Trials as Topic; Combine

1985
Postoperative radiotherapy and radiotherapy combined with CCNU chemotherapy for treatment of brain gliomas.
    Journal of neuro-oncology, 1988, Volume: 6, Issue:3

    Topics: Adolescent; Adult; Aged; Brain Neoplasms; Clinical Trials as Topic; Female; Glioma; Humans; Lomustin

1988
Brain-stem tumors in childhood: a prospective randomized trial of irradiation with and without adjuvant CCNU, VCR, and prednisone. A report of the Childrens Cancer Study Group.
    Journal of neurosurgery, 1987, Volume: 66, Issue:2

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Brain Stem; Chil

1987
Benznidazole with CCNU: a clinical phase I toxicity study.
    International journal of radiation oncology, biology, physics, 1985, Volume: 11, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Brain Neoplasms; Drug Evaluation;

1985

Other Studies

295 other studies available for lomustine and Benign Neoplasms, Brain

ArticleYear
Lomustine and nimustine exert efficient antitumor effects against glioblastoma models with acquired temozolomide resistance.
    Cancer science, 2021, Volume: 112, Issue:11

    Topics: Animals; Antineoplastic Agents; Brain Neoplasms; DNA Modification Methylases; DNA Repair Enzymes; Dr

2021
Viability fingerprint of glioblastoma cell lines: roles of mitotic, proliferative, and epigenetic targets.
    Scientific reports, 2021, 10-13, Volume: 11, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Brain Neoplasms; Cell Cycle; Cell Line,

2021
Early Postoperative Treatment versus Initial Observation in CNS WHO Grade 2 and 3 Oligodendroglioma: Clinical Outcomes and DNA Methylation Patterns.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2022, 10-14, Volume: 28, Issue:20

    Topics: Adult; Brain Neoplasms; DNA Methylation; Humans; Isocitrate Dehydrogenase; Lomustine; Methyltransfer

2022
Current therapeutic options for glioblastoma and future perspectives.
    Expert opinion on pharmacotherapy, 2022, Volume: 23, Issue:14

    Topics: Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasms; Combined Modality Therapy; Glioblas

2022
Prediction of response to lomustine-based chemotherapy in glioma patients at recurrence using MRI and FET PET.
    Neuro-oncology, 2023, 05-04, Volume: 25, Issue:5

    Topics: Adult; Brain Neoplasms; Glioma; Humans; Lomustine; Magnetic Resonance Imaging; Positron-Emission Tom

2023
Tumor Treating Fields (TTFields) increase the effectiveness of temozolomide and lomustine in glioblastoma cell lines.
    Journal of neuro-oncology, 2023, Volume: 163, Issue:1

    Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line; Cell Line, Tumor; DNA Modification Me

2023
T2-Fluid-attenuated inversion recovery (FLAIR) pseudoprogression in patients with anaplastic oligodendrogliomas treated with procarbazine, lomustine and vincristine (PCV) chemotherapy alone.
    European journal of neurology, 2023, Volume: 30, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Humans; Lomustine; Magnetic Resonan

2023
Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analyses.
    Journal of neuro-oncology, 2023, Volume: 164, Issue:3

    Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Glioblastoma; Humans; Lomustine; Ma

2023
Pediatric glioblastoma in the setting of constitutional mismatch-repair deficiency treated with upfront lomustine and nivolumab.
    Pediatric blood & cancer, 2024, Volume: 71, Issue:1

    Topics: Brain Neoplasms; Child; Colorectal Neoplasms; Glioblastoma; Humans; Lomustine; Nivolumab

2024
Craniotomy for recurrent glioblastoma: Is it justified? A comparative cohort study with outcomes over 10 years.
    Clinical neurology and neurosurgery, 2020, Volume: 188

    Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immu

2020
Tumour Treating Fields (TTFields) in combination with lomustine and temozolomide in patients with newly diagnosed glioblastoma.
    Journal of cancer research and clinical oncology, 2020, Volume: 146, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Com

2020
A troublesome burden, the amplification of EGFR in glioblastoma!
    Neuro-oncology, 2020, 05-15, Volume: 22, Issue:5

    Topics: Antibodies, Monoclonal, Humanized; Brain Neoplasms; ErbB Receptors; Glioblastoma; Humans; Lomustine;

2020
Salvage chemotherapy after failure of targeted therapy in a child with BRAF V600E low-grade glioma.
    Pediatric blood & cancer, 2021, Volume: 68, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child, Preschool; Glioma; Humans; L

2021
Microangiopathy, lomustine, and karyomegalic mesangial cells.
    Kidney international, 2020, Volume: 98, Issue:2

    Topics: Brain Neoplasms; Humans; Lomustine; Mesangial Cells

2020
A comparative study of the effectiveness and safety of combined procarbazine, lomustine, and vincristine as a therapeutic method for recurrent high-grade glioma: A protocol for systematic review and meta-analysis.
    Medicine, 2020, Sep-18, Volume: 99, Issue:38

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Glioma; Humans;

2020
Radiotherapy Plus Procarbazine, Lomustine, and Vincristine Versus Radiotherapy Plus Temozolomide for IDH-Mutant Anaplastic Astrocytoma: A Retrospective Multicenter Analysis of the French POLA Cohort.
    The oncologist, 2021, Volume: 26, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Humans; Lomustine; Pro

2021
One year of procarbazine lomustine and vincristine is poorly tolerated in low grade glioma: a real world experience in a national neuro-oncology centre.
    BMC cancer, 2021, Feb-08, Volume: 21, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Drug-Related Side Effects an

2021
PCV chemotherapy alone for WHO grade 2 oligodendroglioma: prolonged disease control with low risk of malignant progression.
    Journal of neuro-oncology, 2021, Volume: 153, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Humans; Lomustine; Neoplasm Staging

2021
Diagnosis of Pseudoprogression Following Lomustine-Temozolomide Chemoradiation in Newly Diagnosed Glioblastoma Patients Using FET-PET.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2021, 07-01, Volume: 27, Issue:13

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai

2021
Increased infiltration of CD8 T cells in recurrent glioblastoma patients is a useful biomarker for assessing the response to combined bevacizumab and lomustine therapy.
    International immunopharmacology, 2021, Volume: 97

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizu

2021
Combination chemotherapy versus temozolomide for patients with methylated MGMT (m-MGMT) glioblastoma: results of computational biological modeling to predict the magnitude of treatment benefit.
    Journal of neuro-oncology, 2021, Volume: 153, Issue:3

    Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Artificial Intell

2021
Cost-effectiveness of radiation and chemotherapy for high-risk low-grade glioma.
    Neuro-oncology, 2017, Nov-29, Volume: 19, Issue:12

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Cost-Bene

2017
Estrogen and soy isoflavonoids decrease sensitivity of medulloblastoma and central nervous system primitive neuroectodermal tumor cells to chemotherapeutic cytotoxicity.
    BMC pharmacology & toxicology, 2017, 09-06, Volume: 18, Issue:1

    Topics: Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Cisplatin; Equol; Estradiol

2017
Targeting glioma stem-like cell survival and chemoresistance through inhibition of lysine-specific histone demethylase KDM2B.
    Molecular oncology, 2018, Volume: 12, Issue:3

    Topics: Antineoplastic Agents; Apoptosis; Astrocytes; Brain Neoplasms; Cell Line; DNA Damage; Drug Resistanc

2018
Regimen of procarbazine, lomustine, and vincristine versus temozolomide for gliomas.
    Cancer, 2018, 07-01, Volume: 124, Issue:13

    Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neop

2018
Survival times in dogs with presumptive intracranial gliomas treated with oral lomustine: A comparative retrospective study (2008-2017).
    Veterinary and comparative oncology, 2018, Volume: 16, Issue:4

    Topics: Administration, Oral; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dog Diseases; Dog

2018
Achievable Central Nervous System Concentrations of the Green Tea Catechin EGCG Induce Stress in Glioblastoma Cells in Vitro.
    Nutrition and cancer, 2018, Volume: 70, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Brain Neoplasms; Catechin; Cen

2018
OIP5 Expression Sensitize Glioblastoma Cells to Lomustine Treatment.
    Journal of molecular neuroscience : MN, 2018, Volume: 66, Issue:3

    Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Chromosom

2018
Radiotherapy plus temozolomide or PCV in patients with anaplastic oligodendroglioma 1p19q codeleted.
    Revista de neurologia, 2018, Oct-16, Volume: 67, Issue:8

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai

2018
Improving survival in molecularly selected glioblastoma.
    Lancet (London, England), 2019, 02-16, Volume: 393, Issue:10172

    Topics: Adult; Brain Neoplasms; Combined Modality Therapy; DNA Modification Methylases; DNA Repair Enzymes;

2019
Lomustine-temozolomide combination efficacious in newly diagnosed glioblastoma.
    Nature reviews. Clinical oncology, 2019, Volume: 16, Issue:5

    Topics: Brain Neoplasms; Clinical Trials, Phase III as Topic; DNA Methylation; DNA Modification Methylases;

2019
A Real-World Claims Analysis of Costs and Patterns of Care in Treated Patients with Glioblastoma Multiforme in the United States.
    Journal of managed care & specialty pharmacy, 2019, Volume: 25, Issue:4

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasm

2019
Imaging necrosis during treatment is associated with worse survival in EORTC 26101 study.
    Neurology, 2019, 06-11, Volume: 92, Issue:24

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasms; Clinical T

2019
PCV for anaplastic oligodendrogliomas: back to the future or a step backwards? A point/counterpoint discussion.
    Journal of neuro-oncology, 2013, Volume: 113, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Clinical Trials, Phase III as Topic

2013
How to use molecular markers when caring for a patient with brain cancer: 1P/19Q as a predictive and prognostic marker in the neuro-oncology clinic.
    American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 2013

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chromosome Deletion; Chromosomes, H

2013
Anaplastic oligodendroglioma: a new treatment paradigm and current controversies.
    Current treatment options in oncology, 2013, Volume: 14, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Therapy; Female;

2013
Addition of lomustine for bevacizumab-refractory recurrent glioblastoma.
    Acta oncologica (Stockholm, Sweden), 2014, Volume: 53, Issue:10

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemo

2014
Retrospective study of carmustine or lomustine with bevacizumab in recurrent glioblastoma patients who have failed prior bevacizumab.
    Neuro-oncology, 2014, Volume: 16, Issue:11

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Renewing interest in targeting angiogenesis in glioblastoma.
    The Lancet. Oncology, 2014, Volume: 15, Issue:9

    Topics: Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Female; Glioblastoma; Humans; Lomus

2014
CNS cancer: it takes two to tango.
    Nature reviews. Clinical oncology, 2014, Volume: 11, Issue:9

    Topics: Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Female; Glioblastoma; Humans; Lomus

2014
Neuro-oncology: It takes two to tango.
    Nature reviews. Neurology, 2014, Volume: 10, Issue:9

    Topics: Antibodies, Monoclonal, Humanized; Brain Neoplasms; Female; Glioblastoma; Humans; Lomustine; Male; N

2014
Bevacizumab alone or in combination with chemotherapy in glioblastomas?
    The Lancet. Oncology, 2014, Volume: 15, Issue:11

    Topics: Antibodies, Monoclonal, Humanized; Brain Neoplasms; Female; Glioblastoma; Humans; Lomustine; Male; N

2014
Bevacizumab alone or in combination with chemotherapy in glioblastomas?--authors' reply.
    The Lancet. Oncology, 2014, Volume: 15, Issue:11

    Topics: Antibodies, Monoclonal, Humanized; Brain Neoplasms; Female; Glioblastoma; Humans; Lomustine; Male; N

2014
Treatment of large low-grade oligodendroglial tumors with upfront procarbazine, lomustine, and vincristine chemotherapy with long follow-up: a retrospective cohort study with growth kinetics.
    Journal of neuro-oncology, 2015, Volume: 121, Issue:2

    Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Disease Progression; Drug Therapy, Combination; Femal

2015
Enhanced anticancer properties of lomustine in conjunction with docosahexaenoic acid in glioblastoma cell lines.
    Journal of neurosurgery, 2015, Volume: 122, Issue:3

    Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation;

2015
Salvage therapy with lomustine for temozolomide refractory recurrent anaplastic astrocytoma: a retrospective study.
    Journal of neuro-oncology, 2015, Volume: 122, Issue:2

    Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Biomarkers, Tumor; Brain Neoplasms; Dacarbazi

2015
Clinical benefit in recurrent glioblastoma from adjuvant NovoTTF-100A and TCCC after temozolomide and bevacizumab failure: a preliminary observation.
    Cancer medicine, 2015, Volume: 4, Issue:3

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkyla

2015
Comparative efficacy of bevacizumab and PCV chemotherapy in recurrent glioblastoma.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 2015, Volume: 27, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Glioblastoma; Humans;

2015
The role of bevacizumab in recurrent glioblastoma: new insights from randomized trials.
    CNS oncology, 2015, Volume: 4, Issue:3

    Topics: Antibodies, Monoclonal, Humanized; Brain Neoplasms; Female; Glioblastoma; Humans; Lomustine; Male; N

2015
Treating anaplastic oligodendrogliomas and WHO grade 2 gliomas: PCV or temozolomide? The case for PCV.
    Oncology (Williston Park, N.Y.), 2015, Volume: 29, Issue:4

    Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms;

2015
Kinetic evaluation of low-grade gliomas in adults before and after treatment with CCNU alone.
    Journal of neurosurgery, 2015, Volume: 123, Issue:5

    Topics: Adolescent; Adult; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy

2015
Second-Line Chemotherapy in Recurrent Glioblastoma: A 2-Cohort Study.
    Oncology research and treatment, 2015, Volume: 38, Issue:7-8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothe

2015
PC or PCV, That Is the Question: Primary Anaplastic Oligodendroglial Tumors Treated with Procarbazine and CCNU With and Without Vincristine.
    Anticancer research, 2015, Volume: 35, Issue:10

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Astr

2015
Progression-free and overall survival in patients with recurrent Glioblastoma multiforme treated with last-line bevacizumab versus bevacizumab/lomustine.
    Journal of neuro-oncology, 2016, Volume: 126, Issue:3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Female; Follow-

2016
High-grade glioma in children and adolescents: a single-center experience.
    Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery, 2016, Volume: 32, Issue:2

    Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Astro

2016
Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of High-Grade Glioma.
    Annals of the Academy of Medicine, Singapore, 2015, Volume: 44, Issue:10

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Beva

2015
Increasing the Time Interval between PCV Chemotherapy Cycles as a Strategy to Improve Duration of Response in Low-Grade Gliomas: Results from a Model-Based Clinical Trial Simulation.
    Computational and mathematical methods in medicine, 2015, Volume: 2015

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Clinical Protocols; Clinical

2015
Lomustine Nanoparticles Enable Both Bone Marrow Sparing and High Brain Drug Levels - A Strategy for Brain Cancer Treatments.
    Pharmaceutical research, 2016, Volume: 33, Issue:5

    Topics: Animals; Antineoplastic Agents, Alkylating; Bone Marrow; Brain; Brain Neoplasms; Cell Line, Tumor; D

2016
Chemotherapy for intracranial ependymoma in adults.
    BMC cancer, 2016, Apr-23, Volume: 16

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Dis

2016
Toca 511 plus 5-fluorocytosine in combination with lomustine shows chemotoxic and immunotherapeutic activity with no additive toxicity in rodent glioblastoma models.
    Neuro-oncology, 2016, Volume: 18, Issue:10

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cytosine Deaminase; Diseas

2016
Case of a miniature dachshund with a primitive neuroectodermal tumor confined to the forebrain region treated with a combination of surgery and chemotherapy.
    The Journal of veterinary medical science, 2016, Dec-01, Volume: 78, Issue:11

    Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dog Diseases

2016
Inhibition of histone deacetylases sensitizes glioblastoma cells to lomustine.
    Cellular oncology (Dordrecht), 2017, Volume: 40, Issue:1

    Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western

2017
Myoinositol as a Biomarker in Recurrent Glioblastoma Treated with Bevacizumab: A 1H-Magnetic Resonance Spectroscopy Study.
    PloS one, 2016, Volume: 11, Issue:12

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Bevacizumab; Biomarkers, Tumor; Brain N

2016
Nitrosoureas inhibit the stathmin-mediated migration and invasion of malignant glioma cells.
    Cancer research, 2008, Jul-01, Volume: 68, Issue:13

    Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Movement; Glioma; Lomustine; Mice;

2008
Low-grade glioma: a challenge in therapeutic options: the role of radiotherapy.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19 Suppl 7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine

2008
Procarbazine and CCNU as initial treatment in gliomatosis cerebri.
    Oncology, 2008, Volume: 75, Issue:3-4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease-Free Survival;

2008
[Clinical features and combined treatment of the central nervous system in Hodgkin's disease].
    Voprosy onkologii, 2008, Volume: 54, Issue:5

    Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols

2008
Assessment of cetuximab efficacy by bioluminescence monitoring of intracranial glioblastoma xenograft in mouse.
    Journal of neuro-oncology, 2009, Volume: 95, Issue:1

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineopl

2009
Retrospective analysis of treatment outcome in 315 patients with oligodendroglial brain tumors.
    BMC neurology, 2009, Jul-16, Volume: 9

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Chi

2009
De novo germline TP53 mutation presenting with synchronous malignancies of the central nervous system.
    Pediatric blood & cancer, 2009, Dec-15, Volume: 53, Issue:7

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma; Choroid Plex

2009
Anaplastic glioma: how to prognosticate outcome and choose a treatment strategy. [corrected].
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Dec-10, Volume: 27, Issue:35

    Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms;

2009
Bevacizumab is active as a single agent against recurrent malignant gliomas.
    Anticancer research, 2010, Volume: 30, Issue:2

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem

2010
Prolonged response without prolonged chemotherapy: a lesson from PCV chemotherapy in low-grade gliomas.
    Neuro-oncology, 2010, Volume: 12, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Female; Glioma; Humans; Lomustine;

2010
Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma.
    Journal of neuro-oncology, 2011, Volume: 102, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Capecitabine; Celecoxi

2011
HPLC method validation for the quantification of lomustine to study pharmacokinetics of thermosensitive liposome-encapsulated lomustine containing iohexol for CT imaging in C6 glioma rats.
    European journal of drug metabolism and pharmacokinetics, 2011, Volume: 36, Issue:2

    Topics: Animals; Antineoplastic Agents; Area Under Curve; Brain Neoplasms; Calibration; Cell Line, Tumor; Ch

2011
International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors.
    Neuro-oncology, 2011, Volume: 13, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chr

2011
[Brain metastasis in breast cancer].
    Voprosy onkologii, 2011, Volume: 57, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Antineopl

2011
[Retrospective analysis of 24 recurrent glioblastoma after chemoradiation and treated with nitrosoureas or irinotecan and bevacizumab].
    Bulletin du cancer, 2012, Feb-01, Volume: 99, Issue:2

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che

2012
Late and prolonged pseudoprogression in glioblastoma after treatment with lomustine and temozolomide.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jul-20, Volume: 30, Issue:21

    Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms;

2012
Comparison between symptomatic treatment and lomustine supplementation in 71 dogs with intracranial, space-occupying lesions.
    Veterinary and comparative oncology, 2014, Volume: 12, Issue:1

    Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dog Diseases; Dogs; Female; Lomustine;

2014
Chemotherapy and radiotherapy combination extends survival for patients with oligodendroglial tumors.
    Cancer, 2012, Sep-15, Volume: 118, Issue:18

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Proliferation; Chemoradiothera

2012
Cervicothoracic syringohydromyelia associated with a prosencephalic mass in a dog.
    The Journal of small animal practice, 2012, Volume: 53, Issue:10

    Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Ne

2012
Intensified PCV-chemotherapy with optional stem cell support in recurrent malignant oligodendroglioma.
    Journal of neurology, 2002, Volume: 249, Issue:8

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Brain Neoplasms; Female

2002
Complete response of a recurrent, multicentric malignant glioma in a patient treated with phenylbutyrate.
    Journal of neuro-oncology, 2002, Volume: 59, Issue:3

    Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Femal

2002
Dramatic response to chemotherapy in oligodendroglial gliomatosis cerebri.
    Neurology, 2003, Jan-14, Volume: 60, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brain Neoplasms; Corpus Callosum; Fro

2003
Long-term sequelae in children treated for brain tumors: impairments, disability, and handicap.
    Pediatric hematology and oncology, 2003, Volume: 20, Issue:2

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Atrophy; Brain; Brain Damage, Chronic; B

2003
Glioma treatment, radionecrosis, and growth factors. In regard to Levin et al., IJROBP 2002;53:58-66.
    International journal of radiation oncology, biology, physics, 2003, Mar-01, Volume: 55, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Diseases; Brain Neoplasms; Carbop

2003
Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features.
    Cancer, 2003, Mar-01, Volume: 97, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chromosome Aberrations; Chromosomes

2003
Interobserver variability in the radiological assessment of response to chemotherapy in glioma.
    Neurology, 2003, Mar-11, Volume: 60, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carboplat

2003
Survival improvement in patients with glioblastoma multiforme during the last 20 years in a single tertiary-care center.
    Wiener klinische Wochenschrift, 2003, Jun-24, Volume: 115, Issue:11

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating

2003
Malignant transformation of a dysembryoplastic neuroepithelial tumor after radiation and chemotherapy.
    Annals of diagnostic pathology, 2003, Volume: 7, Issue:4

    Topics: Adolescent; Antineoplastic Agents, Alkylating; Astrocytoma; Biomarkers, Tumor; Brain Neoplasms; Cell

2003
[Use of modern technologies in the diagnosis and combined treatment of brain stem tumors].
    Vestnik Rossiiskoi akademii meditsinskikh nauk, 2003, Issue:10

    Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols

2003
Monitoring individual response to brain-tumour chemotherapy: proton MR spectroscopy in a patient with recurrent glioma after stereotactic radiotherapy.
    Neuroradiology, 2004, Volume: 46, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Astrocytoma; Brain Neoplasms;

2004
Long-term outcome of oligodendrogliomas.
    Neurology, 2004, May-25, Volume: 62, Issue:10

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brain Neoplasms; Ci

2004
[Neoadjuvant chemotherapy for symptomatic non operable grade II fibrillary astrocytoma in adults].
    Revue neurologique, 2004, Volume: 160, Issue:5 Pt 1

    Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Astrocytom

2004
Gliomatosis cerebri: better definition, better treatment.
    Neurology, 2004, Jul-27, Volume: 63, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Astrocyt

2004
Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine.
    Cancer, 2005, Feb-15, Volume: 103, Issue:4

    Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neo

2005
Semi-quantification of methionine uptake and flair signal for the evaluation of chemotherapy in low-grade oligodendroglioma.
    Journal of neuro-oncology, 2005, Volume: 71, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Female; Humans; Lomust

2005
Combination chemotherapy with carmustine and cisplatin followed by procarbazine, lomustine, and vincristine for adult high-grade astrocytoma.
    Chang Gung medical journal, 2005, Volume: 28, Issue:1

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasm

2005
P450 enzyme inducing and non-enzyme inducing antiepileptics in glioblastoma patients treated with standard chemotherapy.
    Journal of neuro-oncology, 2005, Volume: 72, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Antineoplastic Agents; Blood Cell Count; Brain Neop

2005
Complete remission of brain metastases in three patients with stage IV melanoma treated with BOLD and G-CSF.
    Japanese journal of clinical oncology, 2005, Volume: 35, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brain Neoplasms; Dacarbazine

2005
Effects of lipid association on lomustine (CCNU) administered intracerebrally to syngeneic 36B-10 rat brain tumors.
    Cancer letters, 2006, Dec-08, Volume: 244, Issue:2

    Topics: Alkylating Agents; Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Ethylni

2006
Toxic epidermal necrolysis after PCV combination chemotherapy for relapsed B-cell lymphoma.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 2006, Volume: 18, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Humans; Lomustine; Lymphoma, B-Cell

2006
Clinical use of genotype to predict chemosensitivity in oligodendroglial tumors.
    Neurology, 2006, Jun-13, Volume: 66, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Case-Control Studies;

2006
Anaplastic oligodendroglial tumors: a tale of two trials.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jun-20, Volume: 24, Issue:18

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Tr

2006
[Palliative therapy in glioblastoma multiforme: a multimodal concept].
    Wiener medizinische Wochenschrift (1946), 2006, Volume: 156, Issue:9-10

    Topics: Aged; Brain Neoplasms; Catheters, Indwelling; Chemotherapy, Adjuvant; Combined Modality Therapy; Cra

2006
Gliomatosis cerebri treatment in 11 elderly patients.
    Journal of experimental & clinical cancer research : CR, 2006, Volume: 25, Issue:2

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined M

2006
Re-evaluation of the cost effectiveness of temozolomide for malignant gliomas in British Columbia.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2006, Volume: 12, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; British Columbia

2006
Genetic and metabolic predictors of chemosensitivity in oligodendroglial neoplasms.
    British journal of cancer, 2006, Nov-20, Volume: 95, Issue:10

    Topics: Adult; Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chromosomes,

2006
Astrocytic tumors in children: treatment results from a single institution.
    Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery, 2007, Volume: 23, Issue:3

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Child; Chi

2007
[Long-term outcome in patients with symptomatic low-grade oligodendrogliomatous tumors treated by cytotoxic agents].
    Revue neurologique, 2006, Volume: 162, Issue:11

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemo

2006
Radiotherapy plus concurrent and adjuvant procarbazine, lomustine, and vincristine chemotherapy for patients with malignant glioma.
    Oncology reports, 2007, Volume: 17, Issue:6

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemothera

2007
Nitrosourea efficacy in high-grade glioma: a survival gain analysis summarizing 504 cohorts with 24193 patients.
    Journal of neuro-oncology, 2008, Volume: 88, Issue:1

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms;

2008
Cryptococcal meningitis in patients with glioma: a report of two cases.
    Journal of neuro-oncology, 2008, Volume: 89, Issue:1

    Topics: Adult; Aged; Amphotericin B; Anti-Inflammatory Agents; Antifungal Agents; Antineoplastic Agents, Alk

2008
5-Fluorouracil and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) followed by hydroxyurea, misonidazole, and irradiation for brain stem gliomas: a pilot study of the Brain Tumor Research Center and the Childrens Cancer Group.
    Neurosurgery, 1984, Volume: 14, Issue:6

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Bra

1984
Radiation therapy for brain metastases from malignant melanoma.
    Acta radiologica. Oncology, 1984, Volume: 23, Issue:4

    Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Radiation; Female; Humans; Lo

1984
[What is safe in the treatment of small-cell bronchial carcinoma?].
    Der Internist, 1980, Volume: 21, Issue:12

    Topics: Brain Neoplasms; Bronchial Neoplasms; Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Drug The

1980
Late results of multimodality therapy of high-grade supratentorial astrocytomas.
    Surgical neurology, 1981, Volume: 15, Issue:2

    Topics: Adult; Antineoplastic Agents; Astrocytoma; Bleomycin; Brain Neoplasms; Drug Therapy, Combination; Fe

1981
Therapeutic evaluation of five nitrosoureas in a human melanoma xenograft system.
    Cancer chemotherapy and pharmacology, 1983, Volume: 11, Issue:3

    Topics: Animals; Bone Marrow; Brain Neoplasms; Carmustine; Dose-Response Relationship, Drug; Female; Humans;

1983
Multimodality treatment of malignant gliomas. Comparison of several adjuvant approaches.
    Zentralblatt fur Neurochirurgie, 1981, Volume: 42, Issue:2-3

    Topics: Antineoplastic Agents; Brain; Brain Neoplasms; Drug Therapy, Combination; Ependymoma; Glioblastoma;

1981
[Postoperative treatment of malignant glial tumors of the brain with CCNU].
    Vestnik Akademii meditsinskikh nauk SSSR, 1981, Issue:11

    Topics: Astrocytoma; Brain Neoplasms; Follow-Up Studies; Glioblastoma; Humans; Lomustine; Nitrosourea Compou

1981
Methotrexate in the chemotherapy of lung cancer.
    Cancer treatment reports, 1981, Volume: 65 Suppl 1

    Topics: Brain Neoplasms; Carcinoma, Bronchogenic; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cyclophos

1981
Combination chemotherapy for metastatic brain tumors.
    Tumori, 1981, Dec-31, Volume: 67, Issue:6

    Topics: Adenocarcinoma; Brain Neoplasms; Breast Neoplasms; Carcinoma, Small Cell; Doxorubicin; Drug Therapy,

1981
Clinical toxicity of combined modality treatment with nitrosourea derivatives for central nervous system tumors.
    Neurosurgery, 1982, Volume: 11, Issue:3

    Topics: Bone Marrow Diseases; Brain Neoplasms; Carmustine; Gastrointestinal Diseases; Glioblastoma; Glioma;

1982
[Glioblastoma multiforme. Postoperative therapy].
    ZFA. Zeitschrift fur Allgemeinmedizin, 1983, Feb-20, Volume: 59, Issue:5

    Topics: Adult; Aged; Brain Neoplasms; Drug Therapy, Combination; Female; Glioblastoma; Humans; Lomustine; Ma

1983
[Antimitotic chemotherapy of supratentorial cerebral glioma in adults. Apropos of 56 cases].
    La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris, 1983, Feb-17, Volume: 59, Issue:7

    Topics: Adult; Aged; Brain Neoplasms; Drug Therapy, Combination; Female; Glioma; Humans; Lomustine; Male; Mi

1983
[Prognostic value of gliofibrillary protein assay in malignant gliomas treated with chemo- and radiotherapy].
    La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris, 1983, Feb-17, Volume: 59, Issue:7

    Topics: Adolescent; Adult; Brain Neoplasms; Drug Therapy, Combination; Female; Follow-Up Studies; Glial Fibr

1983
[Irradiation of the brain in the combined treatment of small-cell lung cancer].
    Voprosy onkologii, 1983, Volume: 29, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Small Cell;

1983
Megadose chemotherapy with bone marrow rescue.
    Progress in experimental tumor research, 1984, Volume: 28

    Topics: Animals; Bone Marrow Transplantation; Brain Neoplasms; Carmustine; Combined Modality Therapy; Glioma

1984
Influence of polyamine depletion caused by alpha-difluoromethylornithine, an enzyme-activated irreversible inhibitor of ornithine decarboxylase, on alkylation- and carbamoylation-induced cytotoxicity in 9L rat brain tumor cells in vitro.
    Cancer research, 1983, Volume: 43, Issue:10

    Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carboxy-Lyases; Carmustine; Cell Line; Cell Surviva

1983
Procarbazine, CCNU and vincristine (PCV) combination chemotherapy for brain tumors.
    Oncology, 1984, Volume: 41, Issue:4

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Combined Modali

1984
Hypoxic cells and in situ chemopotentiation of the nitrosoureas by misonidazole.
    British journal of cancer, 1984, Volume: 49, Issue:6

    Topics: Animals; Brain Neoplasms; Carmustine; Cell Survival; Dose-Response Relationship, Drug; Drug Synergis

1984
Use of phenobarbital and high doses of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea in the treatment of brain tumor-bearing mice.
    Cancer research, 1983, Volume: 43, Issue:5

    Topics: Animals; Brain Neoplasms; Cell Survival; Dose-Response Relationship, Drug; Drug Interactions; Female

1983
Treatment of brain giomas with high dose of CCNU and autologous bone marrow transplantation.
    Biomedicine / [publiee pour l'A.A.I.C.I.G.], 1980, Volume: 32, Issue:2

    Topics: Bone Marrow Transplantation; Brain Neoplasms; Glioma; Hematologic Diseases; Humans; Lomustine; Nitro

1980
Quantitative dose-response relations for the cytotoxic activity of chloroethylnitrosoureas in cell culture.
    Cancer research, 1982, Volume: 42, Issue:3

    Topics: Animals; Biotransformation; Brain Neoplasms; Carmustine; Cell Survival; Cells, Cultured; Dose-Respon

1982
[The effects of combined chemotherapy (adriamycin/VM/26/CCNU) in brian tumours in adults and animal experiments (author's transl)].
    Fortschritte der Neurologie-Psychiatrie, 1982, Volume: 50, Issue:3

    Topics: Adult; Aged; Animals; Brain Neoplasms; Doxorubicin; Drug Therapy, Combination; Ethylnitrosourea; Fem

1982
Pulmonary fibrosis associated with lomustine (CCNU): a case report.
    Cancer treatment reports, 1982, Volume: 66, Issue:10

    Topics: Astrocytoma; Brain; Brain Neoplasms; Child; Humans; Lomustine; Male; Nitrosourea Compounds; Pulmonar

1982
[Analysis of long-term effects of CCNU on gliomas of the brain].
    Zhonghua shen jing jing shen ke za zhi = Chinese journal of neurology and psychiatry, 1982, Volume: 15, Issue:3

    Topics: Adolescent; Adult; Brain Neoplasms; Child; Female; Glioma; Humans; Lomustine; Male; Middle Aged; Nit

1982
[Results of combined modality treatment of malignant gliomas. Comparison of postoperative irradiation, chemotherapy, and combined radio-polychemotherapy (author's transl)].
    Der Nervenarzt, 1981, Volume: 52, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Drug Therapy, Combination; Female; Glioma; Huma

1981
Nephrotoxicity of nitrosoureas.
    Cancer, 1981, Sep-15, Volume: 48, Issue:6

    Topics: Adolescent; Adult; Aged; Biopsy; Blood Urea Nitrogen; Brain Neoplasms; Carmustine; Child; Creatinine

1981
The effect of phenobarbital on the toxicity and tumoricidal activity of CCNU in a murine brain tumor model.
    Journal of neurosurgery, 1980, Volume: 52, Issue:3

    Topics: Animals; Brain Neoplasms; Drug Therapy, Combination; Ependymoma; Female; Lomustine; Mice; Mice, Inbr

1980
Cell growth rate of human brain tumours in vitro.
    The Indian journal of medical research, 1980, Volume: 71

    Topics: Brain Neoplasms; Humans; In Vitro Techniques; Lomustine

1980
[Progressive insufficiency after CCNU therapy].
    Lakartidningen, 1980, Apr-30, Volume: 77, Issue:18

    Topics: Adult; Brain Neoplasms; Glomerulosclerosis, Focal Segmental; Humans; Kidney Failure, Chronic; Lomust

1980
Synergistic effect of combined hyperthermia and a nitrosourea in treatment of a murine ependymoblastoma.
    Cancer research, 1980, Volume: 40, Issue:8 Pt 1

    Topics: Animals; Brain Neoplasms; Ependymoma; Female; Hot Temperature; Lomustine; Mice; Neoplasm Transplanta

1980
Combination chemotherapy with VM 26 and CCNU in primary malignant brain tumors of children.
    Helvetica paediatrica acta, 1980, Volume: 35, Issue:1

    Topics: Adolescent; Brain Neoplasms; Child; Child, Preschool; Drug Therapy, Combination; Female; Humans; Lom

1980
CCNU chemotherapy in adult patients with tumors of the basal ganglia and brain stem.
    Journal of neurosurgery, 1980, Volume: 53, Issue:3

    Topics: Adolescent; Adult; Aged; Basal Ganglia Diseases; Brain Neoplasms; Brain Stem; Female; Humans; Lomust

1980
CCNU therapy in basal germinomas.
    Journal of neurosurgery, 1981, Volume: 54, Issue:3

    Topics: Brain Neoplasms; Dysgerminoma; Humans; Lomustine; Nitrosourea Compounds

1981
The effect of topical CCNU(1-(2-chloroethyl)-3 cyclohexyl 1 nitrosurea) treatment on lipid peroxidation of glial tumours transplanted on rat brain.
    General pharmacology, 1995, Volume: 26, Issue:2

    Topics: Administration, Topical; Animals; Brain; Brain Neoplasms; Glioma; Injections, Intralesional; Lipid P

1995
Multiorgan failure associated with lomustine overdose.
    The Annals of pharmacotherapy, 1995, Volume: 29, Issue:4

    Topics: Adult; Astrocytoma; Brain Neoplasms; Combined Modality Therapy; Drug Overdose; Female; Frontal Lobe;

1995
Response and control: lessons from oligodendroglioma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Humans; Lomustine; Oligodendrogliom

1995
Chemoradiation and adjuvant chemotherapy for glioblastoma: why does so much therapy yield so little improvement in survival?
    International journal of radiation oncology, biology, physics, 1995, Sep-30, Volume: 33, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Chemotherapy, Adjuvant

1995
Interleukin-2 gene therapy in a patient with glioblastoma.
    Gene therapy, 1995, Volume: 2, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cells, Cultured; Combined Modality

1995
Restrictive lung disease following treatment for malignant brain tumors: a potential late effect of craniospinal irradiation.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:6

    Topics: Adolescent; Adult; Brain Neoplasms; Child; Child, Preschool; Cranial Irradiation; Female; Humans; Lo

1995
Brain tumor chemotherapy trials: slow start, but quickly gaining.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1994, Volume: 12, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Clinical Trials as Topic; Humans; L

1994
Consolidative thoracic radiotherapy and prophylactic cranial irradiation in limited disease small cell lung cancer.
    Lung cancer (Amsterdam, Netherlands), 1993, Volume: 10, Issue:3-4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Small Cell;

1993
Long survival in patients with acquired immune deficiency syndrome-related primary central nervous system lymphoma.
    Cancer, 1994, Mar-15, Volume: 73, Issue:6

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Therapy; C

1994
Aplastic anemia induced by cyclohexylchloroethylnitrousurea.
    Anti-cancer drugs, 1994, Volume: 5, Issue:1

    Topics: Adult; Anemia, Aplastic; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Blood Cell Cou

1994
Low-grade oligodendroglioma responds to chemotherapy.
    Neurology, 1996, Volume: 46, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Female; Humans; Lomustine; M

1996
Procarbazine, lomustine, and vincristine (PCV) chemotherapy for grade III and grade IV oligoastrocytomas.
    Journal of neurosurgery, 1996, Volume: 85, Issue:4

    Topics: Adult; Astrocytoma; Brain Neoplasms; Female; Humans; Lomustine; Male; Middle Aged; Procarbazine; Pro

1996
Quantitative DNA analysis of an intracerebrally transplanted brain tumour model after experimental chemotherapy with BCNU and CCNU.
    Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie, 1995, Volume: 47, Issue:4

    Topics: Animals; Brain Neoplasms; Brain Tissue Transplantation; Carmustine; Cell Division; Cytophotometry; D

1995
Combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas.
    Neurosurgery, 1996, Volume: 39, Issue:5

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease Pr

1996
Radiation and chemotherapy improve outcome in oligodendroglioma.
    International journal of radiation oncology, biology, physics, 1997, Jan-15, Volume: 37, Issue:2

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine

1997
Intracranial Hodgkin's disease in two patients with familial Hodgkin's disease.
    Medical and pediatric oncology, 1997, Volume: 28, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modalit

1997
Retreatment of patients with intracranial gliomas by external beam radiotherapy and cytotoxic chemotherapy.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 1997, Volume: 9, Issue:3

    Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Case-Control Studies; Child; Combined Modality Therap

1997
Pretreatment prediction of the chemotherapeutic response of human glioma cell cultures using nuclear magnetic resonance spectroscopy and artificial neural networks.
    Cancer research, 1997, Oct-01, Volume: 57, Issue:19

    Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Division; Drug Resistance, Neoplasm; Drug S

1997
[Assessment of procarbazine, vincristine and lomustine association (PCV protocol) in oligodendroglioma and mixed glioma].
    Bulletin du cancer, 1997, Volume: 84, Issue:10

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Female; Gl

1997
Neurotoxicity of combination chemotherapy with procarbazine, CCNU and vincristine (PCV) for recurrent glioma.
    Journal of neuro-oncology, 1998, Volume: 38, Issue:1

    Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neop

1998
Bihemispheric malignant glioma: one size does not fit all.
    Journal of neuro-oncology, 1998, Volume: 38, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Fatal Outcome; Glioblastoma;

1998
CCNU overdose during PCV chemotherapy for anaplastic astrocytoma.
    Journal of neurology, 1998, Volume: 245, Issue:4

    Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neo

1998
Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group.
    Neurology, 1998, Volume: 51, Issue:4

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Co

1998
A retrospective study of the value of chemotherapy as adjuvant therapy to surgery and radiotherapy in grade 3 and 4 gliomas.
    European journal of cancer (Oxford, England : 1990), 1998, Volume: 34, Issue:10

    Topics: Administration, Oral; Adult; Age Distribution; Antineoplastic Combined Chemotherapy Protocols; Brain

1998
The efficacy of CCNU in non-small cell lung carcinoma presenting with cranial metastases.
    Journal of experimental & clinical cancer research : CR, 1998, Volume: 17, Issue:3

    Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease-Free Sur

1998
Reirradiation and lomustine in patients with relapsed high-grade gliomas.
    International journal of radiation oncology, biology, physics, 1999, Mar-01, Volume: 43, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Disease

1999
Sensitivity of short-term cultures derived from human malignant glioma to the anti-cancer drug temozolomide.
    Anti-cancer drugs, 1999, Volume: 10, Issue:2

    Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Dose-Response R

1999
Neoadjuvant procarbazine, CCNU, and vincristine for anaplastic and aggressive oligodendroglioma.
    Neurology, 1999, Sep-22, Volume: 53, Issue:5

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Fem

1999
BUdR radiosensitization in anaplastic astrocytoma.
    International journal of radiation oncology, biology, physics, 1999, Dec-01, Volume: 45, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Bromodeoxyuridine; Che

1999
Cytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors.
    Clinical pharmacology and therapeutics, 1999, Volume: 66, Issue:6

    Topics: Adult; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carbamazepi

1999
Locally delivered chemotherapy and repeated surgery can improve survival in glioblastoma patients.
    Italian journal of neurological sciences, 1999, Volume: 20, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brain Neoplasms; Carmustine; Chemotherapy

1999
Effects of carmustine and lomustine on arylamine N-acetyltransferase activity and 2-aminofluorene-DNA adducts in rat glial tumor cells.
    Neurochemical research, 2000, Volume: 25, Issue:6

    Topics: Animals; Arylamine N-Acetyltransferase; Brain Neoplasms; Carmustine; DNA Adducts; Fluorenes; Glioma;

2000
Chemosensitivity in childhood brain tumours in vitro: evidence of differential sensitivity to lomustine (CCNU) and vincristine.
    European journal of cancer (Oxford, England : 1990), 2000, Volume: 36, Issue:15

    Topics: Adult; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Child; Dose-Response Relationship, Drug;

2000
Chemotherapy for aggressive or anaplastic high grade oligodendrogliomas and oligoastrocytomas: better than a salvage treatment.
    British journal of neurosurgery, 1998, Volume: 12, Issue:3

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasm

1998
Distinct radiochemotherapy protocols differentially influence cellular proliferation and expression of p53 and Bcl-2 in glioblastoma multiforme relapses in vivo.
    Journal of neuro-oncology, 2000, Volume: 48, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apop

2000
Myeloablative chemotherapy for recurrent aggressive oligodendroglioma.
    Neuro-oncology, 2000, Volume: 2, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone Marrow Transplanta

2000
Lipid association improves the therapeutic index of lomustine [1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea] to suppress 36B-10 tumor growth in rats.
    Cancer research, 2001, May-01, Volume: 61, Issue:9

    Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Cell Division; Dose-Respon

2001
[Post-operative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of German prospective randomised trial HIT'91].
    Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2001, Volume: 5, Issue:2

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant;

2001
PCV chemotherapy for recurrent glioblastoma multiforme.
    Neurology, 2001, Jun-26, Volume: 56, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease Progression; Female; Gliobl

2001
CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release.
    Oncogene, 2001, Jul-12, Volume: 20, Issue:31

    Topics: Antineoplastic Agents, Alkylating; Apoptosis; Apoptosis Regulatory Proteins; Blotting, Western; Brai

2001
Adenovirus-mediated expression of HSV1-TK or Fas ligand induces cell death in primary human glioma-derived cell cultures that are resistant to the chemotherapeutic agent CCNU.
    Cancer gene therapy, 2001, Volume: 8, Issue:8

    Topics: Adenoviridae; Antineoplastic Agents, Alkylating; Apoptosis; beta-Galactosidase; Brain Neoplasms; Com

2001
Medical Research Council adjuvant trial in high-grade gliomas.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Oct-01, Volume: 19, Issue:19

    Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Chemotherapy, Adjuvant

2001
Improved efficacy of chemotherapy for glioblastoma by radiation-induced opening of blood-brain barrier: clinical results.
    International journal of radiation oncology, biology, physics, 2001, Nov-15, Volume: 51, Issue:4

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain Neoplasms; Ch

2001
Radiotherapy combined with procarbazine, bleomycin, and CCNU in the treatment of high-grade supratentorial astrocytomas.
    Journal of neurosurgery, 1978, Volume: 48, Issue:6

    Topics: Adolescent; Adult; Aged; Astrocytoma; Bleomycin; Brain Neoplasms; Child; Drug Therapy, Combination;

1978
Treatment of grade III and IV astrocytoma with dimethyl triazeno imidazole carboxamide (DTIC, NSC-45388) alone and in combination with CCNU (NSC-79037) or methyl CCNU (MeCCNU, NSC-95441).
    Cancer, 1975, Volume: 36, Issue:4

    Topics: Adult; Brain Neoplasms; Dacarbazine; Drug Evaluation; Drug Therapy, Combination; Female; Glioblastom

1975
Single-agent chemotherapy of brain tumors. A five-year review.
    Archives of neurology, 1976, Volume: 33, Issue:11

    Topics: Astrocytoma; Bone Marrow Diseases; Brain Neoplasms; Carmustine; Glioma; Humans; Imidazoles; Lomustin

1976
[Treatment of inoperable glioblastomas using a combination of adriamycin, VM 26 and CCNU].
    Bulletin du cancer, 1977, Volume: 64, Issue:1

    Topics: Adult; Aged; Brain Neoplasms; Doxorubicin; Drug Therapy, Combination; Drug Tolerance; Glioblastoma;

1977
[Polychemotherapy of glioblastoma multiforme].
    Deutsche medizinische Wochenschrift (1946), 1977, Sep-09, Volume: 102, Issue:36

    Topics: Adult; Brain Neoplasms; Carmustine; Glioblastoma; Humans; Lomustine; Male

1977
Cerebral pseudocysts following chemotherapy of glioblastomas.
    Acta neurochirurgica, 1977, Volume: 39, Issue:3-4

    Topics: Adult; Astrocytoma; Brain Diseases; Brain Neoplasms; Cysts; Glioblastoma; Humans; Lomustine; Male; M

1977
Brain tumors in children.
    Pediatric annals, 1978, Volume: 7, Issue:8

    Topics: Adolescent; Astrocytoma; Brain; Brain Neoplasms; Child; Diagnosis, Differential; Ependymoma; Female;

1978
Prevention of brain extension in small-cell carcinoma of the bronchus.
    Medical and pediatric oncology, 1978, Volume: 4, Issue:4

    Topics: Antineoplastic Agents; Brain Neoplasms; Bronchial Neoplasms; Carcinoma, Small Cell; Drug Therapy, Co

1978
Combination chemotherapy of malignant glioma. Effect of postoperative treatment with CCNU, vincristine, amethopterine and procarbazine.
    European journal of cancer, 1978, Volume: 14, Issue:11

    Topics: Adolescent; Adult; Aged; Brain Neoplasms; Drug Therapy, Combination; Glioma; Humans; Lomustine; Meth

1978
Adjuvant chemotherapy with nitrosourea compounds following surgery plus radiotherapy in glioblastoma multiforme.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 1978, Volume: 68

    Topics: Brain Neoplasms; Carmustine; Glioblastoma; Humans; Lomustine; Nitrosourea Compounds; Semustine

1978
[Value of chemotherapy associated with conventional treatment of malignant gliomas of the brain. Study of 95 cases with histological verification and follow-up of 1 to 6 years 9 months].
    Revue neurologique, 1979, Volume: 135, Issue:3

    Topics: Administration, Oral; Adult; Brain Neoplasms; Carmustine; Drug Evaluation; Drug Therapy, Combination

1979
Preoperative radiotherapy and chemotherapy in hypervascular, high-grade supratentorial astrocytomas.
    Surgical neurology, 1979, Volume: 12, Issue:2

    Topics: Adult; Aged; Brain Neoplasms; Drug Therapy, Combination; Female; Glioblastoma; Humans; Lomustine; Ma

1979
Delayed response to brain tumor chemotherapy.
    Surgical neurology, 1979, Volume: 11, Issue:2

    Topics: Adult; Brain Neoplasms; Glioma; Humans; Lomustine; Male; Middle Aged; Nitrosourea Compounds; Prednis

1979
Treatment of primitive malignant tumors of the central nervous system. Clinical evaluation of 91 cases.
    Acta neurologica, 1979, Volume: 1, Issue:1

    Topics: Astrocytoma; Brain Neoplasms; Carmustine; Ependymoma; Glioma; Humans; Lomustine; Oligodendroglioma

1979
Chemotherapy of experimental metastatic brain tumors in female Wistar rats.
    Cancer research, 1979, Volume: 39, Issue:7 Pt 1

    Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carcinoma 256, Walker; Carotid Arteries; Cells, Cul

1979
Brain tumor chemotherapy using a rat glioma model.
    Journal of cancer research and clinical oncology, 1979, May-14, Volume: 94, Issue:1

    Topics: Animals; Bone Marrow; Brain Neoplasms; Cell Nucleus; Disease Models, Animal; Dose-Response Relations

1979
Combination chemotherapy with VM 26 and CCNU in primary malignant brain tumors.
    Surgical neurology, 1979, Volume: 11, Issue:3

    Topics: Adolescent; Adult; Aged; Brain Neoplasms; Child; Drug Therapy, Combination; Female; Humans; Lomustin

1979
Combination chemotherapy for extracranial metastases of a primary malignant cerebral neoplasm.
    Cancer treatment reports, 1979, Volume: 63, Issue:8

    Topics: Adult; Antineoplastic Agents; Bone Neoplasms; Brain Neoplasms; Cisplatin; Cyclophosphamide; Doxorubi

1979
Malignant gliomas treated after surgery by combination chemotherapy and delayed irradiation. Part I: Analysis of results.
    Acta neurochirurgica, 1979, Volume: 51, Issue:1-2

    Topics: Adolescent; Adult; Aged; Astrocytoma; Brain Neoplasms; Cobalt Radioisotopes; Drug Therapy, Combinati

1979
Malignant gliomas treated after surgery by combination chemotherapy and delayed radiation therapy. Part II. Tolerance to irradiation after chemotherapy.
    Acta neurochirurgica, 1979, Volume: 51, Issue:1-2

    Topics: Brain; Brain Neoplasms; Drug Therapy, Combination; Glioma; Humans; Lomustine; Neoplasm Recurrence, L

1979
Comparison of the CCNU and BCNU modification of the in vitro radiation response in 9L brain tumor cells of rats.
    International journal of radiation oncology, biology, physics, 1979, Volume: 5, Issue:9

    Topics: Animals; Brain Neoplasms; Carmustine; Cell Survival; Cells, Cultured; Dose-Response Relationship, Dr

1979
Adjuvant chemotherapy with intraventricular methotrexate and CCNU after surgery and radiotherapy of medulloblastomas.
    Helvetica paediatrica acta, 1978, Volume: 33, Issue:3

    Topics: Brain Neoplasms; Humans; Injections, Spinal; Lomustine; Medulloblastoma; Methotrexate; Nitrosourea C

1978
Experimental brain tumor chemotherapy: DNA damage in the rat gliosarcoma 9L treated with CCNU.
    Clinical neurosurgery, 1977, Volume: 24

    Topics: Animals; Brain Neoplasms; DNA, Neoplasm; DNA, Single-Stranded; Drug Evaluation, Preclinical; Glioma;

1977
Desmosterol: a biochemical marker of glioma growth.
    Surgical neurology, 1977, Volume: 8, Issue:6

    Topics: Astrocytoma; Brain Neoplasms; Carmustine; Cholesterol; Chromatography, Gas; Desmosterol; Diagnosis,

1977
Chemotherapy of human nervous system tumors: influence on cerebrospinal fluid sterols.
    National Cancer Institute monograph, 1977, Volume: 46

    Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Carmustine; Cholesterol; Desmosterol; Female; Humans;

1977
Development of Hodgkin's disease in a patient receiving procarbazine, CCNU, and vincristine therapy for a gemistocytic astrocytoma.
    Cancer treatment reports, 1978, Volume: 62, Issue:1

    Topics: Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Drug Therapy, Combination; Female; Hodgkin Dise

1978
Adriamycin and 1-(2-chlorethyl)-3-cyclohexyl-1-nitrosourea (CCNU) in the treatment of metastatic breast cancer.
    Cancer, 1978, Volume: 41, Issue:4

    Topics: Adult; Aged; Bone Marrow; Brain Neoplasms; Breast Neoplasms; Doxorubicin; Drug Therapy, Combination;

1978
The effect of amphotericin B on the survival of brain-tumor-bearing mice treated with CCNU.
    Journal of neurosurgery, 1978, Volume: 49, Issue:4

    Topics: Amphotericin B; Animals; Brain Neoplasms; Drug Synergism; Female; Lomustine; Mice; Neoplasm Transpla

1978
Chemotherapy of recurrent medulloblastoma with combined procarbazine, CCNU, and vincristine.
    Journal of neurosurgery, 1978, Volume: 49, Issue:4

    Topics: Adolescent; Adult; Brain Neoplasms; Child; Child, Preschool; Drug Therapy, Combination; Humans; Lomu

1978
Experiments on the chemotheraphy of a transplantable glioblastoma in the rat, employing 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).
    Acta neurochirurgica, 1978, Volume: 42, Issue:1-2

    Topics: Animals; Brain Neoplasms; Glioma; Lomustine; Male; Methylnitrosourea; Neoplasm Transplantation; Neop

1978
Chemotherapy of malignant gliomas: comparison of the effect of polychemo- and CCNU-therapy.
    Acta neurochirurgica, 1978, Volume: 42, Issue:1-2

    Topics: Adult; Aged; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Drug Therapy, Combination; Humans;

1978
The contemporary role of chemotherapy in the treatment of malignant brain tumor.
    Clinical neurosurgery, 1978, Volume: 25

    Topics: Adrenal Cortex Hormones; Animals; Brain Neoplasms; Carmustine; Dose-Response Relationship, Drug; Dru

1978
Central nervous system tumors of childhood treated with CCNU, vincristine, and radiation.
    Medical and pediatric oncology, 1978, Volume: 4, Issue:4

    Topics: Adolescent; Astrocytoma; Bone Marrow; Brain Neoplasms; Child; Child, Preschool; Drug Therapy, Combin

1978
[Interim results of the SIOP study (author's transl)].
    Monatsschrift fur Kinderheilkunde, 1978, Volume: 126, Issue:11

    Topics: Adolescent; Brain Neoplasms; Child; Ependymoma; Humans; Lomustine; Medulloblastoma; Methods; Vincris

1978
[Neurogliale cerebral tumors: test of chemotherapy treatment. Forty five cases (author's transl)].
    La Nouvelle presse medicale, 1978, Dec-02, Volume: 7, Issue:43

    Topics: Adult; Aged; Brain Neoplasms; Child, Preschool; Drug Therapy, Combination; Echoencephalography; Elec

1978
Relationship of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) pharmacokinetics of uptake, distribution, and tissue/plasma partitioning in rat organs and intracerebral tumors.
    Cancer chemotherapy and pharmacology, 1978, Volume: 1, Issue:4

    Topics: Animals; Brain Neoplasms; Carmustine; DNA; Kinetics; Lomustine; Male; Neoplasm Proteins; Nitrosourea

1978
Treatment of adult malignant gliomas.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 1978, Volume: 68

    Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Drug Administration Schedule; Drug Therapy, Com

1978
Adjuvant chemotherapy in malignant brain gliomas.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 1978, Volume: 68

    Topics: Brain Neoplasms; Drug Administration Schedule; Glioma; Humans; Lomustine

1978
The effect of phenobarbital pretreatment on the antitumor activity of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) and 1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidyl-1-nitrosourea (PCNU), and on the plasma p
    The Journal of pharmacology and experimental therapeutics, 1979, Volume: 208, Issue:1

    Topics: Alkylating Agents; Animals; Biotransformation; Brain Neoplasms; Carmustine; Dexamethasone; Drug Inte

1979
Management of Burkitt's lymphoma involving the central nervous system.
    African journal of medicine and medical sciences, 1976, Volume: 5, Issue:2

    Topics: Antineoplastic Agents; Brain Neoplasms; Burkitt Lymphoma; Child; Cyclophosphamide; Cytarabine; Human

1976
Chemotherapy of an experimental glioma with nitrosoureas.
    Cancer research, 1977, Volume: 37, Issue:2

    Topics: Animals; Brain Neoplasms; Drug Administration Schedule; Ependymoma; Female; Glioma; Injections; Inje

1977
Intraneoplastic injection of CCNU for experimental brain tumor chemotherapy.
    Surgical neurology, 1977, Volume: 7, Issue:2

    Topics: Animals; Brain Neoplasms; Drug Evaluation, Preclinical; Ependymoma; Female; Lomustine; Mice; Neoplas

1977
[Therapy of medulloblastoma and ependymoma in childhood].
    Deutsche medizinische Wochenschrift (1946), 1977, Jun-17, Volume: 102, Issue:24

    Topics: Age Factors; Brain Neoplasms; Child; Child, Preschool; Ependymoma; Humans; Infant; Lomustine; Medull

1977
DNA damage in the intracerebral rat gliosarcoma 9L treated with 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea.
    Cancer research, 1977, Volume: 37, Issue:10

    Topics: Animals; Brain Neoplasms; Centrifugation, Density Gradient; DNA Repair; DNA, Neoplasm; DNA, Single-S

1977
Letter: Effects of CCNU.
    Journal of neurosurgery, 1976, Volume: 45, Issue:1

    Topics: Brain Neoplasms; Drug Evaluation; Humans; Lomustine; Nitrosourea Compounds

1976
Chemotherapy of brain tumors.
    Advances in neurology, 1976, Volume: 15

    Topics: Brain Neoplasms; Carmustine; Drug Combinations; Glioma; Humans; Lomustine; Methotrexate; Podophyllot

1976
Meningeal carcinomatosis. Case report and review of the literature.
    Neurology, 1976, Volume: 26, Issue:3

    Topics: Adult; Brain Neoplasms; Breast Neoplasms; Carcinoma; Female; Humans; Lomustine; Meninges; Methotrexa

1976
Nitrosourea pharmacodynamics in relation to the central nervous system.
    Cancer treatment reports, 1976, Volume: 60, Issue:6

    Topics: Animals; Blood-Brain Barrier; Brain Neoplasms; Carmustine; Glioma; Humans; Lomustine; Mice; Molecula

1976
Nitrosourea chemotherapy for primary malignant gliomas.
    Cancer treatment reports, 1976, Volume: 60, Issue:6

    Topics: Brain Neoplasms; Carmustine; Drug Therapy, Combination; Fluorouracil; Glioma; Humans; Lomustine; Neo

1976
Lomustine (CeeNU).
    The Medical letter on drugs and therapeutics, 1976, Nov-19, Volume: 18, Issue:24

    Topics: Brain Neoplasms; Glioma; Hodgkin Disease; Humans; Lomustine; Nitrosourea Compounds

1976
Sterols in cerebrospinal fluid during nitrosourea chemotherapy of human brain tumors.
    Pharmacological research communications, 1976, Volume: 8, Issue:2

    Topics: Adult; Astrocytoma; Brain Neoplasms; Carmustine; Cholesterol; Desmosterol; Female; Glioma; Humans; I

1976
Chemotherapy of malignant glioma with CCNU alone and CCNU combined with vincristine sulfate and procarbazine hydrochloride.
    Transactions of the American Neurological Association, 1976, Volume: 101

    Topics: Brain Neoplasms; Drug Evaluation; Drug Therapy, Combination; Glioma; Humans; Lomustine; Nitrosourea

1976
Environmental factors modifying the effect of CCNU on glioma in vitro and in vivo.
    Transactions of the American Neurological Association, 1976, Volume: 101

    Topics: Animals; Brain Neoplasms; Cells, Cultured; Glioma; In Vitro Techniques; Lomustine; Mice; Nitrosourea

1976
Treatment of malignant gliomas and brain metastases in adults with a combination of adriamycin, VM 26, and CCNU. Results of a phase II trail.
    Cancer, 1976, Volume: 38, Issue:5

    Topics: Adult; Aged; Brain Neoplasms; Doxorubicin; Drug Therapy, Combination; Drug Tolerance; Female; Glioma

1976
Phase II study of procarbazine, CCNU, and vincristine combination chemotherapy in the treatment of malignant brain tumors.
    Cancer, 1975, Volume: 35, Issue:5

    Topics: Brain Neoplasms; Drug Therapy, Combination; Evaluation Studies as Topic; Humans; Lomustine; Neoplasm

1975
CCNU in brain tumours.
    Clinical radiology, 1975, Volume: 26, Issue:2

    Topics: Adolescent; Adult; Brain Neoplasms; Bronchial Neoplasms; Cerebellar Neoplasms; Child, Preschool; Fem

1975
Combination chemotherapy with CCNU, vincristine and methotrexate in primary and metastatic brain tumors.
    European journal of cancer, 1975, Volume: 11, Issue:8

    Topics: Brain Neoplasms; Drug Therapy, Combination; Humans; Lomustine; Methotrexate; Neoplasm Metastasis; Ni

1975
Brachytherapy of brain tumors.
    Stereotactic and functional neurosurgery, 1992, Volume: 59, Issue:1-4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Brain Neoplasms; Child; Combined Moda

1992
[Diagnosis and treatment of recurrent brain glioma].
    Neurologia i neurochirurgia polska, 1992, Volume: Suppl 1

    Topics: Adult; Brain Neoplasms; Cobalt Radioisotopes; Female; Glioma; Humans; Lomustine; Male; Middle Aged;

1992
[Rapid complete regression of liver, brain and bone metastases from previously treated breast cancer, with combination of platin, fluorouracil and lomustine].
    Presse medicale (Paris, France : 1983), 1992, Apr-04, Volume: 21, Issue:13

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Breast Neopl

1992
The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with PCV chemotherapy.
    Journal of neurosurgery, 1992, Volume: 76, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Drug Admi

1992
2-Nitroimidazole potentiation of nitrosourea induced cytotoxicity in subcutaneous implants of rat 9L brain tumor cells.
    Journal of neuro-oncology, 1991, Volume: 11, Issue:1

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Car

1991
Thyroid function after treatment of brain tumors in children.
    The Journal of pediatrics, 1991, Volume: 119, Issue:5

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine

1991
Chemotherapy for oligodendroglioma. Progress report.
    Archives of neurology, 1991, Volume: 48, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Humans; Lomustine; Neoplasm Recurre

1991
[Possible role of 06-methylguanine-DNA-transferase in the response of patients with primary tumor of the brain to chemotherapy using chloro-ethyl-nitroso-urea: results of a current study].
    Bollettino della Societa italiana di biologia sperimentale, 1990, Volume: 66, Issue:5

    Topics: Astrocytoma; Brain Neoplasms; Female; Glioblastoma; Humans; Lomustine; Male; Methyltransferases; Neo

1990
The chemotherapeutic response of a murine (VM) model of human glioma.
    British journal of cancer, 1990, Volume: 61, Issue:1

    Topics: Animals; Astrocytoma; Brain Neoplasms; Carmustine; Disease Models, Animal; Lomustine; Mice; Mice, In

1990
Postoperative radiotherapy and radiotherapy combined with CCNU chemotherapy for treatment of brain gliomas.
    Journal of neuro-oncology, 1990, Volume: 8, Issue:1

    Topics: Antineoplastic Agents; Brain Neoplasms; Glioma; Humans; Lomustine

1990
Chemotherapy for malignant gliomas of the brain: a review of ten-years experience.
    Acta neurochirurgica, 1990, Volume: 103, Issue:1-2

    Topics: Antineoplastic Agents; Aziridines; Benzoquinones; Brain Neoplasms; Carmustine; Cyclohexenes; Glioma;

1990
Successful chemotherapy for newly diagnosed aggressive oligodendroglioma.
    Annals of neurology, 1990, Volume: 27, Issue:5

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Female; Humans; Lomustine; M

1990
Efficiency of the radio-chemo-surgical. Treatment in cerebral astrocytomas.
    Zentralblatt fur Neurochirurgie, 1989, Volume: 50, Issue:2

    Topics: Adult; Astrocytoma; Brain Neoplasms; Cobalt Radioisotopes; Combined Modality Therapy; Female; Gliobl

1989
Ovarian function following chemotherapy for childhood brain tumours.
    Medical and pediatric oncology, 1989, Volume: 17, Issue:2

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Child; Chil

1989
Thyroid dysfunction after radiotherapy and chemotherapy of brain tumours.
    Archives of disease in childhood, 1989, Volume: 64, Issue:4

    Topics: Brain Neoplasms; Child; Combined Modality Therapy; Growth Hormone; Humans; Lomustine; Radiotherapy;

1989
Criteria for termination of phase II chemotherapy for patients with progressive or recurrent brain tumor.
    Neurology, 1989, Volume: 39, Issue:1

    Topics: Adolescent; Antineoplastic Agents; Astrocytoma; Aziridines; Benzoquinones; Brain Neoplasms; Cohort S

1989
Irradiation and CCNU in glioma therapy.
    Journal of neurosurgery, 1989, Volume: 71, Issue:5 Pt 1

    Topics: Brain Neoplasms; Combined Modality Therapy; Glioma; Humans; Lomustine

1989
Glutathione and related enzymes in rat brain tumor cell resistance to 1,3-bis(2-chloroethyl)-1-nitrosourea and nitrogen mustard.
    Cancer research, 1987, May-15, Volume: 47, Issue:10

    Topics: Animals; Brain Neoplasms; Buthionine Sulfoximine; Carmustine; Cell Line; Cell Survival; Chromatograp

1987
Supraophthalmic carotid infusion for recurrent glioma: rationale, technique, and preliminary results for cisplatin and BCNU.
    Journal of neuro-oncology, 1985, Volume: 3, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Car

1985
Variation in response to CCNU of glioblastoma multiforme in brain and cervical lymph node. Case report.
    Journal of neurosurgery, 1985, Volume: 62, Issue:6

    Topics: Adult; Brain Neoplasms; Female; Glioblastoma; Humans; Lomustine; Lymphatic Metastasis

1985
[Multimodal treatment of undifferentiated astrocytomas of the cerebrum. Indications for chemotherapy].
    Fortschritte der Medizin, 1985, Jun-06, Volume: 103, Issue:21

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Therapy; Glioblas

1985
In vitro analysis of BCNU-sensitivity in human malignant gliomas. II. Cross-resistance studies with cisplatinum and nitrosoureas.
    Acta neurologica Scandinavica, 1986, Volume: 73, Issue:1

    Topics: Brain Neoplasms; Carmustine; Cells, Cultured; Cisplatin; Drug Resistance; Glioblastoma; Humans; Lomu

1986
Neurologic dysfunction in patients treated for small cell carcinoma of the lung: a clinical and radiological study.
    International journal of radiation oncology, biology, physics, 1986, Volume: 12, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Diseases; Brain Neoplasms;

1986
Sudden onset of blindness in patients treated with oral CCNU and low-dose cranial irradiation.
    Cancer, 1987, Mar-01, Volume: 59, Issue:5

    Topics: Administration, Oral; Aged; Blindness; Brain; Brain Neoplasms; Carcinoma, Small Cell; Combined Modal

1987
Misonidazole and CCNU chemotherapy for recurrent primary brain tumor.
    Journal of neuro-oncology, 1987, Volume: 4, Issue:4

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Bone Marrow Diseases; Brain Neop

1987
Eight drugs in one day chemotherapy for brain tumors: experience in 107 children and rationale for preradiation chemotherapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1987, Volume: 5, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Child; Cisplatin; Comb

1987
Testicular damage after chemotherapy for childhood brain tumors.
    The Journal of pediatrics, 1988, Volume: 112, Issue:6

    Topics: Adolescent; Adult; Brain Neoplasms; Carmustine; Child; Follicle Stimulating Hormone; Follow-Up Studi

1988
[New developments in chemotherapy for experimental brain metastasis].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1985, Volume: 12, Issue:3 Pt 2

    Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Daunorubicin; Doxorubicin; Flo

1985
Efficacy of adjuvant chemotherapy for patients with poor-risk medulloblastoma: a preliminary report.
    Annals of neurology, 1988, Volume: 24, Issue:4

    Topics: Adolescent; Adult; Brain Neoplasms; Child; Child, Preschool; Cisplatin; Combined Modality Therapy; D

1988
Results of the treatment of children with recurrent gliomas with lomustine and vincristine.
    Cancer, 1988, Mar-01, Volume: 61, Issue:5

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Preschool

1988
Central nervous system involvement in malignant melanoma.
    Cancer, 1988, May-01, Volume: 61, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Therapy; Dexameth

1988
Treatment of recurrent brain stem gliomas and other central nervous system tumors with 5-fluorouracil, CCNU, hydroxyurea, and 6-mercaptopurine.
    Neurosurgery, 1988, Volume: 22, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Brain Stem; Chil

1988
[Use of nitrosourea derivatives in the treatment of patients with Hodgkin's disease with lesions of the central nervous system].
    Voprosy onkologii, 1988, Volume: 34, Issue:5

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Drug Evaluation;

1988
Successful chemotherapy for recurrent malignant oligodendroglioma.
    Annals of neurology, 1988, Volume: 23, Issue:4

    Topics: Adult; Antineoplastic Agents; Aziridines; Benzoquinones; Brain Neoplasms; Carmustine; Female; Humans

1988
Gonadal dysfunction after treatment of intracranial tumours.
    Archives of disease in childhood, 1988, Volume: 63, Issue:5

    Topics: Adolescent; Brain Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Female; Gonadotropi

1988
[Efficacy of the "8 drugs in a day" protocol in brain tumors in children].
    Archives francaises de pediatrie, 1988, Volume: 45, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Cer

1988
[Abdominal metastasis of a pineal germinoma in a child with a ventriculo-peritoneal shunt].
    Anales espanoles de pediatria, 1987, Volume: 27, Issue:4

    Topics: Abdominal Neoplasms; Brain Neoplasms; Cerebrospinal Fluid Shunts; Child; Humans; Liver Neoplasms; Lo

1987
Effect of cell cycle position on the survival of 9L cells treated with nitrosoureas that alkylate, cross-link, and carbamoylate.
    Cancer research, 1986, Volume: 46, Issue:5

    Topics: Alkylating Agents; Animals; Brain Neoplasms; Carbamates; Carmustine; Cell Cycle; Cell Line; Cell Sur

1986
Astroblastoma revisited: a report of three cases.
    Acta neuropathologica, 1986, Volume: 70, Issue:1

    Topics: Adult; Aged; Astrocytoma; Brain Neoplasms; Combined Modality Therapy; Electroencephalography; Female

1986
Myelofibrosis following treatment with a nitrosourea for malignant glioma.
    Cancer, 1986, Oct-01, Volume: 58, Issue:7

    Topics: Brain Neoplasms; Glioma; Humans; Lomustine; Male; Middle Aged; Primary Myelofibrosis

1986
Dibromodulcitol-based combined postoperative chemotherapy of malignant astrocytomas and glioblastomas.
    Journal of neuro-oncology, 1986, Volume: 4, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Combined

1986
Chemotherapy in intracerebrally transplanted tumors induced with transplacental administration of ethylnitrosourea in rats.
    Journal of cancer research and clinical oncology, 1986, Volume: 112, Issue:3

    Topics: Animals; Brain Neoplasms; Drug Administration Schedule; Ethylnitrosourea; Female; Lomustine; Methyln

1986
Sequential treatment with interferon and chemotherapy of metastatic malignant melanoma. Total remission of cutaneous and visceral metastasis, but not of cerebral metastasis.
    Tumori, 1987, Feb-28, Volume: 73, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carmus

1987
Metastatic malignant melanoma treated with procarbazine, vincristine and lomustine (POC).
    Chemioterapia : international journal of the Mediterranean Society of Chemotherapy, 1987, Volume: 6, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Female

1987
Assay of anti-cancer drugs in tissue culture: relationship of relapse free interval (RFI) and in vitro chemosensitivity in patients with malignant cerebral glioma.
    British journal of cancer, 1985, Volume: 51, Issue:4

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cells, Cultured; Female; Gli

1985
Nephrotoxicity of lomustine. A case report and literature review.
    Cancer chemotherapy and pharmacology, 1985, Volume: 15, Issue:2

    Topics: Adult; Astrocytoma; Brain Neoplasms; Humans; Kidney Diseases; Kidney Glomerulus; Lomustine; Male

1985
Chemosensitivity testing in the treatment of malignant gliomas.
    Progress in experimental tumor research, 1985, Volume: 29

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Glioma; Humans; Lomustine; Procarba

1985
[Brain tumors in infants and children--factors affecting prognosis, (Part-3). Mode of metastasis and prognosis in medulloblastoma].
    No shinkei geka. Neurological surgery, 1985, Volume: 13, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Brain Stem; Cerebellar Neoplasms; C

1985